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Newly synthesized polypeptides fold and assemble with the assistance from protein chaperones. 
Full maturation of folding might involve multiple cycles of binding and release of chaperones. 
Protein quality control (QC) machineries play essential roles in taking improperly folded 
molecules out of their folding cycles and targeting them for degradation. Such a process is 
important because prolonged substrate cycling expends chaperone and energy resources and 
increases toxic reactive oxygen species. Failure to destroy the recalcitrant client proteins is 
related to many diseases, such as Parkinson’s, Huntington’s, antitrypsin deficiency and cystic 
fibrosis. However, how the decision is made to terminate protein folding in the transition from 
the anabolic phase to catabolism remains largely unknown.   
 
This thesis aims to uncover the machinery that specifically terminates protein folding inside the 
endoplasmic reticulum (ER) in budding yeast. To this end, two proteins with different folding 
rates were generated. ER-GFP was engineered to mimic proteins that required prolonged folding 
for maturation, and ER-GFPfast was generated to represent molecules that folded efficiently.  
Compared with ER-GFPfast, majority of ER-GFP is misfolded in wild type cells. This indicates 
that the cells can specifically recognize the slow folding substrates. Importantly, the expression 
of ER-GFP does not affect the maturation of other proteins, which suggests that the folding 
termination machinery likely acts directly on the targets instead of impairing the general folding 
factors. Interestingly, we found that majority of ER-GFP, but not ER-GFPfast, is O-mannosylated. 
The modification is mainly carried out by the Pmt1/Pmt2 complex, which covalently adds the 
mannose residue to the hydroxyl group of Ser/Thr in the protein. The Pmt1/Pmt2 complex 
modifies ER-GFP post-translationally, which suggests that the O-mannosylation occurs after 
failed folding attempts. Biochemical results showed that, once ER-GFP becomes O-
mannosylated, the folding process is terminated. The modification removes them from folding 
cycles by reducing engagement with the Hsp70 chaperone.  Conversely, the folding of ER-GFP 
can be remarkably improved by genetic disruption of the O-mannosylation machinery. Using an 
 vi 
 
in vitro protein refolding assay, we showed that O-mannosylation intrinsically impairs protein 
folding. In an effort to search for additional factors that are involved in protein folding 
termination, we identified a set of factors that might be involved in the pathway directly or 
indirectly.  
 
Together, our results showed that a protein folding termination can involve a covalent 
glycosylation event, which represents a conceptual advancement in our current understanding of 
protein folding in vivo. Because of the clear links between protein folding and diseases, the 
Pmt1/Pmt2 pathway can now be added to the growing list of critical mechanisms that maintain 
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Chapter1 Introduction  
 
1.1 Chaperone assisted protein folding 
When nascent polypeptides emerge from ribosomes, they have no defined conformation. The 
unstructured polypeptide has to go through a folding process to pack its amino acids in a defined 
three dimensional shape. Such a unique conformational arrangement not only minimizes the free 
energy of the entire molecule and keeps the protein in an energetically stable state but also 
determines the protein’s function. Thus, folding is crucial for protein stability and functionality. 
Not surprisingly, protein misfolding has been related to numerous human diseases. It is of great 
interest to study factors that guide protein to fold correctly. 
 
The first mechanistic insight came from Christian Anfinsen’s refolding experiment (Anfinsen, 
1973). He elegantly showed that denatured ribonuclease alone can spontaneously refold by 
gradually removing denaturant and reducing reagent in an in vitro system. Thus, he concluded 
that folded protein structure is solely dictated by the intrinsic primary amino acid sequence, 
which later becomes the Anfinsen’s dogma. The importance of this experiment could not be 
overstated. Because the primary protein sequence is determined by the DNA sequence, 
Anfinsen’s model actually bridges the gap between genetic material and protein function.  
 
However, it was also found that the refolding of many protein complexes cannot be achieved in 
vitro. Ulrich Hartl and Arthur Horwich pioneered the field of protein folding inside the cell. 
Most mitochondria proteins are synthesized in the cytosol and imported into the mitochondria as 
unstructured conformation. As a result, those mitochondria imported substrates are ideal models 
to study protein folding in vivo. Making use of these tools, they successfully isolated a 
mitochondria chaperone Hsp60/GroEL mutant in which the mitochondrial import is intact but the 
translocated substrate fails to fold inside the mitochondria (Cheng et al., 1989). Subsequently, 
they showed that Hsp60 facilitates mitochondria protein folding in an ATP-dependent manner 
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(Ostermann et al., 1989). This pioneering work, together with the following studies, clearly 
showed that proteins require the assistance of chaperones to fold in vivo (Frydman et al., 1994; 
Langer et al., 1992).  
 
Now, it becomes clear that, chaperones assist protein folding through cycles of binding and 
release until the substrate completely folds, which is a ubiquitous folding mechanism throughout 
evolution (Hartl et al., 2011). Generally, chaperones bind to hydrophobic segments of proteins to 
prevent unfavorable interactions and thus facilitate folding. Upon the release of chaperones, the 
properly folded proteins are released from the folding cycle and delivered to their destination, 
while the incompletely folded species re-associate with chaperones for another round of folding. 
The existence of such folding cycles guarantees proper protein folding in vivo. 
 
1.2 Protein folding termination 
It should be noted that, even with the presence of chaperones, protein folding is still an intrinsic 
error-prone process. This is because the folding reactions are heterogeneous. Molecules that take 
the off-pathways during the folding process might get kinetically trapped as non-native 
intermediates and fail to reach the native status (Hartl et al., 2011). It has been shown that around 
30% of the newly synthesized proteins are targeted for degradation in vivo, which suggests that a 
significant portion of the nascent polypeptides fails to fold under physiological conditions 
(Schubert et al., 2000). Furthermore, a lot of factors might cause irreversible folding failures, 
such as genetic mutations, transcription and translation errors, physical stress (e.g. temperature 
stress and osmotic stress) and chemical stress (e.g. toxic compounds).  Thus, cells have to 
consistently deal with folding-incompetent proteins. It is very unlikely that cellular machinery 
would allow those problematic molecules to go through unlimited folding cycles. Molecules that 
fail to fold are actually eliminated by the protein quality control (PQC) machinery. The decision 
to terminate folding plays a pivotal role in preventing futile folding cycles from consuming 
limited chaperone and energy resources needed for ongoing the protein synthesis. Although 
 3 
 
protein folding termination is recognized as a critical facet of cellular protein homeostasis, its 
mechanism is currently little known. 
 
The PQC machineries in different organelles, such as the endoplasmic reticulum (ER), Golgi, 
mitochondria, plasma membrane, cytosol and nucleus, have been identified and characterized. 
Among them, the endoplasmic reticulum protein quality (ERQC) machinery is the best 
characterized. The ER is a major site of protein folding. Around one third of the proteins in 
eukaryotic cells are targeted to the secretory pathway and are primarily folded and assembled in 
the ER. There, with the help of ER chaperones, the properly folded proteins are sent to their 
destination while misfolded proteins are recognized and removed by the ERQC system.  Unlike 
the poorly defined PQC system in cytosol, mitochondria or nucleus, most of the factors involved 
in ER protein folding, modification and degradation are known. Thus, it represents a better 
system to probe the unknown protein termination machinery.  
 
In the following sections, I will describe the emergence and maturation of the ERQC field. The 
current knowledge about ERQC, including ER protein folding and degradation, will be 
summarized. I will also highlight how the rational design of ERQC substrates drives the 
development of field. 
 
1.3 ER protein quality control and degradation 
1.3.1 The emergence of ER protein quality control: a brief reflection 
The concept of ERQC was emerged in the 1980s. Previously, it was believed that all the 
misfolded proteins in the secretory pathways were targeted to the lysosome for degradation. It 
was a reasonable hypothesis. First, neither proteases nor proteasomes were found in the ER, and 
thus, it was very unlikely that misfolded proteins were degraded inside the ER. Second, there 
was no evidence showing that any ER proteins could be retrotranslocated into the cytosol for 
degradation. Third, it has already been established that abnormal organelles or proteins were 
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engulfed and digested in the lysosome through the autophagy pathway. Collectively, it was 
expected that misfolded secretory proteins were exclusively delivered to the lysosome for 
degradation.   
 
The emergence of the concept of ERQC came from the work of T cell antigen receptor (TCR) 
assembly and processing (Lippincott-Schwartz et al., 1988). TCR is a plasma membrane protein 
complex of T lymphocytes, which is able to recognize the major histocompatibility complex 
(MHC) bound antigens. This complex consists of seven chains (α, β, γ, δ, ε, ζ2) (Samelson et al., 
1985). The α and β subunits form heterodimers via disulfide links, which are required for antigen 
recognition. The additional associated γ, δ, ε, and homodimeric ζ chains are important for the 
signal transduction of the complex. Studies on the assembly of TCR complex from the 
Klausner’s group found that different chains are not synthesized stoichiometrically (Minami et 
al., 1987). Rather, α, β, γ, δ, and ε chains are in excess over ζ chains. Only around 10% of the 
receptors could form heptameric complexes and be transported to the plasma membrane. This 
implies that the unassembled chains have to be degraded (Sussman et al., 1988). A following 
study showed that both the lysosomal pathway and a pre-Golgi degradative pathway are involved 
in the turnover of the unassembled chains (Lippincott-Schwartz et al., 1988). Importantly, the 
pre-Golgi degradative pathway is not blocked by lysosomal protease inhibitors. Thus, these 
findings strongly suggest the existence of an ER-based protein quality control mechanism. Such 
a mechanism was further confirmed by subsequent studies. It was found that the degradation of 
unassembled human asialoglycoprotein receptor (AGPR), truncated Ribophorin I, alpha-1 
antitrypsin (AAT) mutant protein, non-glycosylated yeast pheromone pro-α-factor, and 3-
hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA) are housed in the ER, which is not 
sensitive to lysosomal protease inhibitors or ER-to-Golgi transportation inhibitors (Amara et al., 
1989; Caplan et al., 1991; Chun et al., 1990; Le et al., 1990; Tsao et al., 1992). 
 
Importantly, early studies also found that ER chaperones, particularly Bip (immunoglobulin 
heavy-chain binding protein), are associated with unassembled or misfolded proteins. Bip was 
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initially identified from pre-B lymphocytes (Haas and Wabl, 1983). It binds to free 
immunoglobulin heavy (IgH) chains non-covalently but not IgH that are associated with light 
chains. Because the Bip binding with IgH occurs in a post-translational manner and could be 
released by the addition of ATP, it was proposed that Bip is involved in protein assembly and 
retention in the secretory pathway (Bole et al., 1986; Munro and Pelham, 1986). In addition, Bip 
can associate with wild type proteins while they are folding. Studies on hemagglutinin-
neuraminidase (HN) glycoprotein assembly showed that Bip specifically recognizes and 
transiently associates with unfolded HN molecules during the folding process (Ng et al., 1989). 
Bip expression can be induced by the presence of misfolded proteins (Kozutsumi et al., 1988). It 
was shown that Bip binds misfolded proteins until they are degraded (Hurtley et al., 1989). 
Interestingly, it was also found that Bip can associate with incorrectly N-linked glycosylated 
proteins, which suggests the roles of N-linked glycosylation in protein folding and retention 
(Dorner et al., 1987; Ng et al., 1990). The Bip association with aberrantly folded or aberrantly 
glycosylated proteins can be in vitro reconstituted (Kassenbrock et al., 1988). Intriguingly, 
Kassenbrock et al. pointed out that “Bip’s characteristic association with aberrant proteins is 
more likely to be due to a futile attempt to correct their aberration than a preference for their 
company”. This study has not only provided convincing evidence to elucidate the roles of Bip in 
protein folding but also asked a fundamental question, that is, how the futile attempts of Bip 
association with incorrectly folded proteins could be terminated in vivo. Apart from Bip, other 
chaperones, such as GRP94 and calnexin, were also shown to participate in ER protein folding 
and quality control and would be discussed later (Hebert et al., 1995; Kozutsumi et al., 1988). 
 
Even though accumulating evidence showed that misfolded proteins can be recognized and 
retained by ER chaperones and degraded by the ER-centered quality control machinery, how the 
degradation was carried out was still not clear at that time. Are there any ER proteases that 
specifically degrade misfolded proteins? Some studies had proposed the existence of such 
proteases but it later turned out to be wrong (Lindquist et al., 1998; Urade et al., 1992). 
Serendipitously, the big leap in understanding the degradation process came from a genetic 
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study. Sommer and Jentsch found that loss of Ubc6p function suppresses the temperature 
sensitive phenotype and translocation defects in a sec61 mutant (Sommer and Jentsch, 1993). 
Ubc6p is an integral ER resident membrane protein, which is a ubiquitin-conjugating enzyme. 
The mutant form of sec61p was shown to be degraded by the ubiquitin-proteasome pathway 
(Biederer et al., 1996).  This explained why the mutation of ubc6 stabilizes the Sec61p mutant 
and rescues the translocation defects at restrictive temperature. Because Ubc6p has a cytosolic 
catalytic domain and yeast proteosomes are present in the cytosol and nucleus, these studies 
suggest that the degradation of ER membrane proteins might require the involvement of 
cytosolic factors. In mammalian cells, it was found that a mutant form of the cystic fibrosis 
transmembrane conductance regulator (CFTR) in the ER is also degraded via the ubiquitin-
proteasome pathway (Ward et al., 1995). Hampton and Rine showed that this conserved 
degradation pathway regulates the physiological sterol level by modulating the turnover of 
HMG-CoA reductase, the rate limiting enzyme of sterol biosynthesis (Hampton and Rine, 1994).  
 
The conclusive evidence that showed misfolded ER proteins were transported back, in other 
words, retrotranslocated to the cytosol for degradation were still missing at that time. The 
misfolded soluble glycoproteins were proven to be good candidates to demonstrate the existence 
of retrotranslocation. Wolf and colleagues developed two mutated soluble glycoproteins in yeast, 
carboxypeptidase Y (CPY*) and proteinase A (PrA*) (Finger et al., 1993). Interestingly, the 
glycosylated species of these two proteins were found to be ubiquitinated and degraded by the 
proteasome (Hiller et al., 1996). The N-linked glycosylation can only occur inside the ER via the 
catalysis of the oligosaccharyl transferase (OST) complex. Thus, the detection of the 
ubiquitinated solube glycoproteins in vivo has provided strong evidence for the existence of 
retrotranslocation. Importantly, such a process could be biochemically recapitulated. MaCracken 
and Brodsky developed an in vitro system to reconstitute the degradation of the non-glycosylated 
pro-α-factor (McCracken and Brodsky, 1996). It was found that the degradation requires the 
involvement of cystosol, ATP, calnexin and proteasome (McCracken and Brodsky, 1996; 
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Werner et al., 1996). Thus, it is clear that the misfolded ER proteins need to be retrotranslocated 
to cytosol for degradation.  
 
Together, the unassembled or misfolded ER proteins could be recognized, retrotranslocated and 
degraded by the ubiquitin-proteasome pathway. Chaperone binding and glycosylation were also 
shown to be involved in this process. Since then, chaperones, glycosylation and degradation 
machineries as well as their interplays have become the key topics of ERQC.  
1.3.2 ERAD: defining by various of engineered substrates 
 
Since compelling evidence showed the existence of the ER associated degradation (ERAD) 
machinery, several laboratories initiated the efforts to identify the components of ERAD. By that 
time, there were a handful of ERAD substrates characterized by the early studies. Mutant cells 
defective in ERAD should accumulate the substrate and show relevant phenotypes. Based on the 
phenotypes, ERAD mutant alleles could be isolated and cloned by genetic complementation. 
Thus, budding yeast served as an ideal system to identify novel ERAD components. 
 
As discussed above, Wolf and colleagues characterized CPY* and PrA* as two soluble yeast 
ERAD substrates (Finger et al., 1993). The steady state level of these two misfolded proteins was 
higher in ERAD mutants than in wild type cells. Thus, genetic screen was designed to search for 
der (degradation in the ER) mutants that accumulated those two proteins (Knop et al., 1996).  
They isolated a set of der mutants. Der1 encodes an ER transmembrane protein which is required 
for the degradation of CPY* and PrA*.  The second gene emerged from the screen was der2, 
which is identical to ubc7 and encodes a soluble ubiquitin-conjugating enzyme (Hiller et al., 
1996). Because the ubiquitin-conjugating enzyme form covalent bond with ubiquitin with the 
presence of ATP, Ubc7p was immobilized by ubiquitin and served as a bait to search for novel 
factors that were associated with the machinery. Using the ubiquitin affinity chromatography, 
Sommer and colleagues identified a new membrane protein, called Cue1p (factor for coupling of 
ubiquitin conjugation to ER degradation) (Biederer et al., 1997). Cue1p recruits Ubc7p to the ER 
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outer membrane. In Δcue1 cells, Ubc7p is mislocalized in the cytosol. The third gene cloned 
from the screen was named der3, which is an ubiquitin ligase and will be discussed in the 
following paragraph (Bordallo et al., 1998). 
 
Hampton et. al. designed a genetic selection based on the property of another ERAD substate, 
HMG-CoA reductase, to search for hrd (HMG-CoA reductase degradation) mutants (Hampton et 
al., 1996). HMG-CoA reductase is the rate limiting enzyme for cholesterol synthesis in the 
mevalonate pathway and is essential for yeast and mammalian cells. They designed a genetic 
selection to search for mutants that were resistant to HMG-CoA reductase inhibitors (e.g. 
lovastatin) due to deficiency in HMG-CoA reductase degradation. Three hrd genes were cloned, 
all of which were novel candidates for ERAD. Hrd1, which was also isolated from the der 
mutants and designated as der3, encodes a ubiquitin ligase. The N terminus of Hrd1p contains 
the transmembrane segments and the C terminus contains a cytosolic RING-H2 finger motif 
(Bordallo et al., 1998). The RING-H2 finger motif is also present in some other soluble ubiquitin 
ligases and is critical for the enzyme activity. Hrd1p was the first characterized ubiquitin ligase 
for ERAD and was shown to have the ubiquitin-ligase activity in vitro and in vivo (Bays et al., 
2001).  Hrd2 encodes a protein which is a subunit of 26S proteasome (Hampton et al., 1996). 
Hrd3p forms a stoichiometric complex with Hrd1p (Gardner et al., 2000). Such an interaction not 
only regulates the enzyme activity of Hrd1p but also stabilizes Hrd1p in the ER membrane.  
 
Another ubiquitin ligase of ERAD, Doa10p, was identified through a genetic selection for doa 
(degradation of alpha2) mutants (Swanson et al., 2001). Alpha2p is a transcription factor that 
regulates yeast mating specific genes and is degraded quickly thorough the ubiquitin-proteasome 
pathway (Chen et al., 1993). It was found that the first 62 residues of alpha2p contain a 
degradation signal, which is named Deg1. Thus, any Deg1-containing protein can be quickly 
degraded by the ubiquitin-proteasome pathway. Hochstrasser and colleagues engineered wild 
type yeast cells by fusing ura3 with Deg1 (Swanson et al., 2001).  Cells that have intact 
ubiquitin-proteasome pathways degrade Deg1-Ura3p quickly and display uracil auxotroph while 
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mutant cells that fail to degrade Deg1-Ura3p grow normally in the absence of uracil. Doa10p 
emerged as a novel ubiquitin ligase from the selection. It turned out that Doa10p is not only 
required for the Deg1-containing protein degradation but also necessary for the degradation of 
some ER proteins.  
 
How did those ERAD factors organized together to eliminate ER proteins? Were there any 
specific ERAD pathways? To address this issue, Vashist and Ng generated a set of ERAD 
substrates with distinct lesion sites and tested their degradation dependency on the known ERAD 
factors (Vashist and Ng, 2004). They found that misfolded proteins with luminal lesions require 
Cue1p, Der1p, Hrd1p, and Htm1p for degradation while only Cue1p and Doa10p are necessary 
for the degradation of misfolded proteins with cytosolic lesions. Hence, at least two distinct 
ERAD pathways should exist, which are designated as ERAD-L (ERAD-Luminal) and ERAD-C 
(ERAD-Cytosolic). Interestingly, a chimeric protein with both luminal and cytosolic lesions was 
primarily degraded through the ERAD-C pathway, which suggests the existence of a sequential 
checkpoint mechanism for ERQC. 
 
Together, a rough picture of the ERAD pathways was defined with those engineered substrates, 
which indicates the importance of substrate design on the study of ERQC.  
1.3.3 ERAD: a clear picture 
 
Even though the ERAD components were known to fall into two functional groups, their 
biochemical interaction and organization were still not clear. Furthermore, biochemical evidence 
was needed to verify the existence of these two distinct ERAD pathways. Rapoport’s and 
Weissman’s groups independently defined ERAD system biochemically and uncovered the 
mechanistic differences between different ERAD pathways using the budding yeast system. The 
function of the ERAD components would be briefly mentioned here and discussed in a more 
detailed way later.  
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Rapoport and colleagues fused the two ubiquitin ligases of ERAD, Doa10p and Hrd1p, with 
tandem affinity purification (TAP) tags, performed TAP purification, and identified their binding 
partners with mass spectrometry (Carvalho et al., 2006) (Figure 1-1). Doa10p interacts with both 
Ubc7p and Ubx2p. Ubc7p requires Cue1p to be attached to the ER membrane. Ubx2p links the 
cytosolic Cdc48-Ufd1-Npl4 complex to the machinery. The Cdc48-Ufd1-Npl4 complex provides 
the driving force for substrate retrotranslocation. Importantly, the function groups of all the 
components of the Doa10p complex are facing the cytosolic side, which provides strong 
evidence for its function in the ERAD-C pathway. The Hrd1p complex shares some similarities 
with the Doa10p complex, but turns to be more complicated. Cue1p was also found to recruit 
Ubc7p to Hrd1p and, similarly, Cdc48-Ufd1-Npl4 complex associates with the machinery 
through Ubx2p. Interestingly, a novel ERAD component, Usa1p, was identified, which is a 
transmembrane protein with a large cytosolic domain. Usa1p functions as a linker that bridges 
Der1p to the stoichiometric Hrd1p/Hrd3p core complex. In Δusa1 cells, Der1p fails to associate 
with the Hrd1p/Hrd3p core complex. The luminal domain of Hrd3p interacts with an ER lectin, 
Yos9p, which is able to bind to the glycan of misfolded glycoproteins directly and target them to 
the Hrd1p complex. In such a way, the Hrd1p complex is organized to function in the ERAD-L 
pathway. Furthermore, it was found that both Der1p and Usa1p are dispensable for the 
degradation of membrane proteins with intramembrane lesions or mutations adjacent to the 
transmembrane domain, which indicates the existence of an ERAD-M pathway (Figure 1-1). The 
ERAD-M pathway was further verified by the generation of specific hrd1 mutants, in which only 
ERAD-M pathway, but not ERAD-L pathway, was impaired (Sato et al., 2009).  
  
Weissman and colleagues took a similar biochemical approach but started the native purification 
with Yos9p rather than the ubiquitin ligases (Denic et al., 2006). Apart from the factors that 
Rapoport’s group found in the ERAD-L pathway, two additional factors, Kar2p and Emp47p, 
were identified (Figure 1-1). Yos9p forms a stable complex with the luminal domain of Hrd3p. 
As such, Yos9p is directly connected with the degradation machinery, which indicates the 





Figure 1-1 The Doa10 and Hrd1 complexes in yeast. 
 
The components and organization patterns of the Doa10 (top) and Hrd1 (bottom) complexes are 
illustrated. The ERAD-C pathway is dependent on the Doa10 complex while the Hrd1 complex 
is required for both ERAD-L and ERAD-M pathways.  
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Yos9p and Hrd3p bind to misfolded proteins independently of each other. In the meantime, Yos9 
also interacts with Kar2p, the yeast homologue of Bip. Kar2p has been shown to be required for 
ERAD to prevent misfolded proteins forming aggregates (Kabani et al., 2003). Emp47p is an 
integral membrane component of the COPII- vesicles. The association of Emp47p with the 
Hrd1p complex might be related to some ERAD-L substrates that are transported between ER 
and Golgi before degradation (Vashist et al., 2001). Interestingly, overexpression of Hrd1p 
partially bypasses Hrd3p function and renders Yos9p to be dispensable for misfolded 
glycoprotein degradation. Furthermore, promiscuous degradation of an otherwise stable protein 
was observed when Hrd1p was overexpressed in hrd3 mutants, which suggests the role of Hrd3p 
in regulating Hrd1p activity. Thus, the Kar2p-Yos9p-Hrd3p complex might function as a luminal 
gatekeeper that specifically targets terminally misfolded proteins for ERAD. 
 
Together, these two seminal studies provided a clear picture about organization of the ERAD 
system. Similar machineries were also found in mammalian cells but with more complexity.  
1.3.4 Soluble glycoprotein folding and destruction: fold now or never! 
 
Even though the major components of ERAD were identified and classified into three distinct 
pathways, how the cells made a decision to destroy a folding molecule was still not clear. 
Specifically, there should be a sorting mechanism which is able to differentiate folding-disabled 
molecules from folding intermediates. So far, the soluble glycoprotein folding and degradation 
mechanism is arguably the best understood in ERQC. 
 
A bioinformatic study showed that glycoproteins account for more than half of the eukaryotic 
proteome, and around 90% of which are N-linked glycosylated (Apweiler et al., 1999). Apart 
from N-linked glycosylation, O-linked glycosylations, C-mannosylation and 
glycosylphosphatidylinositol (GPI)-anchor are also found (Maeda and Kinoshita, 2008). Among 
them, N- and O-linked glycosylations are proposed to be involved in ERQC. Here, only roles of 
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N-linked glycosylation in ERQC are discussed and the roles of O-linked glycosylation will be 
discussed in the following section. 
1.3.4.1 N-glycan trimming and soluble glycoprotein folding 
 
In eukaryotic cells, when the polypeptide is translocating into ER, the evolutionarily conserved 
oligosaccharyl transferase complex (OST) covalently transfers the N-glycan, Glc3Man9GlcNAc2 
(glucose3-mannose9-N-acetylglucosamine2), to the Asn of the specific Asn-X-Ser/Thr motif (X 
could be any amino acid but not Proline) (Helenius and Aebi, 2004). It should be noted that N-
linked glycosylation can occur in both co-translational and post-translational manners, while the 
co-translational modification is the dominant case. The N-glycans are synthesized by a series of 
reactions that are carried out on the both sides of the ER membrane. Interestingly, the core 
oligosaccharide, which consists seven sugars (Man5GlcNAc2), is first synthesized on the 
cytosolic face of the leaflet and then translocated into the luminal side by the catalysis of flippase 
(Helenius et al., 2002). The additional four mannose and three glucose residues are added by the 
glycosyltransferases with luminal enzyme active sites. The detailed branch structure of the newly 
synthesized N-glycan is illustrated in Figure 1-2.  
 
During the folding process, the two outermost glucose residues are sequentially removed by the 
glucosidase I and glucosidase II in mammals. The first glucose is rapidly removed by 
glucosidase I. The efficient trimming of the second glucose by glucosidase II requires the 
existence of an additional N-glycan (Deprez et al., 2005). This suggests the second glucose 
trimming is a regulated process. Adding sugars to the newly synthesized polypeptides first but 
removing them subsequently seems to be a waste of energy for the cells. But it turns out that the 
sugar-trimming serves as an indicator for the ERQC machinery. Specifically, the 
monoglycosylated glycan generated by glucosidase II acts as a ligand and directs the folding 
intermediate to interact with the ER chaperons, calnexin and calreticulin. Even though 
calreticulin is a soluble protein and calnexin is a transmembrane protein, the luminal domain of 
calnexin, which contains the substrate binding domain, shares high sequence similarity with 
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calreticulin (Helenius et al., 1997). Such a similarity explains their overlaps in substrate binding 
(Vassilakos et al., 1998). Using hemagglutinin (HA) of influenza virus as a model substrate, 
Helenius and colleagues showed that only the folding intermediates of HA with 
monoglycosylated glycans could transiently associate with calnexin and calreticulin (Hammond 
et al., 1994; Peterson et al., 1995).  The cycles of calnexin/calreticulin binding and releasing 
retain the incompletely fold molecules and prevent the aggregation and degradation, and thus 
promote protein folding (Hebert et al., 1996).  Calnexin and calreticulin can also function as 
chaperones, even without the lectin function (Ireland et al., 2008; Leach and Williams, 2004). In 
the meantime, calnexin/calreticulin recruits a thiol-disulfide oxidoreductase, named ERp57, to 
assist the folding intermediate to form disulfide bridges. In turn, ERp57 also requires 
calnexin/calreticulin for substrate recognition (Jessop et al., 2009). Interestingly, the activity of 
calnexin can be regulated by a post-translational modification, named palmitoylation. The 
palmitoylated calnexin is targeted to the mitochondria-associated membrane (MAM) region to 
facilitate the calcium exchange from ER to mitochondria or is associated with the ribosome-
translocon complex to assist the newly synthesized glycoprotein folding (Lakkaraju et al., 2012; 
Lynes et al., 2012). Upon ER stress, the plamitoylated calnexin in the MAM region will quickly 
undergo de-plamitoylation and re-associated with ERp57 to facilitate protein folding (Lynes et 
al., 2013).  
 
To be out of the calnexin/calreticulin binding cycles, the remaining glucose residue of the 
monoglycosylated glycan needs to be trimmed by glucosidase II. If the released molecule still 
fails to reach its native status, a luminal enzyme, named UDP-glucose:glycoprotein 
glucosyltransferase (GT), could re-glycosylate the glycan and send it back to the 
calnexin/calreticulin binding cycles (D'Alessio et al., 2010). How does GT function to sense 
protein folding and specifically re-glycosylated the incompletely folded molecules? Studies on 
the substrate binding preference of GT showed that GT will only bind and re-glycosylate 
glycoproteins that nearly complete the folding rather than the well-folded or severely misfolded 
proteins (Caramelo et al., 2004; Ritter et al., 2005). Currently, little is known about how GT 
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could act as such a precise protein folding sensor, which perceives the folding potential of the 
intermediates and specifically targets proteins with mild folding defects back to the 
calnexin/calreticulin binding cycles. Presumably, there might be a substrate binding competition 
between GT and other ERQC factors. For example, the folding intermediates that extensively 
expose their hydrophobic patches might be recognized by the ER mannosidase I (ERManI) and 
ER degradation-enhancing α-mannosidase-like lectins (EDEMs) and receive progressive 
mannose trimming. Once the terminal mannose residues are removed, the re-glycosylation of 
efficiency of GT is drastically decreased in cell-free assays (Sousa et al., 1992). Due to a lack of 
re-mannosylation mechanism on the trimmed N-glycan, the modification carried out by ERManI 
and EDEMs virtually terminates the calnexin/calreticulin folding cycles. Alternatively, it is also 
possible that the grossly misfolded proteins are recognized by ER chaperones. The chaperon 
binding prevents aggregate formation, which in turn blocks the GT binding. Nevertheless, the 
termination mechanism of calnexin/calreticulin mediated folding cycles is not well understood.  
1.3.4.2 The mannose timing mechanism for glycoprotein breakdown  
 
In budding yeast, the glucose trimming process is relatively simpler and the calnexin/calreticulin 
functional equivalent homologues are not found. The three outermost glucose residues are 
sequentially removed by glucosidase 1 and 2 (Gls1p and Gls2p) to generate the Man9GlcNAc2 
(Figure 1-2). It is believed that this glycan protects the nascent polypeptides from disposal and 
the ER chaperone system assists in protein folding accordingly. The yeast work on the 
subsequent mannose trimming provides mechanistic insights into how the cells make a decision 
to destroy a soluble glycoprotein.  
 
The mannose residue from the B branch of Man9GlcNAc2 glycan is trimmed by the yeast 
homologue of ERManI, Mns1p. Interestingly, analysis of the glycan processing of CPY in vivo 
showed that the glucose-trimming by Gls1p and Gls2p occurs rapidly while the mannose 
cleavage mediated by Mns1p is quite slow (Jakob et al., 1998). Moreover, in this case, the glycan 





Figure 1-2 The trimming of N-glycan during protein folding and degradation. 
 
The N-glycan trimming during protein folding and degradation in yeast and mammals is similar 
to each other. The enzymes involved in this process are also evolutionary conserved. However, 
in mammals, glucosyltransferase (GT) will send the glycoproteins that have not reached their 
native status back to the calnexin/calreticulin binding and releasing cycles, which has not been 
found in yeast. The extensive mannose trimming process defines a time window that allows the 
protein to fold. Proteins that exceed the time window are trimmed by Htm1/EDEMs and thus 
expose the terminal α 1,6-linked mannose, which is highlighted by a red circle. The exposed α 
1,6-linked mannose serves as a degradation signal that triggers the degradation.  
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structure is associated with the turnover of CPY* (Jakob et al., 1998). Either disruption of 
glucose trimming or mutation of mns1 impairs the degradation of misfolded glycoproteins. Thus, 
this slow mannose-trimming process is believed to provide a time window for the cells to make 
decisions to select folding-disabled molecules and target them for degradation. In an effort to 
search for the proteins with similarity to Mns1p, Htm1p (homologous to mannosidase 1) was 
identified (Jakob et al., 2001; Nakatsukasa et al., 2001). Because the disruption of htm1 only 
affected glycoprotein breakdown but did not delay the turnover of misfolded non-glycoprotein, it 
was proposed that Htm1p acted as a Man8GlcNAc2 binding lectin that initiated glycoprotein 
degradation. However, a previous study showed that the Man8GlcNAc2 glycan is the essential 
intermediate during the mannose trimming process (Byrd et al., 1982). If such a predominant 
structure of glycan could be recognized by lectin and targeted for degradation, the ERQC 
machinery would have no substrate specificity. Later, it was found that Htm1p functions in 
trimming the mannose residue from the C branch of Man8GlcNAc2, to generate Man7GlcNAc2 
(Clerc et al., 2009). The Man7GlcNAc2 structure is specifically recognized by the lectin, Yos9p, 
which targets the substrate for degradation (Bhamidipati et al., 2005; Kim et al., 2005; 
Szathmary et al., 2005). Importantly, Yos9p can specifically recognize glycans with a terminal 
α1,6-linked mannose, which can only be generated by Htm1p but not Mns1p trimming (Quan et 
al., 2008). Disruption in the carbohydrate binding domain of Yos9p impairs the turnover of 
misfolded glycoproteins. Interestingly, it was recently shown that Htm1p interacts the protein 
disulfide isomerase (Pdi1p), an enzyme that is essential for disulfide bond formation and protein 
folding inside the ER (Clerc et al., 2009). Such an association retains Htm1p within the ER 
(Gauss et al., 2011). In a specific pdi1 allele, named pdi1-1, in which the association is disrupted, 
Htm1p cannot be retained in the ER due to a lack of retention signal, and thus, its stability 
decreases. More importantly, the pdi1-1 mutation diminishes Htm1p activity in vivo, which 
delays the degradation of misfolded glycoproteins. Because Pdi1p is synthesized in excess over 
Htm1p, only a small amount of Pdi1p is associated with Htm1p. Even though the folding 
intermediates carrying the Man8GlcNAc2 have similar binding affinity with free Pdi1p and 
Htm1p bound Pdi1p, only the polypeptides with prolonged folding would have higher chance to 
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be encountered with Pdi1p-Htm1p and be flagged for degradation. The involvement of Pdi1p in 
glycoprotein breakdown suggests that protein folding and degradation are not separated but 
interconnected. However, the generation of the glycan with a terminal α1,6-linked mannose is 
not sufficient to trigger glycoprotein breakdown. As discussed above, the core oligosaccharide, 
Man5GlcNAc2, that is flipped into the lumen, contains a terminal α1,6-linked mannose at the C 
branch. This intermediate oligosaccharide is firstly modified by Alg3p (Verostek et al., 1991). 
Thus, all glycoproteins would carry the “lethal” glycans in ∆alg3 cells. Interestingly, it was 
observed that the degradation of misfolded glycoproteins in ∆alg3 cells is accelerated while the 
wild type glycoproteins are stable (Clerc et al., 2009). Such an observation indicates that there 
should be an additional determinant that flags misfolded glycoproteins for degradation. 
Systematical analysis of protein regions adjacent to the glycans showed that the terminal α1,6-
linked mannose can only be recognized if the glycan is attached to a disordered protein region 
(Xie et al., 2009). The exposure of the unfolded structure not only reflects the folding status of 
the proteins but also make the Man7GlcNAc2 glycan accessible to the ERAD machinery (Figure 
1-3). This finding also explains why only one N-glycan is important for the turnover of CPY* 
and PrA*, even though they contain multiple N-glycans (Spear and Ng, 2005). 
 
Together, a sequential manner of a specific N-glycan processing not only allows wild type 
glycoproteins to fold inside the ER by providing a reasonable time window, but also selects 
folding-disabled molecules, which are featured with prolonged exposure of a Man7GlcNAc2 
glycan in an unfolded region, for degradation (Figure 1-3). Such a timer set by mannose 
trimming is termed as “mannose timer”. 
 
Similar mannose trimming process is also utilized by mammals for glycoprotein quality control. 
Even though some recent studies indicated that ERManI might localize at Golgi rather than ER, 
the function of ERManI is very similar to the yeast Mns1p (Pan et al., 2013; Pan et al., 2011). It 





Figure 1-3 The stochastic model of soluble glycoprotein recognition and degradation in 
ERAD-L. 
 
When the polypeptide is emerging from the ribosome and translocating into the ER lumen 
through the Sec61 pore complex, the oligosaccharyl transferase (OST) transfers the N-glycan to 
the modification motif. Chaperones, such as Bip and PDI, assist the protein folding through 
cycles of binding and releasing. During the folding process, the three outer most glucose residues 
and one mannose residue are gradually removed. Protein has to fold efficiently to pack the 
unfolded structure (in red) and the adjacent N-glycan. The fully folded protein is released out of 
the folding cycles and targeted to the site of function. However, if the protein stay unfolded over 
the time, the N-glycan adjacent to unfolded structure will have higher possibility to be 
recognized by the Pdi1p-Htm1p complex. The Htm1p further modifies the N-glycan and 
generates the terminal α 1,6-linked mannose. The Bip that associates with the unfolded structure 
will present the protein to the Hrd1 complex, which eventually triggers the degradation.  
 20 
 
may not be sufficient to trigger glycoprotein breakdown, because ERManI can only trim the 
mannose residue from the B branch of the Man9GlcNAc2 and substrates that are targeted to 
ERAD carrying the Man5-6GlcNAc2 structure (Frenkel et al., 2003). However, Lederkremer and 
colleagues argued that, in vitro, it is true that ERManI can only excise one mannose residue at 
low concentration, but at very high concentration, ERManI can remove up to four α1,2-linked 
mannose residues (Avezov et al., 2008). In vivo, they found that ERManI co-localized with the 
misfolded glycproteins at a sub-area of ER in a very concentrated manner. Thus, the local 
concentration of ERManI might be high enough to generate the Man5-6GlcNAc2 glycan, which is 
required for ERAD recognition. Even though further evidence is needed, it is clear that the 
generation of Man8GlcNAc2 is neither sufficient for yeast ERAD nor mammalian ERAD.  
 
Followed by the ERManI trimming, the progressive mannose trimming is carried out by the ER 
degradation-enhancing α-mannosidase-like lectins (EDEMs), which include EDEM1/2/3 (Figure 
1-2). Like their yeast homologue Htm1p, all of them contain the conserved mannosidase 
homology domain (MHD) (Kanehara et al., 2007). However, the roles of each EDEM might be 
different. Unlike ERManI, the expression of EDEM1 can be induced by various ER stress 
(Hosokawa et al., 2001).  EDEM1 can directly bind with misfolded glycoproteins and 
overexpression of EDEM1 accelerates ERAD (Hosokawa et al., 2001). Subsequent studies found 
that EDEM1 interacts with calnexin to release the folding-disabled molecules from the 
unproductive folding cycles and promotes the degradation (Molinari et al., 2003; Oda et al., 
2003). This explains why overexpression of EDEM1 promotes degradation. Analysis of the N-
glycan processing of misfolded null Hong Kong α1-antitrypsin (NHK) revealed that EDEM1 
functions to remove the mannose residue from the C branch of the N-glycan (Hosokawa et al., 
2010). Interestingly, overexperssion of a variant of EDEM1, in which the α 1,2-mannosidase 
activity is abolished, is still able to enhance ERAD. This suggests that EDEM 1 has an additional 
role in ERAD apart from mannose trimming. Indeed, it was found that EDEM1 can prevent 
aggregation of NHK and such an activity is also intact in the mannosidase defective mutant 
(Hosokawa et al., 2010; Olivari et al., 2006). To search for the novel factors that trigger 
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glycoprotein breakdown, EDEM2 and EDEM3 were identified by analysis of the homologues of 
EDEM1. Like EDEM 1, EDEM2 is also a stress-regulated protein, which associates with the 
misfolded glycoprotein and promotes degradation by taking them out of the calnexin cycles 
(Mast et al., 2005; Olivari et al., 2005). However, no 1,2-mannosidease activity of EDEM2 could 
be detected (Mast et al., 2005). EDEM3 has the 1,2-mannosidease activity. Overexpression of 
EDEM3 enhances the mannose trimming of both misfolded and wild type glycoproteins and 
generates Man5-7GlcNAc2 glycans (Hirao et al., 2006). As such, EDEM3 promotes the turnover 
of misfolded glycoproteins. Unlike EDEM1, EDEM3 does not have an additional chaperone-like 
function, because disruption of the mannosidase activity fully abolishes EDEM3’s role in ERAD 
(Hirao et al., 2006).  
 
After the extensive mannose trimming, the misfolded glycoproteins can be recognized by the 
mammalian Yos9 homologues, OS-9 and XTP3-B (Christianson et al., 2008). Like their yeast 
homologue, they all share a mannose-6 phosphate receptor homology (MRH) domain, which is 
able to bind to the exposed terminal α-1,6 linked mannose residue. However, OS-9 and XTP3-B 
only share around 23% identity regarding their primary amino acid sequences. Similar to Yos9p, 
both of them are associated with the HRD1 complex through the lumen domain of SEL1L, the 
mammalian homologue of yeast Hrd3p. These two lectins also associate with the ER chaperones, 
but in a different manner. XTP3-B forms a stable complex with both SEL1L and Bip, which is 
reminiscent of the Kar2p/Yos9p/Hrd3p gatekeeper identified by Weissman’s group in yeast 
(Hosokawa et al., 2008). OS-9 can interact with Bip and GRP94, the ER-resident Hsp90. But 
such an interaction is mutually exclusive from the interaction with SEL1L. Even though OS-9 
and XTP3-B have relative low sequence similarity and assemble with the ERAD components in 
a different way, whether they have distinct function in ERAD is still not clear. The ERAD 
defects caused by silencing either OS-9 or XTB-3B are mild, if not ignorable, but can be 
exacerbated by knocking them down together (Bernasconi et al., 2010; Christianson et al., 2008). 
This result might suggest that OS-9 and XTP-3B have redundant functions. Whether an 
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additional structural determinant is required, like the yeast, to present the trimmed glycan to the 
degradation machinery is not known.  
 
Together, it is clear that targeting the soluble glycoprotein for degradation is based on an 
evolutionarily conserved ligand-receptor-like mechanism. The generation of degradation ligand 
is mediated by multiple steps of mannose trimming which in turn defines a time window that 
allows the glycoprotein to fold. Only the proteins that fail to fold in the defined time will receive 
extensive mannose trimming and be targeted for degradation.  
   
Compared with the soluble glycoprotein breakdown, the detailed mechanism of soluble non-
glycoprotein and membrane protein degradation is not well understood. It was found that neither 
Yos9 nor Htm1p is required for the degradation of a soluble non-glycoprotein. For a membrane 
protein, only Hrd1p, Cue1p and Cdc48p are sufficient for the degradation (Kanehara et al., 
2010). This is because the lesion embedded in the transmembrane region could be directly 
detected by the transmembrane domain of Hrd1p (Sato et al., 2009).   It was also found that a 
variant of Yos9p, in which the essential amino acid for carbohydrate binding is mutated, is 
required for the turnover of some non-glycoproteins (Jaenicke et al., 2011). However, how the 
decision is made to target soluble non-glycoproteins or membrane proteins for degradation is not 
known.   
1.3.5 ERAD execution: ubiquitination, retrotranslocation and degradation 
 
From the early works of ERAD, it has been known that the ubiquintin-proteasome system is 
needed to eliminate the unassembled or misfolded ER proteins. And it is the involvement of the 
cytosolic protein degradation system that indicates that targeted ER proteins are retrotranslcoated 
to the cytosol for disposal. As discussed above, the major ubiquitin ligases required for ERAD 
are membrane proteins with their enzyme active sites on the cytoslic leaflet. How is the 
unbiquitin chain attached to the misfolded proteins? Is ubiquitination necessary for 
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retrotranslocation? What is the driving force for retrotranslocation? Finally, and most 
mysteriously, what is/are the retrotranslocons? 
 
Some virus proteins are able to hijack the mammalian ERAD system to specifically destroy host 
proteins that are essential for the immune responses. Ploegh and colleagues found that human 
cytomegalovirus (HCMV) can hijack the ERAD system to degrade the newly synthesized heavy 
chains of the major histocompatibility (MHC) class I molecules by the expression of virus 
protein, US11 or US2 (Wiertz et al., 1996a; Wiertz et al., 1996b). To study how the MHC class I 
heavy chains were retrotranslocated into the cytosol, Rapoport and colleagues developed a 
permeabilized cell system to recapitulate the in vivo experiment (Shamu et al., 1999). Such a 
system enabled the analysis of the cytosolic factors that were required for the retrotranslocation 
and thus delineated the late steps of ERAD.  It was found that polyubiquitination is required for 
the complete dislocation of the substrate from the ER membrane but not for the initiation of the 
dislocation (Flierman et al., 2003; Shamu et al., 2001; Shamu et al., 1999). When the substrate is 
emerging from the cytosolic leaflet of the ER membrane, it is recognized by the conserved 
Cdc48/p97-Ufd1-Npl4 complex (Cdc48 in yeast and p97 in mammals) (Ye et al., 2001). 
Cdc48/p97 is an AAA ATPase, which can utilize ATP and provide the driving force for 
retrotranslocation. Detailed study showed that p97 binds to the non-ubiquitinated substrates at 
the early step of retrotranslocation (Ye et al., 2003). Upon the addition of polyubiquination 
chains to the substrates, the specific lysine 48 linked polyubiquitination chain could be 
recognized by both p97 and Ufd1 through the conserved ubiquitin binding domain. Thus, the 
polyubiquitination of the ERAD substrates might act as a signal to present the substrates to the 
Cdc48/p97-Ufd1-Npl4 complex, which eventually leads to the completion of retrotranslocation 
(Flierman et al., 2003). Compared with the most terminal steps of retrotranslocation discussed 
above, little is known about how the retrotranslocation is initiated. In the case of transmembrane 
protein, the driving force provided by the p97-Ufd1-Npl4 complex is not a prerequisite for the 
initiation of polyubiquitination. Thus, there might be a factor from the ER luminal side to 
provide the first force to push the protein towards the cytosol.  Such a speculation might also fit 
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for the retrotranslocation of soluble substrates. Neither the polyubiquitin chains nor the p97-
Ufd1-Npl4 complex could get access to the misfolded soluble proteins until they emerge from 
the retrotranslocon. Thus, a pushing force is needed from the luminal side to insert the substrate 
into the retrotranslocon and prevent the backward movement until the substrate becomes 
available to the cytosolic ERAD factors. 
 
Last, but not least, what are the retrotranslocons? There are several candidates postulated. Even 
though the conclusive evidence for each of the candidates is missing, it is very unlikely that there 
would not be a unifying retrotranslocon for all the ERAD substrates. The first proposed 
retrotranlocon is actually the translocon, Sec61 complex. It was originally proposed by 
Rapoport’s and Ploegh’s groups (Wiertz et al., 1996b). Specifically, they showed that the MHC 
class I heavy chain, that was slated for degradation, was co-immunoprecipitated with the Sec61 
channel. Subsequent studies in yeast also support such a conclusion (Gillece et al., 2000; Pilon et 
al., 1997; Plemper et al., 1997; Schafer and Wolf, 2009; Scott and Schekman, 2008). However, 
the role of Sec61 in retrotranslocation may not be in accordance with the structural studies on the 
pore size of Sec61.  The pore size was estimated between 40-60 Å by fluorescence-quenching 
experiments which was subsequently challenged by the structural studies on Sec61 complex led 
by the Rapoport’s group (Hamman et al., 1997; Park and Rapoport, 2012).  The structural 
analysis showed that the pore of the Sec61 translocon is not larger than 15-20 Å, which is too 
narrow to accommodate the glycan on the misfolded protein and thus could not serve as a 
retrotranslocon. Other studies also proposed derlin-1, the mammalian homologue of yeast Der1p, 
as well as Hrd1p to be the potential retrotranslocons (Carvalho et al., 2010; Lilley and Ploegh, 
2004; Ye et al., 2004). The ultimate demonstration of retrotranslocon might require in vitro 
reconstitution of the ERAD with defined components, which is still a daunting challenge due to 
the complexity of the complexes.  
 
After retrotranslocation, the N-glycans of the substrates are removed and the ubiquitin chains are 
further elongated. Subsequently, the substrates are targeted to proteasome for degradation. 
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1.4 ER protein O-mannosylation and quality control 
1.4.1 The discovery of the evolutionary conserved ER-housed protein O-mannosylation. 
 
Compared with N-linked glycosylation, the mechanism of O-mannosylation is not well 
understood. The biological significance of this modification was not appreciated until recently. 
The early work on O-mannosylation can be traced back to 1960s. It was found that the serine 
(Ser) and threonine (Thr) residues of glycopeptides extracted from yeast cell walls were 
covalently attached with O-mannosyl glycans (Sentandreu and Northcote, 1968). The mannose 
or mannose oligosaccharides are bound to Ser or Thr through the hydroxyl group. Even after 
more than four decades’ study, it is still unclear whether there is any consensus amino acid 
sequence for the modification, which is distinct from the well-defined N-linked glycosylation. 
By fractionating the yeast protoplasts and measuring the mannosyltransferase activity of each 
fraction, Tanner and colleagues found that O-mannosylation is initiated in the ER (Marriott and 
Tanner, 1979). To study how the whole mannose oligosaccharides were attached to the protein at 
ER, their following study focused on the O-mannosylation in sec18 mutant cells, in which the 
ER to Golgi transport is blocked at non-permissive temperature (Novick et al., 1980). They 
showed that after the addition of the first mannosyl group in the ER, the elongation of the 
mannose oligosaccharides are carried out in the Golgi (Haselbeck and Tanner, 1983). The 
modification was believed to be fungal specific because the mammalian O-glycosylation was 
thought to occur in Golgi exclusively. Now, it is clear that the ER initiated O-mannosylation as 
well as the respective enzymes are conserved in both fungal and animal kingdoms. 
  
The mannosyl donor, dilichol phosphate β-D-mannose (Dol-P-Man), is synthesized on the ER 
membrane. Dol-P-Man is generated by transferring the mannose residue from GDP-α-D-
mannose to the dilichol phosphate (Dol-P). This reaction is catalyzed by the evolutionarily 
conserved GDP-α-D-mannose: dilichol phosphate β-D-mannosyltransferase. The enzyme, named 
Dpm1p was first identified in S. cerevisiae. It is a transmembrane protein and is essential for the 
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viability of the cell (Orlean et al., 1988). In mammalian cells, two additional DPMs were 
identified, which are required for the optimal activity of GDP-α-D-man:Dol-P-
Mannosyltransferase (Maeda et al., 2000). The Dol-P-Man is synthesized on the cytosolic leaflet 
of the ER membrane and is believed to be flipped into the inner leaflet by an unknown flippase. 
It was proposed that Dpm1p might be involved in the flipping process (Haselbeck and Tanner, 
1982). The flipped Dol-P-Man provides a pool of mannoses that are utilized to elongate the B 
and C branches of the core structure of N-glycans, synthesize glycosylphosphatidylinositol (GPI) 
anchors or add O-mannose.  
 
The transferring of mannose residue from Dol-P-Man to the Ser/Thr residue of the ER proteins is 
carried out by the protein Dol-P-Man:O-mannosyltransferase (PMT) family members. The first 
PMT, termed as Pmt1p, was cloned by Tanner and co-workers from S. cerevisiae (Strahl-
Bolsinger et al., 1993). They took the classic biochemical approaches to fractionate the cell 
homogenate and searched for the fraction in which the mannosyltransferase activity was 
enhanced (Strahl-Bolsinger and Tanner, 1991). It was found the appearance of a 92 kDa protein, 
in the membrane fractions, was correlated with the enzyme activity and appeared to be the 
potential Dol-P-Man:mannosyltransferase. To facilitate the purification of this membrane 
protein, they generated an antibody against the 92 kDa protein with fair specificity (Strahl-
Bolsinger and Tanner, 1991). The antibody was conjugated to protein A-Sepharose beads and 
incubated with the enzyme-enriched fraction for immunoprecipitation. The antibody-bound 
proteins were eluted and different fractions were analyzed by immunoblotting. The fractions that 
enriched the 92 kDa protein were subjected to protein precipitation and SDS-PAGE. The 92 kDa 
band was sequenced by Edman degradation. Subsequently, they designed primers based on the 
peptide sequence and eventually amplified the pmt1 gene from the yeast genomic DNA library.  
Interestingly, they found that the disruption of pmt1 could not fully diminish the Dol-P-
Man:mannosyltransferase activity, which indicates the existence of additional 
mannosyltransferases (Strahl-Bolsinger et al., 1993). The second Dol-P-
Man:mannosyltransferase, Pmt2p, was identified serendipitously. Sequencing of S. cerevisiae 
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chromosome I, the smallest chromosome, identified a set of fun (function unknown now) genes 
(Barton and Kaback, 1994; Ouellette et al., 1993). Among them, fun25 encoded a protein that 
showed high sequence similarity to Pmt1p and the gene was renamed as pmt2 (Lussier et al., 
1995). As expected, the deletion of pmt2 resulted in reduced mannosyltransferase activity. In 
Δpmt1Δpmt2 cells, the mannosyltransferase activity was still detected, and thus, it was 
concluded that the cells should have more than two PMTs. Because pmt1 and pmt2 have similar 
amino acid sequences, it suggests that the homologous region might be important for the enzyme 
activity and should also be present in the unknown Dol-P-Man:mannosyltransferases. To search 
for the additional PMTs, Tanner and colleagues designed primers based on the homologous 
region of pmt1 and pmt2 and successfully indentify two more mannosyltransferases, termed 
Pmt3p and Pmt4p (Immervoll et al., 1995). Pmt5 and pmt6 were identified by sequencing the S. 
cerevisiae chromosome VI and VII respectively (Boskovic et al., 1996; Guerreiro et al., 1996). 
Later, the protein O-mannosyltransferases were also identified in animals, such as Drosophila, 
zebra fish, and human (Ichimiya et al., 2004; Jurado et al., 1999; Manya et al., 2004; Martin-
Blanco and Garcia-Bellido, 1996; Willer et al., 2002).  
 
Together, the identification of the GDP-α-D-man:Dol-P-Mannosyltransferases and Dol-P-
Man:mannosyltransferases, first in yeast and later in mammals, clearly showed the ER-housed 
protein O-mannosylation  is evolutionarily conserved. The further elongation of the sugars 
occurs in Golgi and is carried out by different enzymes throughout evolution. 
 1.4.2 The PMTs interaction and substrates modification in S. cerevisiae 
 
The pioneering work on the interaction among PMTs was done by Tanner’s group with S. 
cerevisiae. After identification of Pmt1p and Pmt2p, Tanner and colleagues studied their 
interaction and found that Pmt1p and Pmt2p form a heterodimer (Gentzsch et al., 1995). 
Overexpression of either of them could not significantly increase the enzyme activity. Rather, the 
enhanced mannosyltransferase activity was observed when Pmt1p and Pmt2p were co-
overexpressed. Hence, the data suggests that the interaction might be important for the optimal 
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mannosyltransferase activity. After they isolated pmt1-pmt4, they crossed the mutants and 
studied the genetic interaction among them (Gentzsch and Tanner, 1996). Some of the double 
mutants and triple mutants were inviable under normal condition. For example, Δpmt2Δpmt3 and 
Δpmt2Δpmt4 but not Δpmt1Δpmt2 showed synthetic lethality under normal condition which 
might indicate that Pmt3p and Pmt4p have distinct function from Pmt1p. The death phenotype of 
these two double mutants could be rescued by the addition of sorbitol to provide osmotic 
stabilization, which indicates the cell wall function is severely impaired in those mutants. 
Interestingly, the two triple mutants, Δpmt2Δpmt3Δpmt4 and Δpmt1Δpmt2Δpmt4, were lethal 
and could not be rescued by sorbitol supplementation. Thus, it was concluded that the 
mannosyltransferase activity is essential for the viability of the cells. Actually, 
mannosyltransferases are also indispensible for vertebrates. It was observed that disruption of the 
mouse Dol-P-Man:mannosyltransferase 1 (Pomt1)  results in failure of embryo development 
(Willer et al., 2004).  
 
The detailed analysis of the biochemical interaction among different PMTs was carried out by 
Strahl-Bolsinger’s group (Girrbach and Strahl, 2003). They generated antibodies that specifically 
recognized each individual Dol-P-Man:mannosyltransferase. The immunoprecipitation results 
showed that Pmt1p interacts with Pmt2p while Pmt3p is associated with Pmt5p. The interaction 
between Pmt1p and Pmt3p was also detected when their interaction partners were genetically 
deleted and so did Pmt2p and Pmt5p. Pmt4p was found to form homodimeric complex. Sequence 
alignment showed that those six PMTs belong to three distinct subfamilies: the PMT1 (Pmt1p 
and Pmt5p), PMT2 (Pmt2p, Pmt3p and Pmt6p) and PMT4 (Pmt4p) subfamilies (Girrbach et al., 
2000). Thus, members of PMT1 and PMT2 subfamilies form heterodimers while Pmt4p form 
homodimers. The different interaction patterns suggest that PMT1/2 subfamily members might 
have distinct function from Pmt4p. This might also explain the previously observed phenomenon 
that combination of mutations from PMT1/2 subfamily members and Pmt4p resulted in cell 




The distinct interaction patterns might also determine their substrate binding specificity even 
though most of their endogenous substrates contain Ser/Thr-rich regions. In PMT1/2 subfamilies, 
Pmt1p and Pmt2p show the predominant protein mannosyltransferase activity and thus their 
clients are better understood than Pmt3p and Pmt5p. The substrates of Pmt1p-Pmt2p are different 
from those of Pmt4p (Gentzsch and Tanner, 1997; Lommel et al., 2004; Proszynski et al., 2004; 
Sanders et al., 1999). In some cases, they modify on the same substrate but the modification 
regions are distinct (Ecker et al., 2003). The substrates of Pmt1p-Pmt2p include soluble and 
membrane proteins while the known substrates of Pmt4p are membrane-bound. Pmt4p 
recognizes the luminal Ser/Thr rich domain that is adjacent to membrane anchoring sequence, 
while the substrate recognition mechanism of Pmt1p-Pmt2p is not clear (Hutzler et al., 2007). 
The different substrate modification preference might be due to the different structural 
organization of the heterodimer and homodimer. Failure in O-mannosylation causes defects in 
various aspects, such as maintenance of cell wall integrity, budding process, protein secretion, 
stabilization of proteins and stress response (Gentzsch and Tanner, 1997; Lommel et al., 2004; 
Petkova et al., 2012; Proszynski et al., 2004; Sanders et al., 1999). For example, the O-
mannosylated plasma membrane proteins, Wsc1p, Wsc2p, Mid2p and Mtl1p, are responsible for 
sensing the integrity of cell wall and activating the protein kinase C (PKC) pathway to maintain 
the cell wall structure (Lommel et al., 2004; Petkova et al., 2012; Philip and Levin, 2001). It was 
shown that Wsc1p, Wsc2p and Mid2p are unstable in Δpmt2Δpmt4 cells due to a lack of O-
mannosylation and thus fail to activate the PKC pathway (Lommel et al., 2004). This explains 
the previously observed lethal phenotype of Δpmt2Δpmt4 cells under normal conditions 
(Gentzsch and Tanner, 1996). The O-mannosylation of Mtl1p is mediated by Pmt1p, Pmt2p and 
Pmt4p, but is mainly catalyzed by Pmt2p (Petkova et al., 2012). Mtl1p requires O-mannosylation 
for maturation and appropriate cellular localization. Mtl1p in the pmt mutants also fails to 
activate the PKC pathway and thus causes cell death under oxidative conditions.   




All the PMTs are ER memberane glycoproteins with seven transmembrane domains (TMD). 
Strahl-Bolsinger and colleagues carried out a serial of detailed analysis of the topology and 
function of Pmt1p (Figure 1-4) (Girrbach and Strahl, 2003; Girrbach et al., 2000; Lommel et al., 
2011; Strahl-Bolsinger and Scheinost, 1999).  
 
The N-terminus of Pmt1p faces the cytosol and the C-terminus is in the ER lumen (Strahl-
Bolsinger and Scheinost, 1999). Such a topological arrangement generates three loops, the 
regions between adjacent TMD domains, in the ER lumen and three loops facing the cytosol. 
Interestingly, the loop4 contains hydrophobic amino acids and is thought to be attached to the 
cytosolic leaflet of ER membrane, which is distinct from other hydrophilic loops. On the luminal 
side, it was found that loop1 (between TMD1 and TMD2) is important for substrate binding and 
enzyme activity and loop5 (between TMD5 and TMD6) contains the MIR motifs 
(mannosyltransferase, inositol triphosphate- and ryanodine receptor). Overall, the function of the 
cytosolic loops and transmembrane domains is poorly understood while the luminal regions are 
well studied. The important amino acids or domains of Pmt1p that are essential for the enzyme 
function and interaction also exist in other PMTs and are conserved throughout evolution. Thus, 
the findings on Pmt1p might be applicable to other PMTs. 
 
For Pmt1p, it was found that the arginine at the position of 138, which is at the interface between 
TMD2 and ER lumen, is important for the heterodimer formation of Pmt1p and Pmt2p (Girrbach 
et al., 2000). Changing this arginine to alanine completely diminishes the formation of Pmt1p-
Pmt2p complex and impairs the protein mannosyltransferase activity. Interestingly, the arginine-
138 can be replaced with lysine without disrupting the complex formation. Thus, it seems like a 
positively charged amino acid near the luminal surface of the TMD2 domain is required for the 
enzyme interaction. This arginine residue is conserved among different PMTs and throughout 
evolution. Mutation of this arginine in Pmt4p also causes similar defects (Girrbach and Strahl, 
2003). In loop1, there are two amino acids, aspartic acid and glutamic acid, at the position of 77 





Figure 1- 4 The topology model of S. cerevisiae Pmt1p.  
 
The topology of S. cerevisiae Pmt1p was modified based on Loibl and Strahl (Loibl and Strahl, 
2013). The evolutionary conserved amino acids or domains that are important for the substrate 
binding, complex formation, enzyme activity are highlighted. The N-linked glycosylation sites 
are also indicated.  
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protein mannosyltransferases (Girrbach et al., 2000; Lommel et al., 2011). Mutation analysis 
showed that these two amino acids are important for the heterodimer or homodimer formation 
and enzyme activity. For Pmt1p, the mutation of the aspartic acid only causes mild defect while 
mutation of the glutamic acid significantly impairs enzyme activity in vitro. The combination of 
these two amino acids virtually abolishes the mannosyltransferase activity of Pmt1p. By contrast, 
mutation of either of these two amino acids fully diminishes the enzyme function of Pmt4p. 
Recently, an artificial photoreactive mannosyl acceptor substrate was created and found to be 
directly cross-linked with the glutamic acid of Pmt1p in loop1 (Lommel et al., 2011). Together, 
the loop1 region is critical for the substrate binding and enzyme activity. In loop5, three MIR 
motifs are identified, which are only present in eukaryotes but not bacteria or archaebacteria. The 
deletion of loop5 disrupts the enzyme activity of Pmt1p but may not affect the substrate binding 
(Lommel et al., 2011). Because the proeukaryotic protein mannosyltransferases do not contain 
these MIR domains, it is not clear whether the MIR domains have additional function (Lommel 
and Strahl, 2009). Intriguingly, the MIR domain shows high sequence similarity to the 
mammalian SDF2 (stromal cell-derived factor 2) and SDF2-L1 (SDF2-like1) proteins (Fukuda et 
al., 2001; Hamada et al., 1996). Both of them are present in animals and plants but missing in 
fungus.  In mammalian cells, SDF2-L1 cooperates with other ER chaperones, such as Bip, 
GRP94, PDI, and GT to assist ER protein folding and the expression level can be induced by ER 
stress (Fukuda et al., 2001; Meunier et al., 2002). A similar function of SDF2 is also found in 
plants. In Arabidopsis, SDF2 is a target of UPR (Schott et al., 2010).  It forms a stable complex 
with the ER Hsp40 and Hsp70, which is required for the glycoprotein folding and maturation 
(Nekrasov et al., 2009). Structural analysis revealed that the three MIR motifs of SDF2 form a β-
trefoil fold, which provides a platform for carbohydrate binding and accommodates the 
interaction with other chaperones (Schott et al., 2010). The structural insights of these three MIR 
motifs indicates the loop5 region of the PMT family members might also interact with ER 
protein chaperones and participate in ERQC. Indeed, recent studies in S. cerevisiae have 
provided compelling evidence that Pmt1p and Pmt2p are part of the ERQC machinery, which 
will be discussed in the coming part.   
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1.4.4 The cross talk between PMTs and ER homeostasis 
 
O-mannosylation has been proposed to be involved in ERQC. There are two major links between 
these two pathways: first, a variety of misfolded ER proteins that requires distinct ERAD 
pathways for degradation are O-mannosylated; second, the PMT members are targets of the UPR 
program.   
1.4.4.1 The relationship between O-mannosylation and ERQC 
 
O-mannosylation of misfolded proteins is mediated exclusively by Pmt1p and Pmt2p. The 
modification on misfolded proteins is distinct from that of the endogenous substrates. It was 
showed that the transferring of mannose residues to the endogenous proteins occurs during 
translocation (Elorza et al., 1977). By contrast, the misfolded proteins are O-mannosylated post-
translationally (Harty et al., 2001). The determinant that defines co-translational and post-
translational O-mannosylation is current unknown. It might be possible that the Ser/Thr rich 
sequence is required for co-translational O-mannosylaiton because it can be found in most of the 
endogenous substrates. How the PMTs members are specifically recruited to the position that is 
adjacent to the translocon is also not clear. The post-translational O-mannosylation is probably 
due to a prolonged exposure of unstructured polypeptide chains that contain Ser/Thr sites, which 
makes the individual Ser/Thr accessible to Pmt1p and Pmt2p.  
 
Why other PMTs have not been found to be involved in O-mannosylation of misfolded proteins 
is also not clear. It might be due to the following reasons. First, Pmt1p and Pmt2p are shown to 
carry out the predominant mannosyltransferase activity in vivo from the PMT1/2 subfamilies. 
Thus, Pmt3p and Pmt5p might just have negligible effects in vivo. Second, the Pmt4p only 
recognizes membrane bound substrates. So far, few misfolded membrane proteins are shown to 




The reported misfolded clients of Pmt1p-Pmt2p in S. cerevisiae include mutant α-factor 
precursor (pαF) (Harty et al., 2001), simian virus 5 HN (KHN) (Vashist et al., 2001), bovine 
pancreatic typsin inhibitor (Coughlan et al., 2004), mutant Rhizopus niveus aspartic proteinase-I 
(Δpro )(Nakatsukasa et al., 2004), a misfolded version of plasma membrane protein Gas1p 
(Gas1*p) (Goder and Melero, 2011; Hirayama et al., 2008), Sec62 fused with MATα2 N-
terminal 67 residues (Deg1-Sec62) (Rubenstein et al., 2012) and the A1 chain of Shiga-like toxin 
(Li et al., 2012). Romisch and colleagues reported the first misfolded client of the O-
mannosylation machinery, mutant pαF (Harty et al., 2001). Using an in vitro system, they were 
able to demonstrate the modification of mutant pαF occurs after the protein goes into the ER. 
They found that the O-mannosylation protects the substrate from retrotranslocation in the in vitro 
system and concluded that the modification prevents ERAD. However, the degradation dynamic 
of pαF in wild type and Δpmt2 are similar to each other. Thus, it is inconclusive that O-
mannosylation inhibits misfolded protein degradation. By contrast, other groups found that the 
degradation of KHN, Δpro and Gas1*p is delayed in the O-mannosylation mutants, but not fully 
blocked (Goder and Melero, 2011; Hirayama et al., 2008; Nakatsukasa et al., 2004; Vashist et al., 
2001). The discrepancy can be explained that different misfolded proteins might have different 
dependency for O-mannosylation for degradation. Even though whether O-mannosylation can 
accelerate misfolded protein degradation is controversial, the data suggest that O-mannosylation 
might be cooperative, but not essential, for ERAD. Further analysis showed that the modification 
can increase the solubility of the misfolded proteins. Endo and co-workers showed that O-
mannosylation of the misfolded protein requires intact function of Kar2 (Nakatsukasa et al., 
2004). Microsomes prepared from Kar2 mutant cells failed to O-mannosylate the in vitro 
translocated mutant pαF at non-permissive temperature. Interestingly, they found that the O-
mannosylated misfolded proteins no longer require Kar2 to maintain solubility, and thus, the 
modification reduces ER chaperone load. It was shown that more endogenous proteins receive 
O-mannoslyation under stress condition (Harty et al., 2001). Because the ERAD pathways and 
the ER chaperones might be saturated by overwhelming load of misfolded proteins (Spear and 
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Ng, 2003), the O-mannosylation pathway might function as a fail-safe mechanism to maintain 
ER homeostasis.  
 
It should be noted that the O-mannosylation of the misfolded proteins is very specific. For 
example, the in vitro translocated mutant pαF, but not wild type pαF, receives the modification 
(Harty et al., 2001). Similarly, Pmt1p-Pmt2p recognizes and modifies mutant protein Gas1*p, 
but not wild type Gas1p (Hirayama et al., 2008).Thus, the O-mannosylation of the misfolded 
protein is probably due to the prolonged exposure of modification sites triggered by folding 
failure. And these observations are also consistent with the point that the O-mannosylation of 
misfolded proteins is a post-translational event. If the modification occurs co-translationally, it is 
expected that both the wild type and mutant proteins are O-mannosylated. However, how the 
Pmt1p-Pmt2p complex specifically differentiates folded and misfolded proteins is currently 
unknown. Recently, Goder and Melero fused Pmt1p and Pmt2 with a tag and performed 
immunoprecipitation under native conditions to search for binding partners of the Pmt1p-Pmt2p 
complex. Interestingly, they found that the complex interacts with ER folding chaperones, such 
as Ero1p and Pdi1p, ERAD components and the ER export machinery. The association with 
components of protein folding and degradation pathways suggests the O-mannosylation 
machinery might act as the connector of these two distinct pathways. The interaction between 
Pmt1p and Pmt2p with the ER folding machinery is reminiscent of the interaction between SDF2 
type proteins and ER Hsp70 and Hsp40 chaperones. It is of great interest to study whether such 
interaction is mediated by the MIR motifs in the loop5 region of Pmt1p and Pmt2p.  The β-trefoil 
fold structure formed by the three MIR motifs of the SDF2 type proteins might also exist in the 
loop5 region of PMTs and support the chaperone association and substrate binding.  
1.4.4.2 The connection between UPR and O-mannosyltion  
 
The unfolded protein response (UPR) is an evolutionarily conserved stress response pathway that 
monitors the ER protein folding environment and keeps the proteostasis network under stress 
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conditions. The pathway was first identified in S. cerevisiae and later found in mammals with 
more complex features (Walter and Ron, 2011).  
 
In S. cerevisiae, Ire1p (inositol-requiring transmembrane kinase/endonuclease) is the key 
regulator of UPR. Ire1p is a type I transmembrane receptor consisting of an N-terminal ER 
luminal domain, a transmembrane segment and a cytoplasmic region. The luminal region of 
Ire1p contains a substrate binding groove which can directly bind to misfolded proteins and 
trigger the oligomerization of Ire1p (Credle et al., 2005; Gardner and Walter, 2011). The 
conformational change of the luminal region upon misfolded protein binding in turn activates the 
cytoplasmic kinase and ribonuclease domains. The activated cytoplasmic domain of Ire1p 
cleaves the nonconventional intron of Hac1 mRNA to allow it to be translated into a 
transcription factor (Cox and Walter, 1996). The Hac1p is transported into nucleus to initiate a 
cascade of genes up-regulation to restore the ER homeostasis. Microarray analysis showed that 
the UPR target genes are related to protein translocation, glycosylation, protein folding, ERAD, 
lipid metabolism and protein trafficking (Travers et al., 2000). Among them, all the members of 
PMT1/2 subfamilies are up-regulated (Travers et al., 2000). Correspondingly, UPR is 
constitutively activated in Δpmt1 or Δpmt2 cells (Jonikas et al., 2009). Mutation of pmt2 and the 
ERAD component has synergetic effect in UPR activation (Nakatsukasa et al., 2004).  The 
genetic interaction between pmt1/2 and UPR is important because mutation of hac1 gene in the 
pmt mutants causes synthetic lethality (Arroyo et al., 2011). Recently, Strahl and colleagues 
systematically analyzed the transcription pattern in pmt mutants or wild type cells in the presence 
of O-mannosylation inhibitors and compared that with the gene expression profile in response to 
ER stress or cell wall stress (Arroyo et al., 2011). Previous studies showed that the O-
mannosylation is important for the stability and functionality of some plasma membrane proteins 
(Lommel et al., 2004; Petkova et al., 2012; Philip and Levin, 2001). Aberrant O-mannosylation 
causes their failure in maintaining cell wall integrity and results in cell death. Thus, it is expected 
that the genes related to cell wall stress response are activated in the pmt mutants. However, they 
found a set of up-regulated genes that are related to ER protein folding, lipid metabolism, 
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glycosylation, ERAD and lipid metabolism, which are also the targets of UPR but not the cell 
wall stress response. This suggested that O-mannosylation has an additional role in maintaining 
ER homeostasis which is independent of its role in modification of the endogenous proteins. 
 
Together, the genetic studies revealed that there is an essential coordination between UPR and 
the O-mannosylation pathway. However, due to the complicated roles of O-mannosylation, a 
unifying mechanism is missing to explain the roles of O-mannosylation in ER homeostasis.  
1.4.5 The mammalian PMTs and related human diseases 
 
In animals, only two homologues, POMT1 and POMT2, are found, which belong to the PMT4 
and PMT2 subfamilies respectively. The whole PMT1 subfamily is missing, which is different 
from the fungus. It was shown that co-expression of POMT1 and POMT2 is essential for the 
enzyme activity while expression of either of them fails to O-mannosylate the substrates (Manya 
et al., 2004). Co-immnoprecipitation showed that POMT1 and POMT2 can interact with each 
other (Akasaka-Manya et al., 2006). It has not been observed that members from PMT2 and 
PMT4 subfamilies could form heterodimers in yeast. It is not clear that why the interaction 
patterns of PMTs are different in yeast and metazoans.  
 
Failure in O-mannosylation causes defects in muscular and neural development, which has been 
verified in Drosophila, zebrafish, mouse and human. So far, the best characterized substrate of 
POMT1 and POMT2 is α-dystroglycan (α-DG). POMT1, POMT2 and other five genes are 
required for the normal O-mannosylation of α-DG (Nakamura et al., 2010; Willer et al., 2012). 
In vertebrates, α-DG interacts with both extracellular matrix (ECM) and a plasma membrane 
protein, named β-dystroglycan (β-DG). β-DG interacts with dystrophin, which is a cohesive 
protein that directly binds with cytoskeleton. Thus, α-DG functions as a bridge to connect the 
cytoskeleton with ECM and the dysfunction of α-DG causes defects in the organization of basal 
membranes (Nakamura et al., 2010). α-DG consists of two globular domains and a Ser/Thr-rich 
region in between that is heavily O-mannosylated. The defect in O-mannosylation of α-DG 
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reduces its interaction with ECM and disrupts the assembly of basal membranes. This is believed 
to be the general molecular mechanism of congenital muscular dystrophies (CMD). The CMD is 
clinically associated with brain and eye abnormalities (Nakamura et al., 2010). Walker-Warburg 
syndrome (WWS), most severe case of CMD, is associated with the mutations of POMT1 and 
POMT2.  People suffered from WWS typically live less than one year after birth due to the 
severe defects. In addition, mutations in POMT1 and POMT2 can also be found in patients with 
mild clinical form of CMD. The mutations of POMT1 that are identified in either WWS or mild 
CMD can fully abolish the protein mannosyltransferase activity in mammalian cell line system 
(Akasaka-Manya et al., 2004; Akasaka-Manya et al., 2006). Thus, additional defects, apart from 
aberrant O-mannosylation of α-DG, might contribute to the severe phenotype of WWS. 
 
1.5 Gaps and Purposes 
To understand the ERQC mechanism, a variety of folding-disabled proteins have been generated 
as model substrates (Vembar and Brodsky, 2008). Those substrates with specific folding defects 
have driven the development of the field. Now, it is clear that the substrates with different lesion 
sites are degraded by distinct ERAD pathways (Carvalho et al., 2006; Denic et al., 2006; Vashist 
and Ng, 2004). Even though great advances have been made to understand the ERQC 
mechanisms and ERAD pathways, several important questions discussed in the introduction 
section still remain unsolved. Among them, the most mysterious aspect of the ERQC mechanism 
is how the futile protein folding cycles are terminated. Such a concept has been conceived but 
direct evidence is missing. Because those previously established model substrates could never 
fold, such a caveat limits their scope to the study of protein folding termination. 
 
Therefore, the major purpose of this study was to uncover the potential folding termination 




1. Develop novel substrates which are wild type proteins but fail to fold in wild type cells due to 
the slow folding rate; 
 
2. Study the protein folding termination machinery using the newly developed folding substrates; 
 
3. Address the biological significance of the protein folding termination machinery. 
 
Protein folding is a fundamental function. Not surprisingly, its dysfunction is the underlying 
cause of numerous human diseases. It is of particular importance to understand the early phases 
of ERQC which might advance our current view of protein folding in vivo. In the following 
chapters, I will describe our efforts to seek a folding competent protein that is unable to complete 
its maturation within the constraints of ERQC in wild type cells. Making use of this new 
substrate system, we were able to identify factors that specifically terminate futile protein 
folding. Furthermore, genetic and biochemical assays were set up to study the roles of those 











Chapter2 Materials and Methods 
 
2.1 S. cerevisiae strains and growth media 
2.1.1 List of strains 
Yeast strains used in the study of Pmt1/Pmt2 mediated protein folding termination were listed in 
Table 2-1. Yeast strains used in the screen were listed in Table 2-2. 
 
2.1.2 Growth media 
All the yeast strains were grown at 30°C, except that sec63-1 was grown at 25°C, in synthetic 
complete (SC) medium lacking one or two amino acids for plasmid selection or YPD medium 
(1% bacto-yeast extract, 2% bacto-peptone and 2% dextrose). The SC medium was composed of 
2% dextrose, 0.7% nitrogen base and appropriate amount of amino acids.  
 
2.2 Genetic and molecular methods 
2.2.1 Yeast transformation 
 
Yeast cells were grown on YPD plate overnight. The carrier DNA was boiled at 100°C for 10 
min and chilled on ice. The newly grown cells were resuspended in 100 µl of PLATE buffer (10 
mM Tris pH 7.5, 0.1 M lithium acetate pH 7.5, 40% polyethylene glycol (PEG 3350, Sigma-
Aldrich, St. Louis, MO)) and mixed with 30 µg carrier DNA and 300 ng plasmids of interests. 
The mixture was incubated at room temperature for four to five hours. After a short time of 
centrifugation, the cells were resuspended in 30 µl distilled water and plated onto the selective 





2.2.2 Plasmid construction  
2.2.2.1 Plasmids used in this study 
 
Plasmids and primers used in this study are summarized in Table 2-3, respectively. Plasmids 
used in this study were constructed using standard protocols. All plasmid inserts were confirmed 
by DNA sequence analysis. The original P7 plasmid (pWX191) was kindly provided by Dr 
Matthew DeLisa (Fisher and DeLisa, 2008).  
 
pWX206. The plasmid pWX206 was generated by digesting pDN366 with XbaI and BamHI to 
release the ER-GFP fragment (Ng plasmid collection, published in (Suda et al., 2007)) and the 
TDH3 promoter was amplified with primers G8 and G9 from the W303 strain genomic DNA 
digested with NotI and BamHI before being ligated into pRS316 plasmid containing the ACT1 
terminator.  
 
pWX204. The plasmid pWX204 was generated by amplifying the fragment P7GFP-HDEL from 
pWX191 with primers p7F and p7R and digested with ClaI and XbaI before being ligated into 
the corresponding digestion restriction sites in pWX206.  
 
pWX214. pWX214 was made by two rounds of  site-directed mutagenesis as described 
previously with primers G2 and G6 (Sawano and Miyawaki, 2000).  
 
pCX12. pCX12 was generated by ligating GAL1 promoter, released from pSW182 (Wang et al., 
2011), into NotI and BamHI digested pWX204. 
 
pCX13. pCX13 was generated by ligating GAL1 promoter, released from pSW182 (Wang et al., 
2011), into NotI and BamHI digested pWX206.  
 




pCX34. pCX34 was generated from pWX206 by site-directed mutagenesis with primers RP65. 
 
2.2.2.2 Oligonucleotide primers used in this study 
Primers used in this study are listed in Table 2-4.  
 
2.3 Antibodies 
Mouse anti-Pgk1 and anti-GFP monoclonal antibodies were purchased from Invitrogen and 
Roche, respectively. Rabbit anti-Gas1 antibody was raised against amino acids 40-289 of Gas1 
(Ng et al., 2000). Rabbit anti-Kar2 and anti-CPY were provided by P. Walter (University of 
California, San Francisco) and R. Gilmore (University of Massachusetts, Worchester) 
respectivley. Anti-rabbit IRDye 680 and anti-mouse IRDye 800 secondary antibodies were 
purchased from LI-COR Biosciences (Lincoln, NB). The Alexa Fluor 543 goat anti-rabbit and 
Alexa Fluor 488 goat anti-mouse secondary antibodies were purchased from Molecular Probes 
(Eugene, OR). 
 
2.4 Cell imaging and protein biochemistry 
2.4.1 Protein extraction and Immunoblotting 
Total protein extraction was performed as described previously (Wang et al., 2011). Cells were 
grown to log phase and two OD600 units of cells were collected by centrifugation. Cell pellets 
were resuspended in 1 ml of 10% trichloroacetic acid (TCA). Cells were disrupted with 0.5-mm 
zirconium beads in a mini-bead beater (BioSpec Products Inc.) by two 30 second cycles. The 
lysate was subjected to a 16,000×g spin and the pellet was dissolved in 200 µl TCA resuspension 
buffer (100 mM Tris pH 11.0, 3% SDS, 1 mM PMSF, 20 mM NEM) by boiling at 100°C for 10 
min. The soluble fraction was collected by a 16,000×g spin and used for non-reducing analysis 
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or prepared for reducing analysis by adding dithiothreitol (DTT) to 100 mM. A portion of total 
protein extracts was separated on a 4-15% gradient gel by SDS-PAGE.  
 
For non-quantitative analysis, samples were transferred to nitrocellulose membrane in the 
transfer buffer A (0.025% SDS, 20% methanol, 25 mM Tris, 192 mM glycine) at 4°C. The 
current setting was 300 mA for one hour.  After transferring, the blot was blocked in PBST 
buffer (10 mM Na2HPO4⋅2H2O, 2.7 mM KCl, 2 mM KH2PO4, 137 mM NaCl, 0.1% Tween-20) 
containing 5% non-fat dry milk powder at room temperature for one hour. The primary antibody 
(anti-GFP, anti-Pgk1, anti-Kar2, or anti-Gas1) was diluted in PBST buffer and incubated with 
the blot for one hour at room temperature. The blot was washed with PBST buffer twice at room 
temperature for 8 min and subsequently probed with anti-mouse and/or anti-rabbit HRP 
antibody. After washing with PBST buffer for 30 min at room temperature, the blot was soaked 
in buffer containing the HRP substrates (Pierce Biotechnology) for three to five min at room 
temperature. The protein of interest was visualized by the enhanced chemiluminescence and 
exposed to X-ray film (Pierce Biotechnology).  
 
For quantitative analysis, PVDF membrane was used during the transfer to reduce the 
background. The procedure was similar to the non-quantitative immunoblotting except the 
blocking buffer was purchased from LI-COR Biosciences. The blot was sequentially probed with 
anti-GFP and/or anti-Pgk1 primary antibody and anti-mouse IRDye 800 and/or anti-rabbit IRDye 
680 secondary antibodies. The protein level was quantified based on the fluorescence intensity 
by Odyssey infrared imaging system (LI-COR Biosciences). 
 
2.4.2 Live cell imaging 
Cells expressing GFP constructs were cultured at 30°C to log phase and visualized by a Zeiss 
Axiovert microscope with a 100× 1.4 NA oil Plan-Apochromat objective (Carl Zeiss 
MicroImaging, Inc). Only for the experiments with the sec63-1 mutant, cells were grown at 
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25°C. Typically, GFP fluorescence was detected with a 488 nm laser line with Detector Gain of 
535. In some cases, GFP fluorescence was detected with an increased Detector Gain of 700 as 
specifically indicated. All images were processed using Adobe Photoshop CS4 and brightness 
was enhanced to the same degree using levels in the image adjustment function. 
2.4.3 Indirect immunofluorescence 
Indirect immunofluorescence was performed as previously described (Wang and Ng, 2010). The 
glass slides used for this experiment were coated with 0.1% poly-L-lysine. The methanol and 
acetone were pre-chilled in -20°C. Two to three OD600 units of cells grown to log phase were 
fixed in 10% formaldehyde and incubated at 30°C for 90 min with gentle rotation. The fixed 
cells were collected by a low speed centrifugation at 1,000×g for 5 min and washed with 5 ml of 
ice-cold 0.1 M K3PO4 buffer (pH 7.5). To digest the yeast cell wall, the cells were resuspended 1 
ml spheroplasting buffer containing 0.1 M K3PO4 pH 7.5, 1.2 M sorbitol, 1 mg/ml zymolase and 
incubated at room temperature for 20 min. 30 µl of the spheroplasts were added to the poly-L-
lysine-coated slide and incubated for 10 min for adhesion. The unattached cells were removed by 
washing with TBS (50 mM Tris pH 7.4, 150 mM NaCl). The slide was soaked in cold methanol 
for six min and subsequently in cold acetone for 30 sec. After washing with TBS for three min, 
the samples were blocked with 3% BSA at room temperature for 30 min. Mouse anti-GFP and 
rabbit anti-Kar2 primary antibodies were diluted in TBS buffer containing 1% BSA and 
incubated with the permeabilized cells overnight at at 4°C. The mouse anti-GFP antibody was 
diluted 500 times and the rabbit anti-Kar2 antibody was diluted 1,000 times. The Alexa Fluor 
543 goat anti-rabbit and Alexa Fluor 488 goat anti-mouse secondary antibodies (Molecular 
Probes) were diluted 1,000 times in TBS buffer containing 1% BSA and incubated with cells at 
room temperature for 90 min. Samples were visualized by a Zeiss Axiovert microscope with a 
100× 1.4 NA oil Plan-Apochromat objective (Carl Zeiss MicroImaging, Inc). All images were 
processed using Adobe Photoshop CS4. 
 45 
 
2.4.4 Metabolic pulse-chase assay 
Metabolic pulse-chase experiments were carried out as described previously (Ng et al., 2000). 
Typically, cells were grown into log phase and harvested by low speed centrifugation. The cell 
pellets were resuspended to reach the cell concentration of three OD600 in every 900 µl. The 
resuspension medium was lack of methionine/cysteine. After 30 min incubation at 30°C to allow 
the recovery of the cells, three OD600 units of the cells were labeled with 80 µCi of L-[35S]-
methionine/cysteine mix (Perkin Elmer).   
 
To study the processing of CPY and Gas1, the cells were labeled for 5 min. To invest the 
degradation of KHN-HA, the cells were labeled for 10 min. The cold methionine/cystein was 
added to 2 mM to terminate the labelling and initiate the chase. Three OD600 units of the cells 
were taken at each chasing time point for following experiment. To quickly terminate the 
labeling/chase, 100% TCA was directly added into the culture with the final concentration at 
10%. The whole cell protein extracts were prepared as described above. For the KHN-HA 
degradation experiments, an additional normalization step was required. After protein extract 
preparation, the total amount of isotope labeled proteins was determined by a LS6500 
scintillation counter (Beckman Coulter, Inc.). Thus, the amount of the protein used for the 
subsequent immunoprecipitation could be normalized to be equal. The total protein extracts were 
diluted with IPSII buffer (50 mM Tris pH 7.4, 1% Triton X-100, 1 mM PMSF, 0.3 µl/OD600 U 
protease inhibitor cocktail). After the dilution, the final concentration of SDS should be less than 
0.2%. To reduce the background of the immunoprecipitation, we did not incubate the protein 
extracts with the antibody and Protein A Sepharose beads together at the first step. The diluted 
protein extracts were incubated with mouse anti-HA (KHN-HA) antibody for one hour and was 
subjected to a 16,000×g spin for 20 min. The supernatant was incubated with 30 µl Protein A 
Sepharose bead slurry for two hour at 4°C. After that, the Protein A Sepharose beads were 
washed three times with IPSI buffer (50 mM Tris pH 7.4, 1% Triton X-100, 0.2% SDS) and one 
time with PBS. The immunoprecipitated CPY, Gas1, or KHN-HA was eluted under denaturing 
conditions and separated by 8% SDS-PAGE. Protein visualization and quantification were 
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performed using a Typhoon 8600 scanner and ImageQuantTM TL software (GE Healthcare 
Biosciences). The data quantification reflected three independent experiments with standard 
deviation of the mean value indicated. 
2.4.5 Cycloheximide chase assay 
Cycloheximide chase experiments were carried out as described previously (Wang et al., 2011). 
Typically, cells were grown to log phase and harvested by low speed centrifugation. The cell 
pellet was resuspended to reach the cell concentration of two OD600 in every 900 µl medium. 
Cycloheximide (Sigma-Aldrich) was added to 200 µg/ml to inhibit newly protein synthesis and 
start the chase. At indicated time points, 900 µl of cells were mixed with 100 µl of 100% TCA to 
terminate the chase. The total protein extracts were prepared by TCA precipitation for 
quantitative immunoblotting analysis as described above. The data quantification reflected three 
independent experiments with standard deviation of the mean value indicated. 
2.4.6 Aggregation assay 
Aggregation assay was performed as described previously (Kruse et al., 2006; Nishikawa et al., 
2001). Sixty OD600 units of log-phase cells were collected, washed with cold distilled water and 
resuspended in 600 µl of buffer AH (20 mM HEPES-KOH, pH 7.4, 50 mM KOAc, 2 mM 
EDTA, 1 mM PMSF, 1.5% Protease Inhibitor Cocktail). Cells were disrupted by agitation with 
zirconium beads and cells debris were removed by a five-minute spin at 800×g. Cell lysate was 
incubated with 1% Triton X-100 at 4°C for 10 min and further clarified by a ten-minute spin at 
12,000×g. The supernatant was loaded onto a linear 5-60% sucrose gradient and centrifuged at 
145,000×g for 20 hours at 4°C. Thirteen fractions were collected from top to bottom and the 
pellet was resuspended in buffer containing 50 mM Tris-HCl, pH 7.5, 3% SDS. Equal portion of 
each fraction was used for immunoblotting analysis. 
2.4.7 Concanavalin A (ConA) binding assay 
ConA binding experiments were performed as described previously with some modifications 
(Sweet and Pelham, 1992; Weber et al., 2004). One OD600 unit of log-phase cells was collected, 
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washed with cold distilled water and resuspended in 700 µl of ConA buffer (20 mM Tris pH 7.5, 
500 mM NaCl, 1.6% Triton X-100, 0.1% SDS, 0.02% NaN3). Cells were disrupted by bead-
beating as described above. The lyaste was transferred to a new tube and cell debris was 
removed by a three-minute spin at 2,150×g. A portion of the supernatant was saved as the total 
fraction and the rest was incubated with 100 µl of ConA-Sepharose beads (Sigma-Aldrich) at 
4°C for 4 hours. The ConA bound and unbound fractions were separated by a 16,000×g spin for 
one minute. The ConA bound fraction was washed three times with ConA buffer and eluted with 
1× SDS sample buffer. Equal portions of total, bound and unbound fractions were used for 
immunoblotting analysis. 
2.4.8 Protease sensitivity assay 
Trypsin digestion was carried out as previously described with some modifications (Xie et al., 
2009). Briefly, fifty OD600 units of log-phase cells were harvested by low speed centrifugation, 
washed with cold distilled water and resuspended in 1 ml TN buffer (50 mM Tris, pH 7.4, 50 
mM NaCl, 10% glyceol). Cells were disrupted with 0.5 mm zirconium beads on a vortex mixer. 
The lysate was transferred to a new tube. The zirconium beads were washed twice with 500 µl 
TN buffer, which was subsequently transferred and combined with the lysate. The unbroken cells 
or nucleus were removed by a low speed centrifugation at 800×g for 5 min. The supernatant was 
subjected to a high speed ultracentrifugation at 29,000×g for 30 min to remove the cytosolic 
proteins. The pellet contained the microsomes. It was resuspended in 600 µl of TN buffer 
containing 1% Triton X-100 and incubated at 4°C for one hour. The detergent solubilized 
microsomal proteins were collected after a 10 min ultracentrifugation at 29,000×g. Sixty µg of 
protein from 1% Triton X-100 solubilized microsome was subjected to limited trypsin digestion 
(5 µg/ml) at on ice. Aliquots were taken at times indicated, mixed with 5× SDS sample buffer 
and immediately boiled at 100°C to terminate the reaction. Relative GFP level was measured by 






Coimmunoprecipitation experiments were carried out as described previously with some 
modifications (Xie et al., 2009). The experimental procedure of microsomal protein extract 
preparation was similar to what described above expect a few differences. The cell pellet was 
resuspended in buffer containing 50 mM Tris, pH 7.4, 150 mM NaCl, 10% glycerol, 2 mM 
PMSF, 1.5% protease inhibitor cocktail. Isolated microsomes were solubilized with 1% digitonin 
(Calbiochem) rather than 1% Triton X-100. The clarified supernatant was incubated with mouse 
anti-GFP and protein A-Sepharose beads (Sigma-Aldrich) for 2 hours at 4°C. 
Immunoprecipitates were eluted by SDS loading buffer and analyzed by quantitative 
immunoblotting. Relative co-precipitated Kar2 was calculated by normalizing the co-precipitated 
Kar2 level with the precipitated ER-Δ2GFP level. The data quantification reflected three 
independent experiments with standard deviation of the mean value indicated. 
2.4.10 Fluorescence measurement of O-mannosylated and non-glycosylated ER-GFR from 
microsome extracts 
Microsomes isolated from 100 OD600 units of cells expressing the vector or ER-GFP were 
solubilized in 600 µl of microsome buffer (50 mM Tris pH 7.5, 50 mM NaCl, 10% glycerol, 1% 
Triton X-100, 2 mM PMSF, 1.5% Protease Inhibitor Cocktail). Sixty µl of the final clarified 
supernatant was diluted with 240 µl of ConA buffer 2 (20 mM Tris pH 7.5, 500 mM NaCl, 1 
mM MgCl2, 1 mM MnCl2, 1 mM CaCl2, 0.02% NaN2 and 1% Triton X-100) and mixed with 
pre-washed excess ConA-Sepharose beads in a spin column. After a 4-hour incubation at 4°C, 
flow-through was collected by centrifugation and beads were washed three times with 300 µl of 
ConA buffer 2. Beads were incubated with 300 µl of ConA buffer 2 containing 10% methyl α-D-
mannopyranoside (MMP) at room temperature for 60 min to elute bound proteins. Equal portion 
of flow-through fraction and eluate were subjected to GFP fluorescence measurement 
(excitation: 475 nm; emission: 509 nm; Gain: 100; Tecan i-Control) and quantitative 
immunoblotting. The data quantification reflected three independent ConA binding and 
fluorescence measurement experiments with standard deviation of the mean value indicated. 
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2.4.11 Fluorescence measurement of O-mannosylated and non-glycosylated ER-GFP from 
purified material 
Yeast cells expressing H6-ER-GFP were grown to log phase and 6,000 OD600 units were 
collected. Cells were washed with lysis buffer (50 mM K3PO4 pH 7.5, 500 mM NaCl, 2 mM 
MgCl2) and flash frozen by liquid N2. Cell pellets were disrupted in a coffee grinder in the 
presence of dry ice and resuspended in lysis buffer containing 20 U/ml benzonase (Novagen), 
1mM PMSF, 1.5% Protease Inhibitor Cocktail (Roche), 20 mM imidozole, 5 mM 2-
mercaptoethanol. Unbroken cells were removed by centrifugation at 1,500×g for 10 min at 4°C. 
Membranes were pelleted at 30,000×g for 1 hour at 4°C and solubilized in buffer containing 100 
mM NaH2PO4, 10mM Tris, 6 M Urea, 20 mM imidozole, 5 mM 2-mercarptoethanol, pH 7.8. 
Folded GFP is resistant to high concentration of urea at neutral pH (Saeed and Ashraf, 2009). 
Therefore, urea was used to solubilize unfolded GFP. The clarified supernatant was incubated 
with 2 ml of Ni-NTA slurry (Qiagen) at 4°C with gentle rotation. The bound proteins were eluted 
with 100 mM NaH2PO4, 10 mM Tris, 6 M Urea, 250 mM imidozole, 5 mM 2-mercarptoethanol, 
pH 7.8. The eluates were dialyzed overnight in binding buffer (20 mM Tris pH 7.5, 500 mM 
NaCl, 0.1% TX-100). Twelve µg of purified H6-ER-GFP was diluted in 300 µl of binding buffer 
and incubated with excess ConA-Sepharose beads in a spin column for 4 hours at 4°C. Flow-
through was collected by centrifugation and beads were washed three times with 300 µl of 
binding buffer. Here, unbound fractions refer to both flow-through and wash fractions. The 
ConA-bound fraction was eluted with 300 µl of 1× SDS sample buffer by incubating at 100°C. 
Total mixed H6-ER-GFP was represented by diluting 12 µg purified H6-ER-GFP in 300 µl of 
binding buffer without ConA-Sepharose beads incubation. Equal portion of total and unbound 
H6-ER-GFP was subjected to GFP fluorescence measurement using a microplate reader 
(excitation: 475 nm; emission: 509 nm; Gain: 100; Tecan i-Control). Background signal emitted 
from equal amount of binding buffer was subtracted for the final fluorescence calculation. For 
GFP protein level quantification, equal portion of total, unbound, bound and eluate H6-ER-GFP 
was subjected to quantitative immunoblotting as mentioned above. The data quantification 
reflected three independent experiments with standard deviation of the mean value indicated. 
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2.4.12 ConA binding with galatose-induced ER-GFP or ER-GFPfast  
Cells expressing ER-GFP or ER-GFPfast under the driven of GAL1 promoter were grown in SC 
medium containing 3% raffinose to log phase. Cells were collected and transferred to SC 
medium containing 2% galactose to induce ER-GFP or ER-GFPfast synthesis. After specific time 
of induction, cycloheximide was added to 200 µg/ml. Cells were harvested at indicated time 
points and cell extracts were prepared as described in ConA binding assay. ConA pull down and 
immuneblotting were done as described above. 
2.4.13 GFP in vitro refolding capacity calculation 
Purified H6-ER-GFP was denatured by 10% TCA precipitation and urea buffer resuspension 
(100 mM NaH2PO4, 10mM Tris, 6 M Urea, 20 mM imidozole, pH 7.8). Denatured H6-ER-GFP 
was diluted to 100 µg/ml and dialyzed in refolding buffer (150 mM NaCl, 100 mM Tris pH 7.5, 
1mM CaCl2, 2 mM 2-mercaptoethanol) overnight. Using the refolding buffer as ConA binding 
buffer, the O-mannosylated and non-glycosylated GFP were separated by ConA-Sepharose 
beads and GFP fluorescence measurement and protein quantification were performed as 
described above. The fluorescence intensity of the bound fraction was calculated by subtracting 
the fluorescence of unbound fraction from that of the total fraction. The refolding capacity of O-
mannosylated and non-glycosylated GFP was calculated by normalizing the fluorescence 
intensity to relative protein level respectively. The data quantification reflected three independent 
experiments with standard deviation of the mean value indicated. 
2.4.14 Flow cytometry and relative folded GFP calculation 
Cells expressing different GFP constructs were grown to log phase. One OD600 unit was 
collected, washed with filtered PBS and resuspended in 1 ml of filtered PBS. Cells were gently 
sonicated and filtered (LAB PAK, 30 microns). GFP fluorescence intensity was quantified by 
flow cytometry analysis (CyAnTM ADP Analyzer, Beckman Coulter). 30,000 cells were counted 
and cells in the gated area were used for fluorescence measurement. In the meantime, two OD600 
units of cells were collected for quantitative immunoblotting to determine relative total GFP 
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protein level. As the fluorescence intensity represents folded GFP protein level, relative folded 
GFP level was calculated by normalizing fluorescence intensity with total GFP protein level. 
 52 
 
Table 2-1 Strains used in the study of Pmt1/Pmt2 mediated protein folding termination. 
 
Strain Genotype Source 
W303 Mata, leu2-3, 112, his3-11, trp1-1, ura3-1, can1-100, ade2-1 P. Walter 
(UCSF) 
WXY512 Mata, pWX204, W303 background This study 
WXY514 Mata, pmt2::LEU2, pWX204, W303 background This study 
WXY518 Mata, pWX206, W303 background This study 
WXY519 Mata, pmt2::LEU2, pWX206, W303 background This study 
WXY531 Mata, pmt1:: KANMX, pmt2:: KANMX,  pWX206, W303 
background 
This study 
WXY533 Mata, pmt1:: KANMX, pmt2:: KANMX,  pWX204, W303 
background  
This study 
WXY534 Mata, pRS316, W303 background This study 
WXY536 Mata, pmt1:: KANMX,  pWX206, W303 background This study 
WXY537 Mata, pmt1:: KANMX,  pWX204, W303 background This study 
WXY579 Mata, pWX214, W303 background This study 
WXY612 Mata, erv25:: KANMX,  pWX206, W303 background This study 
WXY632 Mata, pmt1:: KANMX, pSM70, W303 background This study 
WXY633 Mata, pmt2:: KANMX, pSM70, W303 background This study 
WXY634 Mata, pmt1:: KANMX, pmt2:: KANMX,  pSM70, W303 
background 
This study 
WXY674 Mata, pSM70, W303 background This study 
RSY97 Mata, sec63-1, ura3-52, leu2-3,112, cyt1:: HIS3 (Deshaies et 
al., 1991) 
WXY732 Mata, pWX206, RSY97 background This study 
WXY758 Mata, hrd1:: KANMX,  pWX206, W303 background This study 
CXY107 Mata, pCX20, W303 background This study 
CXY130 Mata, pCX34, W303 background This study 
CXY133 Mata, pmt1:: KANMX, pmt2:: KANMX, pCX34, W303 
background 
This study 
CXY172 Mata, erj5:: KANMX,  pWX206, W303 background This study 
CXY179 Mata, pWX206, pRS313, W303 background This study 
CXY180 Mata, pWX206, pJC835, W303 background This study 
CXY181 Mata, alg3::HIS3, pWX206, W303 background This study 
CXY182 Mata, arv1:: KANMX, pWX206, W303 background This study 
WSY544 Mata, pCX12, W303 background This study 
WSY548 Mata, pCX13, W303 background This study 




Table 2-2 Strains used for screening for additional folding termination factors. 
Strain No. Genotype Source 
1 Mata, pRS316, BY4741 background This study 
2 Mata, pWX206, BY4741 background This study 
3 Mata, yet1:: KANMX,  pWX206, BY4741 background This study 
4 Mata, lhs1:: KANMX,  pWX206, BY4741 background This study 
5 Mata, vph2:: KANMX,  pWX206, BY4741 background This study 
6 Mata, cax4:: KANMX,  pWX206, BY4741 background This study 
7 Mata, vma21:: KANMX,  pWX206, BY4741 background This study 
8 Mata, lcb4:: KANMX,  pWX206, BY4741 background This study 
9 Mata, ale1:: KANMX,  pWX206, BY4741 background This study 
10 Mata, yor285w:: KANMX,  pWX206, BY4741 background This study 
11 Mata, opt1:: KANMX,  pWX206, BY4741 background This study 
12 Mata, sop4:: KANMX,  pWX206, BY4741 background This study 
13 Mata, cis3:: KANMX,  pWX206, BY4741 background This study 
14 Mata, lcb3:: KANMX,  pWX206, BY4741 background This study 
15 Mata, ysr3:: KANMX,  pWX206, BY4741 background This study 
16 Mata, zsp1:: KANMX,  pWX206, BY4741 background This study 
17 Mata, are1:: KANMX,  pWX206, BY4741 background This study 
18 Mata, sed4:: KANMX,  pWX206, BY4741 background This study 
19 Mata, erf2:: KANMX,  pWX206, BY4741 background This study 
20 Mata, hmg1:: KANMX,  pWX206, BY4741 background This study 
21 Mata, ssm4:: KANMX,  pWX206, BY4741 background This study 
22 Mata, gip3:: KANMX,  pWX206, BY4741 background This study 
23 Mata, agp2:: KANMX,  pWX206, BY4741 background This study 
24 Mata, ifa38:: KANMX,  pWX206, BY4741 background This study 
25 Mata, ysy6:: KANMX,  pWX206, BY4741 background This study 
26 Mata, npl4:: KANMX,  pWX206, BY4741 background This study 
27 Mata, sec66:: KANMX,  pWX206, BY4741 background This study 
28 Mata, pmt5:: KANMX,  pWX206, BY4741 background This study 
29 Mata, pmt1:: KANMX,  pWX206, BY4741 background This study 
30 Mata, ydr476c:: KANMX,  pWX206, BY4741 background This study 
31 Mata, izh1:: KANMX,  pWX206, BY4741 background This study 
32 Mata, eug1:: KANMX,  pWX206, BY4741 background This study 
33 Mata, fpr2:: KANMX,  pWX206, BY4741 background This study 
34 Mata, scs3:: KANMX,  pWX206, BY4741 background This study 
35 Mata, flc3:: KANMX,  pWX206, BY4741 background This study 
36 Mata, scs2:: KANMX,  pWX206, BY4741 background This study 
37 Mata, far3:: KANMX,  pWX206, BY4741 background This study 
38 Mata, cts1:: KANMX,  pWX206, BY4741 background This study 
39 Mata, far10:: KANMX,  pWX206, BY4741 background This study 
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40 Mata, sec22:: KANMX,  pWX206, BY4741 background This study 
41 Mata, sec72:: KANMX,  pWX206, BY4741 background This study 
42 Mata, gtb1:: KANMX,  pWX206, BY4741 background This study 
43 Mata, rtn1:: KANMX,  pWX206, BY4741 background This study 
44 Mata, ost5:: KANMX,  pWX206, BY4741 background This study 
45 Mata, emc4:: KANMX,  pWX206, BY4741 background This study 
46 Mata, ypr003c:: KANMX,  pWX206, BY4741 background This study 
47 Mata, nce102:: KANMX,  pWX206, BY4741 background This study 
48 Mata, erj5:: KANMX,  pWX206, BY4741 background This study 
49 Mata, die2:: KANMX,  pWX206, BY4741 background This study 
50 Mata, sct1:: KANMX,  pWX206, BY4741 background This study 
51 Mata, alg3:: KANMX,  pWX206, BY4741 background This study 
52 Mata, ygl010w:: KANMX,  pWX206, BY4741 background This study 
53 Mata, cwh41:: KANMX,  pWX206, BY4741 background This study 
54 Mata, mst27:: KANMX,  pWX206, BY4741 background This study 
55 Mata, prm8:: KANMX,  pWX206, BY4741 background This study 
56 Mata, erv14:: KANMX,  pWX206, BY4741 background This study 
57 Mata, alg9:: KANMX,  pWX206, BY4741 background This study 
58 Mata, ynl194c:: KANMX,  pWX206, BY4741 background This study 
59 Mata, nsg2:: KANMX,  pWX206, BY4741 background This study 
60 Mata, sac1:: KANMX,  pWX206, BY4741 background This study 
61 Mata, eps1:: KANMX,  pWX206, BY4741 background This study 
62 Mata, sur2:: KANMX,  pWX206, BY4741 background This study 
63 Mata, cpr5:: KANMX,  pWX206, BY4741 background This study 
64 Mata, pmt7:: KANMX,  pWX206, BY4741 background This study 
65 Mata, dpl1:: KANMX,  pWX206, BY4741 background This study 
66 Mata, kre27:: KANMX,  pWX206, BY4741 background This study 
67 Mata, ted1:: KANMX,  pWX206, BY4741 background This study 
68 Mata, get1:: KANMX,  pWX206, BY4741 background This study 
69 Mata, ice2:: KANMX,  pWX206, BY4741 background This study 
70 Mata, say1:: KANMX,  pWX206, BY4741 background This study 
71 Mata, mga2:: KANMX,  pWX206, BY4741 background This study 
72 Mata, gtt1:: KANMX,  pWX206, BY4741 background This study 
73 Mata, gpt2:: KANMX,  pWX206, BY4741 background This study 
74 Mata, kar5:: KANMX,  pWX206, BY4741 background This study 
75 Mata, cos10:: KANMX,  pWX206, BY4741 background This study 
76 Mata, mpd2:: KANMX,  pWX206, BY4741 background This study 
77 Mata, shr5:: KANMX,  pWX206, BY4741 background This study 
78 Mata, yhr045w:: KANMX,  pWX206, BY4741 background This study 
79 Mata, svp26:: KANMX,  pWX206, BY4741 background This study 
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80 Mata, ylr050c:: KANMX,  pWX206, BY4741 background This study 
81 Mata, cue4:: KANMX,  pWX206, BY4741 background This study 
82 Mata, msc1:: KANMX,  pWX206, BY4741 background This study 
83 Mata, pkr1:: KANMX,  pWX206, BY4741 background This study 
84 Mata, ypr063c:: KANMX,  pWX206, BY4741 background This study 
85 Mata, pho86:: KANMX,  pWX206, BY4741 background This study 
86 Mata, pry1:: KANMX,  pWX206, BY4741 background This study 
87 Mata, jem1:: KANMX,  pWX206, BY4741 background This study 
88 Mata, opi3:: KANMX,  pWX206, BY4741 background This study 
89 Mata, emc2:: KANMX,  pWX206, BY4741 background This study 
90 Mata, hmg2:: KANMX,  pWX206, BY4741 background This study 
91 Mata, ilm1:: KANMX,  pWX206, BY4741 background This study 
92 Mata, mns1:: KANMX,  pWX206, BY4741 background This study 
93 Mata, erv41:: KANMX,  pWX206, BY4741 background This study 
94 Mata, rtn2:: KANMX,  pWX206, BY4741 background This study 
95 Mata, ubx7:: KANMX,  pWX206, BY4741 background This study 
96 Mata, ssh1:: KANMX,  pWX206, BY4741 background This study 
97 Mata, bsd2:: KANMX,  pWX206, BY4741 background This study 
98 Mata, spc1:: KANMX,  pWX206, BY4741 background This study 
99 Mata, yjr015w:: KANMX,  pWX206, BY4741 background This study 
100 Mata, get3:: KANMX,  pWX206, BY4741 background This study 
101 Mata, ydl121c:: KANMX,  pWX206, BY4741 background This study 
102 Mata, ubp1:: KANMX,  pWX206, BY4741 background This study 
103 Mata, yip3:: KANMX,  pWX206, BY4741 background This study 
104 Mata, ynl046w:: KANMX,  pWX206, BY4741 background This study 
105 Mata, lro1:: KANMX,  pWX206, BY4741 background This study 
106 Mata, are2:: KANMX,  pWX206, BY4741 background This study 
107 Mata, ynr021w:: KANMX,  pWX206, BY4741 background This study 
108 Mata, alg12:: KANMX,  pWX206, BY4741 background This study 
109 Mata, zrg17:: KANMX,  pWX206, BY4741 background This study 
110 Mata, rcr1:: KANMX,  pWX206, BY4741 background This study 
111 Mata, ayr1:: KANMX,  pWX206, BY4741 background This study 
112 Mata, cpt1:: KANMX,  pWX206, BY4741 background This study 
113 Mata, msc2:: KANMX,  pWX206, BY4741 background This study 
114 Mata, orm1:: KANMX,  pWX206, BY4741 background This study 
115 Mata, cne1:: KANMX,  pWX206, BY4741 background This study 
116 Mata, flc2:: KANMX,  pWX206, BY4741 background This study 
117 Mata, erv46:: KANMX,  pWX206, BY4741 background This study 
118 Mata, frt2:: KANMX,  pWX206, BY4741 background This study 
119 Mata, prm9:: KANMX,  pWX206, BY4741 background This study 
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120 Mata, swh1:: KANMX,  pWX206, BY4741 background This study 
121 Mata, emc6:: KANMX,  pWX206, BY4741 background This study 
122 Mata, pom33:: KANMX,  pWX206, BY4741 background This study 
123 Mata, aqy2:: KANMX,  pWX206, BY4741 background This study 
124 Mata, yct1:: KANMX,  pWX206, BY4741 background This study 
125 Mata, izh3:: KANMX,  pWX206, BY4741 background This study 
126 Mata, erg3:: KANMX,  pWX206, BY4741 background This study 
127 Mata, per33:: KANMX,  pWX206, BY4741 background This study 
128 Mata, spc2:: KANMX,  pWX206, BY4741 background This study 
129 Mata, gsf2:: KANMX,  pWX206, BY4741 background This study 
130 Mata, ost6:: KANMX,  pWX206, BY4741 background This study 
131 Mata, sel1:: KANMX,  pWX206, BY4741 background This study 
132 Mata, erg5:: KANMX,  pWX206, BY4741 background This study 
133 Mata, hlj1:: KANMX,  pWX206, BY4741 background This study 
134 Mata, sso2:: KANMX,  pWX206, BY4741 background This study 
135 Mata, erg2:: KANMX,  pWX206, BY4741 background This study 
136 Mata, scs7:: KANMX,  pWX206, BY4741 background This study 
137 Mata, prc1:: KANMX,  pWX206, BY4741 background This study 
138 Mata, mid1:: KANMX,  pWX206, BY4741 background This study 
139 Mata, erg24:: KANMX,  pWX206, BY4741 background This study 
140 Mata, alg6:: KANMX,  pWX206, BY4741 background This study 
141 Mata, irc23:: KANMX,  pWX206, BY4741 background This study 
142 Mata, rsb1:: KANMX,  pWX206, BY4741 background This study 
143 Mata, alg8:: KANMX,  pWX206, BY4741 background This study 
144 Mata, ost3:: KANMX,  pWX206, BY4741 background This study 
145 Mata, ecm3:: KANMX,  pWX206, BY4741 background This study 
146 Mata, sly41:: KANMX,  pWX206, BY4741 background This study 
147 Mata, inp54:: KANMX,  pWX206, BY4741 background This study 
148 Mata, flc1:: KANMX,  pWX206, BY4741 background This study 
149 Mata, tyw1:: KANMX,  pWX206, BY4741 background This study 
150 Mata, pgc1:: KANMX,  pWX206, BY4741 background This study 
151 Mata, csm4:: KANMX,  pWX206, BY4741 background This study 
152 Mata, uip4:: KANMX,  pWX206, BY4741 background This study 
153 Mata, ypc1:: KANMX,  pWX206, BY4741 background This study 
154 Mata, rot2:: KANMX,  pWX206, BY4741 background This study 
155 Mata, ydr056c:: KANMX,  pWX206, BY4741 background This study 
156 Mata, yps7:: KANMX,  pWX206, BY4741 background This study 
157 Mata, ste14:: KANMX,  pWX206, BY4741 background This study 
158 Mata, irc22:: KANMX,  pWX206, BY4741 background This study 
159 Mata, yea4:: KANMX,  pWX206, BY4741 background This study 
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160 Mata, nvj2:: KANMX,  pWX206, BY4741 background This study 
161 Mata, yel043w:: KANMX,  pWX206, BY4741 background This study 
162 Mata, avt2:: KANMX,  pWX206, BY4741 background This study 
163 Mata, fmp52:: KANMX,  pWX206, BY4741 background This study 
164 Mata, sbh2:: KANMX,  pWX206, BY4741 background This study 
165 Mata, get2:: KANMX,  pWX206, BY4741 background This study 
166 Mata, sbh1:: KANMX,  pWX206, BY4741 background This study 
167 Mata, cho2:: KANMX,  pWX206, BY4741 background This study 
168 Mata, atf2:: KANMX,  pWX206, BY4741 background This study 
169 Mata, pmt6:: KANMX,  pWX206, BY4741 background This study 
170 Mata, wsc4:: KANMX,  pWX206, BY4741 background This study 
171 Mata, lag1:: KANMX,  pWX206, BY4741 background This study 
172 Mata, msc7:: KANMX,  pWX206, BY4741 background This study 
173 Mata, vma22:: KANMX,  pWX206, BY4741 background This study 
174 Mata, ept1:: KANMX,  pWX206, BY4741 background This study 
175 Mata, chs7:: KANMX,  pWX206, BY4741 background This study 
176 Mata, adp1:: KANMX,  pWX206, BY4741 background This study 
177 Mata, hmx1:: KANMX,  pWX206, BY4741 background This study 
178 Mata, hrd3:: KANMX,  pWX206, BY4741 background This study 
179 Mata, lac1:: KANMX,  pWX206, BY4741 background This study 
180 Mata, spt23:: KANMX,  pWX206, BY4741 background This study 
181 Mata, pmt2:: KANMX,  pWX206, BY4741 background This study 
182 Mata, nte1:: KANMX,  pWX206, BY4741 background This study 
183 Mata, erg6:: KANMX,  pWX206, BY4741 background This study 
184 Mata, scj1:: KANMX,  pWX206, BY4741 background This study 
185 Mata, hor7:: KANMX,  pWX206, BY4741 background This study 
186 Mata, rce1:: KANMX,  pWX206, BY4741 background This study 
187 Mata, scw10:: KANMX,  pWX206, BY4741 background This study 
188 Mata, hsd1:: KANMX,  pWX206, BY4741 background This study 
189 Mata, pmt3:: KANMX,  pWX206, BY4741 background This study 
190 Mata, frt1:: KANMX,  pWX206, BY4741 background This study 
191 Mata, sil1:: KANMX,  pWX206, BY4741 background This study 
192 Mata, isc1:: KANMX,  pWX206, BY4741 background This study 
193 Mata, yck1:: KANMX,  pWX206, BY4741 background This study 
194 Mata, fmo1:: KANMX,  pWX206, BY4741 background This study 
195 Mata, mnl1:: KANMX,  pWX206, BY4741 background This study 
196 Mata, emc1:: KANMX,  pWX206, BY4741 background This study 
197 Mata, orm2:: KANMX,  pWX206, BY4741 background This study 
198 Mata, sur4:: KANMX,  pWX206, BY4741 background This study 
199 Mata, arv1:: KANMX,  pWX206, BY4741 background This study 
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200 Mata, ydc1:: KANMX,  pWX206, BY4741 background This study 
201 Mata, ypr114w:: KANMX,  pWX206, BY4741 background This study 
202 Mata, vps4:: KANMX,  pWX206, BY4741 background This study 
203 Mata, erg4:: KANMX,  pWX206, BY4741 background This study 
204 Mata, swa2:: KANMX,  pWX206, BY4741 background This study 
205 Mata, snl1:: KANMX,  pWX206, BY4741 background This study 
206 Mata, scp160:: KANMX,  pWX206, BY4741 background This study 





Table 2-3 Plasmids used in this study. 
 
Plasmid Encoded protein Promoter Vector  Source 
pDN366 ER-GFP TDH3 YCp50 Ng  plasmid collection 
pWX204 ER-GFPfast TDH3 pRS316 This study 
pWX206 ER-GFP TDH3 pRS316 This study 
pWX214 ER-GFPfast (A64T/A71S) TDH3 pRS316 This study 
pCX12 ER-GFPfast GAL1 pRS316 This study 
pCX13 ER-GFP GAL1 pRS316 This study 
pCX20 H6-ER-GFP TDH3 pRS316 This study 
pCX34 ER-Δ2GFP TDH3 pRS316 This study 
pJC835 Hac1i HAC1 pRS313 (Cox and Walter, 1996) 
pSM70 KHN-HA PRC1 pRS316 (Vashist et al., 2001) 
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Table 2-4 Oligonucleotide primers used in this study. 
 





















When looking back at the history of the ERQC field, the creation of novel ERQC substrates 
plays important roles in identifying new factors and pathways. For example, the genetic selection 
for the mutants that stabilized engineered HMG-CoA reductase led to the discovery of hrd genes 
(Hampton et al., 1996). By checking the requirement of known ERAD components for the 
degradation of engineered misfolded substrates with distinct lesions, the concept of ERAD-L and 
ERAD-C were proposed (Vashist and Ng, 2004). Thus, to uncover the ER protein folding 
termination machinery, a new type of substrate is needed. We aimed to create an ER protein, 
which has the ability to fold but fails to fold efficiently due to the existence of the ERQC 
machinery. Thus, such a molecule should be able to mimic the futile folding cycles and its 
folding competence provides a direct means to evaluate the termination mechanisms deployed. 
Once this substrate is generated, the detailed biochemical analysis can reveal how the folding of 
this molecule is intervened. 
 
The previously developed ERAD substrates are not suitable in this particular case. Because they 
are folding-disabled molecules, they can never fold in the presence or absence of the folding 
termination machinery.  The native proteins are not ideal tools either, because they co-evolve 
with their respective QC systems and should be able to fold efficiently. Hence, the exogenous 
wild type proteins might be a good source of candidates. Even that, designing a model substrate 




3.2.1 Establish a pair of novel ERQC substrates 
Interestingly, we noticed that the ER-targeted green fluorescent protein (ER-GFP) might hold the 
promise. It has been reported by different groups that the ER-GFP fails to fold efficiently in the 
mammalian ER (Aronson et al., 2011; Jain et al., 2001). To test the folding competence of ER-
GFP in yeast ER, we created a yeast ER-GFP, in which the N-terminus is appended with a Kar2 
signal sequence and C-terminus is tagged with the ER retention signal HDEL (Figure 3-2A). The 
primary amino acid sequence of the construct was listed in Figure 3-1. It was previously reported 
that deleting a β strand from the GFP molecule totally disrupts its folding and this misfolded 
version of GFP is termed as Δ2GFP (Figure 3-2A and B) (Prasad et al., 2010). The same 
truncation was introduced into ER-GFP to fully disrupt its folding. The misfolded version of ER-
GFP was named as ER-Δ2GFP, which serves as a control to estimate the extent of ER-GFP 
misfoldness. We first transformed ER-GFP and ER-Δ2GFP into wild type cells and checked 
whether they were properly targeted into the ER by indirect immunostaining. The indirect 
immunofluorescence data showed that both of them co-localized with the ER marker, Kar2, and 
no cytosolic staining was detected (Figure 3-2C). Thus, both ER-GFP and ER-Δ2GFP were 
properly localized in the ER in wild type cells. We next checked the fluorescence intensity 
emitted from ER-GFP or ER-Δ2GFP in live cells under confocal microscopy. Results showed 
that ER-GFP fluorescence in wild type cells could only be visualized with increased detector 
gain but not with the lower setting, which suggests it folds poorly inside the yeast ER (Figure 3-
2D and Figure 3-7A). This is consistent with the previous observations in mammalian cells 
(Aronson et al., 2011; Jain et al., 2001). As expected, the fluorescence of ER-Δ2GFP was 
undetectable regardless of the detector gain setting, which is consistent with its structural 
disorder (Figure 3-2D) (Prasad et al., 2010).  
 
We were wondering whether the poor folding outcome of ER-GFP is due to its intrinsic folding 





Figure 3-1 Protein sequence alignment of GFP variants used in this study.  
 
Residues highlighted in red represented differences between ER-GFP and ER-GFPfast. Cysteine 
residues were denoted in green. Residues numbering was not according to UniProt Aequorea 
Victoria GFP protein. Here, methionine at position 1 was replaced by Kar2 signal sequence (M1-
D45), which included the initiation methionine for translation. ER-GFP variants also contained 






Figure 3-2 ER-GFP and variants localize in the ER. 
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Figure 3-2 ER-GFP and variants localize in the ER. 
 
(A) Schematic depiction of GFP variants. S.S., signal sequence.  
 
(B) A ribbon diagram of GFP structure. The deleted β strand in Δ2GFP was highlighted in red. 
  
(C) Intracellular localization of ER-GFP, ER-GFPfast, or ER-Δ2GFP in WT cells was analyzed 
by indirect immunofluorescenc. Different GFP substrates were detected using anti-GFP primary 
antibody. ER was visualized using anti-Kar2 primary antibody. Samples were analyzed by 
confocal microscope. Scale bar, 5 µm. This experiment showed that all ER-GFP variants co-
localize with the ER marker Kar2p.   
 
(D) WT cells expressing the vector, ER-GFP, or ER-Δ2GFP were grown to log phase at 30°C. 
GFP fluorescence was analyzed by confocal microscope with Detector Gain of 535 and 700 
respectively. Scale bar, 5 µm. ER-GFP fluorescence in WT cells could only be visualized with 
increased Detector Gain but not with the lower setting. For cells expressing ER-Δ2GFP and 




ER-GFP intrinsically folds poorly, it cannot serve as a model substrate to study protein folding 
termination mechanism. To rule out this possibility, we tested the folding of ER-GFP in other 
organelles. The ER-GFP can be easily re-directed to the cytosol by expressing the protein in a 
translocation mutant. To this end, we transformed ER-GFP into a translocation mutant, sec63-1. 
We compared the florescence signal emitted from ER-GFP in wild type and sec63-1 under 
confocal microscope. In wild type cells, ER-GFP localized in the ER and emitted weak 
fluorescent signal, which is consistent with previous result. By contrast, it was found that a 
significant portion of ER-GFP localized in the cytosol in sec63-1. Interestingly, the cytosolic 
localized GFP displayed stronger fluorescence intensity (Figure 3-3).  Thus, we concluded that 
ER-GFP has the capacity to fold but the folding attempts are disrupted in the ER probably by an 
unknown folding termination machinery.  
 
Although the fluorescence itself could reflect GFP folding, two other independent assays were 
designed to confirm its poor folding. Based on GFP structure, two cysteines are located in the 
interior of the β-barrel with a distance of 2.4 nm (Figure 3-4A) (Ormo et al., 1996). Thus, neither 
intermolecular disulfide bonds nor intramolecular disulfide bonds can be formed from these two 
cysteines. However, under two circumstances, these interior cysteines can form intermolecular 
disulfide bonds with other molecules. In one scenario, due to the prolonged folding process, 
these two cysteines are exposed and might form disulfide-linked complexes with other folding 
intermediates, which would eventually cause GFP to become misfolded. In another scenario, 
GFP fails to fold and displays the unstructured conformation, which makes the interior cysteines 
accessible to form intermolecular disulfide bonds. Either of these two cases would suggest the 
poor folding of ER-GFP. To examine the intermolecular disulfide bond formation of ER-GFP, 
we prepared total protein extracts from cells expressing ER-GFP and ER-Δ2GFP with 10% 
trichloroacetic acid (TCA). The precipitated proteins were resolved in TCA resuspension buffer 
with the presence of 20 mM N-Ethylmaleimide (NEM), which prevents post-lysis disulfide bond 





Figure 3-3 ER-GFP folds efficiently in the cytosol but not in the ER. 
 
WT or sec63-1 cells expressing ER-GFP were grown to log phase. GFP fluorescence was 
analyzed by confocal microscope with Detector Gain of 535. Scale bar, 5 µm. 
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oligomers of ER-GFP were detected (Figure 3-4B). As expected, these disulfide-linked 
complexes were fully reduced with the presence of the reducing reagent, dithiothreitol (DTT) 
(Figure 3-4B). Interestingly, the detected disulfide-linked oligomers of ER-GFP were similar to 
those of ER-Δ2GFP, indicating that a substantial portion of ER-GFP is misfolded (Figure 3-4B). 
The monomeric ER-Δ2GFP migrated faster than the monomeric ER-GFP on the SDS-PAGE due 
to the deletion of the β strand. It should be noted that such an assay is not quantitative. Even 
though disulfide-linked oligomers of ER-GFP are misfolded based on the structural information, 
the amount of disulfide-linked ER-GFP does not really reflect the amount of all the misfolded 
ER-GFP. In other words, the monomeric form of ER-GFP might also be misfolded. This could 
be easily verified by the observation that majority of the misfolded ER-Δ2GFP displayed as the 
monomeric form under the non-reducing condition (Figure 3-4B). 
 
Another approach that we designed to quantitatively evaluate the misfoldness of ER-GFP was an 
in vitro trypsinization assay. It is known that unfolded/misfolded proteins are sensitive to 
protease while the folded ones are resistant. Thus, the résistance of ER-GFP to protease reflects 
its folding. We prepared detergent solubilized microsomes from wild type cells expressing ER-
GFP or ERΔ2-GFP. Equal amount of microsomal protein extracts were subjected to limited 
trypsin digestion. The reaction was terminated as time indicated and aliquots were taken for 
quantitative immunoblotting analysis. We also probed a fully folded glycoprotein, named 
glycophospholipid-anchored surface protein (Gas1p), which is resistant to limited trypsin 
digestion and thus can serve as an internal control for normalization.  The relative GFP protein 
level at each time point was calculated by normalizing the detected GFP level to the Gas1p level 
to eliminate the variation caused by loading. The remaining percentage of GFP was calculated by 
normalizing the relative GFP level over the digestion to the GFP level at the beginning. The 
result showed that the sensitivity of ER-GFP and ER-∆2GFP to trypsin was comparable, which 





Figure 3-4 Majority of ER-GFP is misfolded. 
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Figure 3-4 Majority of ER-GFP is misfolded. 
 
(A) A mesh-like structure of GFP. The two cysteines were labeled with blue spheres and the 
fluorophore was labeled with green spheres. The GFP structure clearly showed that those two 
cysteines are located interior of the β barrel and flanked the fluorophore. Once the 
intermoleclular disulfide bond is formed through either of the cysteines or both, the GFP 
becomes misfolded.   
 
(B) Total protein extracts were prepared from wild type cells expressing ER-GFP or ER-Δ2GFP 
by TCA precipitation. The precipitated proteins were resolved in the presence of 20 mM NEM. 
The solubilized proteins were separated by SDS-PAGE under non-reducing (-DTT) or reducing 
(+DTT) conditions and analyzed by immunoblotting using anti-GFP antibody.  
 
(C) The equal amounts (60 µg each) of solubilized microsomal proteins from ER-GFP or ER-
Δ2GFP in WT cells were digested with 5 μg/ml trypsin on ice. The reaction was terminated as 
the times indicated. Proteins were separated by SDS-PAGE and analyzed by quantitative 




Subsequently, we tested whether the misfolded ER-GFP was degraded by ERAD. To this end, 
cycloheximide chase was performed. Cycloheximide was added to wild type cells expressing 
ER-GFP to block new protein synthesis and start the chase. Equal amount of cells were taken to 
analyze the turnover of ER-GFP over the chase. A cytosolic stable protein, 3-phosphoglycerate 
kinase (Pgk1p), was probed as an internal control for normalization. ER-GFP remained stable 
over the chase (Figure 3-5). The stabilization of misfolded ER-GFP is probably due to a lack of 
ERAD signal in its primary sequence. 
 
Whether the accumulation of misfolded ER-GFP would disrupt the folding of endogenous ER 
proteins?  To test this, two endogenous secretory proteins, Cpy1p and Gas1p, with distinct 
processing mechanisms were analyzed. It is well established that, if there are any folding defects, 
these two proteins would be retained in ER and targeted for degradation by the ERQC 
machinery. Thus, any significantly delayed processing or missing of the mature form of these 
two proteins would directly reflect defects in folding.  The details about the processing of Cpy1p 
and Gas1p were illustrated in Figure 3-6A. Wild type cells expressing empty vetor, ER-GPF, or 
ER-Δ2GFP were labeled with [35S] methionine/cysteine for 5 min. The chase was initiated by the 
addition of cold methionine/cysteine and was terminated as the times indicated. The newly 
synthesized and processed Cpy1p and Gas1p were immunoprecipitated and resolved by SDS-
PAGE. It was shown that neither the expression of ER-GFP nor ER-Δ2GFP interferes the folding 
of Cpy1p or Gas1p (Figure 3-6B). Thus, we concluded that the expression of ER-GFP and ER-
Δ2GFP falls into the functional range of the ER folding and QC machineries and thus is very 
unlikely to cause any indirect effects. More importantly, since the folding of endogenous 
proteins was unaffected in cells expressing ER-GFP, it suggests that the folding termination 
mechanism probably acts directly on substrates rather than the general folding machinery. 
Together, ER-GFP might represent the folding substrate that we were looking for, which has the 
competence to fold but failed to fold in vivo due the restriction of the ERQC machinery. In 
addition, the inability of ER-GFP molecules to fold even after extended periods suggests that 





Figure 3-5 ER-GFP is stable and is not degraded by ERAD. 
 
Turnover of ER-GFP in WT cells was determined by cycloheximide chase and quantitative 
immunoblotting. The protein level of Pgk1p served as an internal control for normalization. 










Figure 3-6 ER-GFP and variants’ expression does not disrupt maturation and processing 
of endogenous proteins. 
 
(A) A scheme of CPY and Gas1p processing through the secretory pathway. The signal peptide 
was highlighted in red. The glycophosphatidylinositol (GPI anchor) of Gas1p was highlighted in 
green. The hexagon represented glycans added in the secretory pathway. The change of the 
molecular weight of different forms of CPY was due to the cleavage of signal peptide, 
glycosylation and the removal of the propeptide. The change of the molecular weight of different 
forms of Gas1p was due to the cleavage of signal peptide, glycoslation and the addition of GPI 
anchor.  
 
(B) CPY and Gas1 biosynthesis was examined in WT cells expressing vector, ER-GFP, ER-
GFPfast or ER-Δ2GFP by pulse-chase assay. Positions of the non-translocated, ER, Golgi and 
mature forms of CPY were indicated by pre-CPY, p1, p2 and m, respectively. Positions of the 
non-translocated, ER, Golgi/Plasma membrane (PM) were indicated as pre-Gas1, ER Gas1 and 
Golgi/PM Gas1, respectively. The biosynthesis of CPY and Gas1p was not affected by the 
expression of ER-GFP variants because the processing efficiency of CPY and Gas1p in the cells 
expressing ER-GFP variants was comparable to that in cells expressing empty vector. This result 
suggests that maturation and processing of endogenous proteins are not disturbed by the 
expression of ER-GFP variants. 
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substrate, ER-GFP has some additional advantages. First, it is easy to monitor its folding by 
those assays described previously. Second, due to a lack of ERAD degradation signal, it is a 
stable protein and thus there is no need to account for the effects of turnover.  
 
Why ER-GFP becomes folding incompetent after it is translocated into the ER? What is the 
characteristic that makes it become a client of ERQC? Interestingly, GFP is a well-known slow 
folding molecule (Reid and Flynn, 1997). Coincidentally, it is proposed and confirmed that the 
ERAD-L pathway select its substrates based on a mannose timing mechanism, in which the 
glycoproteins with prolonged folding receive extensive mannose trimming and eventually expose 
the degradation signal to ERAD (Gauss et al., 2011; Helenius and Aebi, 2004). Thus, we 
reasoned that such a concept of a time constraint for folding might also apply for ER-GFP here. 
If this is the case, a fast-folding GFP variant should complete its folding without being subjected 
to the folding termination machinery.  
 
Recently, a fast-folding GFP variant, named P7, was engineered by Fisher and DeLisa (Fisher 
and DeLisa, 2008). We targeted this fast folding GFP into ER by adding the signal sequence and 
ER retention signal like ER-GFP and termed it as ER-GFPfast (Figure 3-2A). The indirect 
inmmunostaining confirmed that ER-GFPfast was localized in the ER properly (Figure 3-2C).  As 
expected, the expression of ER-GFPfast did not interfere with the folding of endogenous proteins 
either (Figure 3-6B). To directly compare the fluorescence intensity emitted from ER-GFP and 
ER-GFPfast, wild type cells expressing either of these two constructs were analyzed by two 
means, confocal microscopy and flow cytometry. The confocal microscopy showed that ER-
GFPfast displayed a qualitatively stronger fluorescence signal than ER-GFP (Figure 3-7A). To 
provide quantitative analysis, the relative fluorescence intensity of ER-GFP and ER-GFPfast was 
accessed by flow cytometry. The relative value of the fluorescence signal emitted by ER-GFP in 
wild type cells was 38, while that of ER-GFPfast was 120 (Figure 3-7B). However, it might be 





Figure 3-7 ER-GFPfast displays stronger fluorescence signal than ER-GFP in wild type 
cells. 
 
Wild type cells expressing ER-GFP, ER-GFPfast, and ER-GFPfast(A64T/A71S) were grown to log 
phase. GFP fluorescence was analyzed by confocal microscopy (A) and flow cytometry (B). 
GFP level of cells in (B) were analyzed by quantitative Western blotting (see Figure 3-8). The 
fluorescence signal was normalized to GFP protein level to calculate relative folded GFP level. 
Scale bar, 5 µm. 
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higher protein expression level. To rule out this possibility, we measured the relative GFP 
protein level of ER-GFP and ER-GFPfast in wild type cells. The whole protein extracts were 
prepared from the cells used for flow cytometry analysis. The protein levels of ER-GFP and ER-
GFPfast were determined by quantitative immunoblotting. Because ER-GFP and ER-GFPfast were 
very similar to each other, their binding affinity to the same antibody should be very similar. The 
protein level of PGK (phosphoglycerate kinase) per cell tends to maintain the same among 
different strains and under various conditions. Thus, the level of PGK usually serves as a loading 
control for both qualitative and quantitative analysis. The total protein level of ER-GFP or ER-
GFPfast was calculated by normalizing the detected GFP level to the detected PGK level. It was 
found that the protein level of ER-GFPfast was slightly lower than that of ER-GFP in wild type 
cells (Figure 3-8). To directly compare the folding outcome of ER-GFP and ER-GFPfast, the 
relative folded GFP level was calculated by normalizing the fluorescence intensity, an indicator 
of folded GFP level, to total GFP protein level. The relative folded ER-GFPfast was four times as 
high as ER-GFP in wild type cells (Figure 3-7B).   
 
The higher fluorescence signal displayed by ER-GFPfast indicates that it folds better than ER-
GFP. If this is the case, ER-GFPfast should be able to complete its folding without forming the 
misfolded disulfide-linked complexes. Indeed, the non-reducing immunoblotting showed that 
ER-GFPfast forms much less disulfide-linked oligomers and could only be detected under the 
condition of over-exposure (Figure 3-9A and Figure 3-16). Furthermore, ER-GFPfast displayed 
stronger resistance against trypsin digestion compared to ER-GFP (Figure 3-9B). Together, we 
provided three independent lines of evidence to confirm the better folding proficiency of ER-
GFPfast. Because ER-GFP and ER-GFPfast share high similarities in their primary sequences and 
three dimensional structures, it is very likely that the distinct folding outcomes are specifically 
due to the different folding rates. Thus, the substrate pair ER-GFP and ER-GFPfast appears to 





Figure 3-8 Quantification of relative GFP level in different strains.  
 
The level of various GFP substrates used for all the flow cytometry analysis was analyzed by 
quantitative immunoblotting. Relative GFP protein level was calculated by normalizing the GFP 





Figure 3-9 ER-GFPfast forms less disulfide linked oligomers and is more resistant to 
protease digestion. 
 
(A) Total proteins were extracted from wild type cells expressing ER-GFP or ER-GFPfast by 
TCA precipitation and subjected to immunoblotting in the presence or absence of DTT. The 
blots were probed with anti-GFP antibody.   
 
(B) The equal amounts (60 µg each) of solubilized microsomal proteins were prepared from wild 
type cells expressing ER-GFP or ER-GFPfast and subjected to trypsin digestion at the 
concentration of 5 μg/ml. The digestion reaction was terminated as the times indicated by adding 
appropriate amount of 5× SDS loading buffer and boiling at 100°C for 5 min. Proteins were 
separated by SDS-PAGE and analyzed by quantitative immunoblotting. The blots were probed 
with anti-GFP and anti-Gas1 antibodies. The Gas1 protein level served as an internal control for 




3.2.2 Unfolded ER-GFP is modified by O-mannosylation, but its faster folding variant is 
unaffected. 
 
We reason that a post translational modification inside the ER causes the poor folding outcome 
of ER-GFP due to the following reasons. First, ER-GFP is a folding competent molecule and 
could fulfill its folding process when translocation is compromised. Second, the poor folding of 
ER-GFP is very unlikely due to the general ER folding environment. Otherwise, the fast folding 
variant should also fold poorly. What could specifically recognize slow folding molecules and 
terminate the futile folding process? A plausible explanation is that an ER based post 
translational modification disrupted ER-GFP folding due to its slow folding. This could resolve 
the discrepant folding outcomes of ER-GFP in the cytosol and inside the ER.  
 
Glycosylation is one the major events that occur on secretory proteins during or after 
translocation.  The roles of protein glycosylation in ERQC, including N-linked glycosylation and 
O-mannosylation, have also been well documented. However, ER-GFP did not contain any N-
linked glycosylation motif, which rules out the involvement of the N-linked glycosylation 
machinery and the N-glycan processing factors (Schwarz and Aebi, 2011). Thus, using ER-GFP 
as a model substrate further simplifies the analysis. Even though there is no currently known 
consensus of amino acid motif for O-mannosylation, over a decade of research clearly showed 
that the O-mannosylaiton machinery covalently modify various of misfolded proteins (Coughlan 
et al., 2004; Goder and Melero, 2011; Harty et al., 2001; Hirayama et al., 2008; Li et al., 2012; 
Nakatsukasa et al., 2004; Rubenstein et al., 2012; Vashist et al., 2001). The ER based O-
mannosylation is catalyzed by the evolutionarily conserved protein O-mannosyltransferases 
(PMT), which add O-linked mannoses at Ser/Thr residues. The further elongation of the O-
mannose chains are carried out by the Golgi localized glycosyltransferases, which are divergent 
throughout evolution. In budding yeast, the PMT family consists of at least six members, Pmt1p-
Pmt6p. Among them, only Pmt1p and Pmt2, which form heterodimeric complexes in vivo and in 
vitro, are responsible for the modification of misfolded proteins (Lommel and Strahl, 2009). It 
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should be noted that Pmt1/Pmt2 complex also modifies some endogenous proteins that require 
O-mannosylation for maturation (Lommel and Strahl, 2009). For example, a plasma membrane 
protein, named Mid2p, is O-mannosylated in a Pmt2p dependent manner (Philip and Levin, 
2001). The modification increases Mid2p stability, which is required for its function as a 
mechanosensor of cell wall integrity (Lommel et al., 2004). The modification of the endogenous 
proteins most likely occurs co-translationally (Elorza et al., 1977; Lommel and Strahl, 2009). 
More recently, it was shown that the O-mannosylation of the misfolded proteins can also happen 
in a post-translational manner (Harty et al., 2001). Such a modification seems to be very specific 
because the Pmt1/Pmt2 protein complex selectively modifies Gas1*p, a misfolded version of 
Gas1p, but not the wild type protein (Hirayama et al., 2008). Interestingly, the expression of 
pmt1 or pmt2 is regulated by the unfolded protein response, which suggests their roles in keeping 
ER protein homeostasis (Travers et al., 2000). Thus, we were wondering whether the Pmt1/Pmt2 
complex was involved in the folding termination of ER-GFP. An attractive hypothesis was that 
modifying small side chains of folding polypeptides with bulky hydrophilic mannose moieties 
might directly terminate folding. 
 
In order to test this hypothesis, we first purified ER-GFP from wild type cells. An N-terminal 
six-histidine tag was inserted into the ER-GFP construct after the Kar2 signal sequence by site-
direct mutagenesis to facilitate the purification. It should be noted that the H6-ER-GFP could 
only be purified from wild type yeast cells but not bacteria cells because there is no ER 
glycosylation system in bacteria. Microsomal protein extracts prepared from wild type cells 
expressing H6-ER-GFP were incubated with Ni-NTA resin and the immobilized proteins were 
subsequently eluted in the presence of 250 mM imidozole. The high concentration of imidozole 
was removed by overnight dialysis. The purified H6-ER-GFP was separated by SDS-PAGE and 
stained with coomassie blue (Figure 3-10B). The staining showed that H6-ER-GFP was relatively 
pure and could be used for further analysis. Next, we aimed to examine whether ER-GFP 
received O-mannosylation and how the modification would affect the property of the protein 





Figure 3-10 A schematic representation of experimental design. 
  
(A) Microsomal protein extracts prepared from wild type cells expressing H6-ER-GFP were 
incubated with Ni-NTA resin. The immobilized proteins were subsequently eluted with high 
concentration of imidozole. After overnight dialysis to exchange the protein buffer, the purified 
H6-ER-GFP was subjected to ConA chromatography. T, U, B denoted total, unbound, and bound 
fractions, respectively. The ConA unbound fraction was defined as the sum of respective flow-
through and wash fractions. An equal portion of the total and unbound fractions were analyzed 
by fluorescence measurement.  
 
(B) The purified H6-ER-GFP was analyzed by SDS-PAGE and stained with coomassie blue. 
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(ConA). ConA is a lectin which specifically binds to mannosyl and glucosyl residues of 
glycoproteins. ConA affinity chromatography is a classical and reliable method to separate 
glycosylated proteins from non-glycosylated proteins (Sweet and Pelham, 1992). As shown in 
Figure 3-1, the primary amino acid sequence of ER-GFP lacks N-linked glycosylation motif so 
any binding is due to O-glyccans (Schwarz and Aebi, 2011). The ConA unbound fractions were 
collected. Equal portion of the ConA unbound fractions and the starting material were subjected 
to fluorescence measurement. Initially, we also tried to elute the ConA bound fractions under 
native conditions with 10% α-methyl mannopyranoside (MMP), which is a binding competitor to 
ConA. However, such a trial failed probably due to the tight binding between ConA and H6-ER-
GFP. We quickly realized that the poor elution efficiency might not be a problem because nearly 
all fluorescence activity of the starting material was recovered in the unbound fraction (Figure 3-
11A). Thus, no fluorescence activity should be expected from the ConA bound fraction. To 
analyze the protein amount of the ConA bound H6-ER-GFP, we eluted ConA bound proteins 
under denaturing conditions. The quantitative immunoblotting showed that the ConA bound 
fraction of H6-ER-GFP accounted for the majority of the loaded material even without 
contributing any fluorescence activity (Figure 3-11B). Based on these unexpected results, we 
concluded that ER-GFP receives O-mannosylation in the wild type cells, which caused the 
modified ER-GFP to be folding-disabled.  
 
To further confirm the conclusion we reached above, we developed a similar experiment using 
the untagged ER-GFP (Figure 3-12A).  This time, we planned to compare the fluorescence 
activity of non-glycosylated ER-GFP and O-mannosylated ER-GFP directly. To this end, we 
prepared microsomal protein extracts from wild type cells expressing ER-GFP. The crude 
protein extracts were incubated with ConA-Sepharose beads. The ConA bound fraction was 
eluted with 10% MMP under native condition. Thus, the unbound fraction contained non-
glycosylated ER-GFP while O-mannosylated ER-GFP was present in the eluate. Equal portion of 
unbound and bound fraction was subjected to fluorescence intensity measurement. Because we 





Figure 3-11 O-mannosylation prevents ER-GFP folding. 
 
(A) The fluorescence measurement of the total and unbound fractions as described in Figure 3-
10.  
 
(B) H6-ER-GFP protein level of each fraction after the ConA chromatography. T, U, F, W, B 
denoted total, unbound, flow-through, wash, and bound fractions, respectively. The unbound 
fraction was defined as the sum of respective flow-through and wash fractions. An equal portion 
of each fraction was subjected to quantitative immunoblotting analysis. The percentage of 
unbound and bound fractions at each time point was quantified and plotted in the graph. The data 
plotted were three independent experiments with standard deviation of the mean indicated. P > 





Figure 3-12 O-mannosylated ER-GFP lacks fluorescence activity.  
 
(A) A scheme of experimental design. Microsomal protein extracts were prepared from wild type 
cells expressing ER-GFP or empty vector and subjected to ConA chromatography. The flow-
through fraction was collected. After washing, the ConA bound fraction was eluted with buffer 
containing 10% MMP. An equal fraction of the flow-through and eluate fractions were subjected 
to fluorescence and protein level measurement. F, B, E: flow-through, bound and eluate 
fractions, respectively. MMP, methyl α-D-mannopyranoside.  
 
(B) – (D) Quantification of the fluorescence intensity and protein level of GFP in unbound 
fraction and eluate fraction. Error bars, mean ± SD (N = 3). *P < 0.01 and P > 0.05 is not 
significant (NS), Student’s t-test. 
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microsomal proteins from wild type cells expressing an empty vector to provide background 
signals for GFP fluorescence measurement. Similarly, the protein level of ConA unbound and 
bound ER-GFP was determined by quantitative immunoblotting. The data showed that, 
compared with non-glycosylated ER-GFP, O-mannosylated ER-GFP failed to emit fluorescence 
(Figure 3-12B), even though their protein levels were similar (Figure 3-12C and D). We were 
aware of the low elution efficiency of O-mannosylated ER-GFP by 10% MMP. But we reasoned 
that, the O-mannosylated ER-GFP, which can be easily eluted by MMP, does not bind to ConA 
tightly and thus it is very possible that they contain less mannose residues. In turn, those that fail 
to be eluted are more likely to carry on more mannose side chains. Since the less O-
mannosylated ER-GFP does not contain any fluorescence activity, it is very likely that those 
more O-mannosylated species cannot emit fluorescence either. Thus, this set of experiment also 
supports the idea that ER-GFP is folding disabled once being O-mannosylated. 
 
We next compared the extent of O-mannosylation on ER-GFP and ER-GFPfast. To this end, total 
protein extracts prepared from wild type cells expressing ER-GFP or ER-GFPfast was incubated 
with ConA-Sepharose beads. The ConA bound fraction was eluted under denaturing condition as 
described before. The same portion of the starting material, unbound and bound fractions was 
subjected to SDS-PAGE and followed by immunoblotting. As shown in Figure 3-13, majority of 
ER-GFP was precipitated by the ConA while ER-GFPfast was found mostly in the unbound 
fraction. Considering the previous observation that O-mannosylated ER-GFP was folding-
disabled, this result explained why ER-GFP was as vulnerable as the misfolded ER-Δ2GFP to 
trypsin digestion. To show the specificity of the ConA pull down from the whole cell extracts, 
two additional unrelated proteins were checked. The cytosolic protein PGK, which is not 
glycosylated, thereby served as a negative control. It was found that PGK was detected 
exclusively in the unbound fraction (Figure 3-13 middle panel). By contrast, Gas1p, a protein 
that receives both N- and O-linked glycosylation was fully recovered in the ConA-bound fraction 
(Figure 3-13 lower panel). We were aware that some of the potential O-mannosylation sites of 





Figure 3-13 Majority of ER-GFP is O-mannosylated while ER-GFPfast remains mostly 
unmodified.  
 
Crude protein extracts were prepared from wild type cells expressing ER-GFP, ER-GFPfast, or 
ER-GFPfast(A64T/A71S) and subjected to ConA chromatography. T, U, B denoted the total, 
unbound and bound fractions respectively. An equal portion of each fraction was analyzed by 
immunoblotting. The blot was also probed with anti-PGK and anti-Gas1 antibodies to serve as 
negative control and positive control respectively.  
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GFPfast is due to a lack of these sites. To test this, we restored those O-mannosylation sites in 
ER-GFPfast and created the ER-GFPfast(A64T/A71S) (Figure 3-1). After transforming this 
construct into wild type cells, the folding status of ER-GFPfast(A64T/A71S) was analyzed by 
measuring the fluorescence signal. Confocal microscopy data showed that ER-
GFPfast(A64T/A71S) displayed very similar fluorescence intensity to ER-GFPfast (Figure 3-7A). 
This was further confirmed by the quantitative analysis of flow cytometry (Figure 3-7B). The 
protein expression levels of ER-GFPfast and ER-GFPfast(A64T/A71S) in wild type cells were 
more or less the same (Figure 3-8). After calculating the relative folded GFP level, the folding 
outcomes of ER-GFPfast and ER-GFPfast(A64T/A71S) were also similar to each other (Figure 3-
7B). The similar folding status of ER-GFPfast and ER-GFPfast(A64T/A71S) suggests that 
machinery differentiates its clients based on the folding rate rather than the potential O-
mannosylation sites. To test this, protein extracts prepared from wild type cells expressing ER-
GFPfast(A64T/A71S) were applied to ConA chromatography. As expected, it was found that 
majority of the ER-GFPfast(A64T/A71S) still remained in the ConA unbound fraction (Figure 3-
13). The result indicates that ER-GFPfast(A64T/A71S) could still evade the modification of the 
O-mannosylation machinery. Together, our results suggest that ER-GFP, but not ER-GFPfast, is 
specifically modified by the O-mannosylation machinery and thus becomes misfolded.  
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3.2.3 The O-mannosylation on ER-GFP occurs in a post-translational manner. 
 
So far, our results did not rule out the possibility that the O-mannosylation on ER-GFP was 
occurred in a co-translational way. If this was the case, it would suggest that the O-
mannosylation machinery cannot be a part of the ERQC pathway or select proteins with 
prolonged folding for modification. Rather, the machinery might just happen to recognize ER-
GFP during translocation for some unknown reasons. However, this scenario is very unlikely to 
be true due to the following reasons. First, ER-GFP, ER-GFPfast  and ER-GFPfast(A64T/A71S) are 
very similar molecules in their primary amino acid sequences. All of them are constructed in the 
same way and carry the same ER targeting sequence. If there was any co-translational 
modification on ER-GFP, it should apply to all the three of them. Since majority of ER-GFPfast  
and ER-GFPfast(A64T/A71S) were detected in the ConA unbound fractions (Figure 3-13), it is 
very unlikely that ER-GFP is O-mannosylated co-translocationally. Second, it has been reported 
by Rӧmisch ’s and Endo’s groups that an ERAD substrate received O-mannosylation in a post-
translocational way (Harty et al., 2001; Nakatsukasa et al., 2004).   
 
To iron out that possibility with our own system, the following experiments were designed. We 
first constructed ER-GFP and ER-GFPfast under the driven of a GAL1 promoter. The galactose 
inducible ER-GFP and ER-GFPfast allowed us to control the protein expression and analyze the 
glycosylation status of the newly synthesized proteins.  Cells carrying these two constructs were 
grown in medium containing 3% raffinose to log phase, in which neither ER-GFP nor ER-GFPfast 
would be expressed. To induce the expression, cells were collected by low speed centrifugation 
and resuspended in medium containing galactose as a new carbon resource. After 45 min of 
induction, cycloheximide was added into the medium to block new protein synthesis and start the 
chase. Cells at each chasing time point were harvested and the whole cell protein extracts were 
prepared. Thus, how the O-mannosylation machinery acted on the newly synthesized ER-GFP or 
ER-GFPfast after the time window of 45 min induction could be analyzed by ConA 
chromatography. The quantitative immunoblotting showed that there was around 30% of the 
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total ER-GFP remained non-glycosylated after 45 min galactose induction, which was 
significantly higher than that at steady state level (Figure 3-14A). Importantly, the non-
glycosylated ER-GFP quickly decreased and converted to the O-mannosylated form upon the 
initiation of the chase (Figure 3-14A). By contrast, majority of the ER-GFPfast remained 
unmodified over the chase (Figure 3-14A). If the modification is a co-translational event, there 
would be no change of the percentage of non-glycosylated ER-GFP over the chase. Hence, our 
results clearly showed the O-mannosylation of ER-GFP occurs post-translationally. However, 
there was only 30% of the total ER-GFP was not O-mannosylated at the beginning of the chase. 
This is because the cells express ER-GFP heterogeneously upon the addition of galactose 
medium. Thus, the earlier synthesized ER-GFP might receive O-mannosylation before the chase 
is started. To further strengthen our point, we shortened the galactose induction time to 30 min 
and repeated similar analysis. As expected, we found that around 50% of the total ER-GFP was 
not O-mannosylated at the beginning of chase (Figure 3-14B). Similarly, the non-glycosylated 
ER-GFP was quickly O-mannosylated over the chase (Figure 3-14B).  
 
Together, we showed conclusively that the modification of ER-GFP is a post-translational event, 
which is also consistent with our own reasoning and the earlier results published by other groups 




Figure 3-14 ER-GFP is modified post-translationally.  
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Figure 3-14 ER-GFP is modified post-translationally. 
 
(A) Cells expressing galactose inducible ER-GFP and ER-GFPfast were grown in SC medium 
containing 3% raffinose. For induction, cells were harvested by low speed centrifugation and 
resuspended in SC medium containing 2% galactose. After 45 min, cycloheximide was added to 
begin the chase. Cell extracts prepared from cells were collected at each time point and subjected 
to ConA chromatography. An equal portion of each fraction was analyzed by quantitative 
immunoblotting. T, U, F, W, B denote total, unbound, flow-through, wash, and bound fractions, 
respectively. The unbound fraction is defined as the sum of respective flow-through and wash 
fractions. The percentage of unbound and bound fractions at each time point was quantified and 
plotted the graph.  
 
(B) The experimental procedure was the same as (A) expect that galactose induction time was 30 
min. The non-glycosylated ER-GFP gradually received O-mannosylation. This result showed 
that the modification is a post-translational event. Otherwise, there would be no change of the 




3.2.4 Unfolded protein O-mannosylation by Pmt1/Pmt2 actively terminates folding. 
  
There are two possibilities that could explain why O-mannosylated ER-GFP is misfolded. It 
might be possible that the O-mannosylation machinery terminates folding midstream because the 
prolonged folding process of ER-GFP exceeds folding parameters defined by the cells. 
Alternatively, if ER-GFP inherently folds poorly in the ER, O-mannosylation could be the 
consequence of folding failure rather than the cause. To differentiate these possibilities, we 
genetically eliminate the O-mannosylation machinery and analyzed ER-GFP folding in the O-
mannosylation defective strains. If O-mannosylation specifically terminates folding, decreasing 
it should allow folding to proceed to completion. On the other hand, no improvement would be 
expected if ER-GFP intrinsically folds poorly in the ER.  
 
We first transformed ER-GFP into ∆pmt1, ∆pmt2 and ∆pmt1∆pmt2 cells. Cell extracts prepared 
from wild type, ∆pmt1, ∆pmt2 or ∆pmt1∆pmt2 cells were applied to ConA chromatography. It 
was found that the ConA bound fraction of ER-GFP was reduced in ∆pmt1 or ∆pmt2 cells 
(Figure 3-15, compare lane 1-9), which suggests the modification of ER-GFP is catalyzed by 
Pmt1p and Pmt2p. As expected, the O-mannosylation of ER-GFP was further decreased in 
∆pmt1∆pmt2 cells (Figure 3-15, compare lane 1-3 and lane 10-12).  
 
Next, we biochemically characterized ER-GFP in those pmt mutants. Previous study in 
mammalian cells suggested that the ER-GFP forms disulfide-linked oligomers merely due to its 
intrinsic slow folding rate and the oxidative folding environment inside the ER (Aronson et al., 
2011). For the fast folding variant of ER-GFP, it folds fast enough to bury those two cysteines 
inside the β barrel, which allows the folding to complete before the formation of disulfide-linked 
complexes in the oxidative ER environment.  If that is the case, the formation of disulfide-linked 
oligomers of ER-GFP in pmt mutants should be similar to that in the wild type cells. We 





Figure 3-15 The O-mannosylation of ER-GFP is mainly mediated by Pmt1p-Pmt2p. 
 
Crude protein extracts prepared from wild type, Δpmt1, Δpmt2 or Δpmt1Δpmt2 cells expressing 
ER-GFP were subjected to ConA chromatography. T, U, B denoted the total, unbound and bound 
fractions. An equal portion of each fraction was separated by SDS-PAGE and analyzed by 
immunoblotting. PGK served as a negative control of the ConA binding experiment and Gas1 
served as a positive control. 
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before. The 3% SDS soluble proteins were analyzed by immunoblotting under non-reducing and 
reducing conditions. The disulfide-linked oligomers of ER-GFP in wild type cells were detected 
to a similar extent to previous observation (Figure 3-4 and Figure 3-16). Interestingly, it was 
found that the disulfide-linked oligomers were decreased in ∆pmt1or ∆pmt2 cells and further 
reduced in ∆pmt1∆pmt2 cells (Figure 3-16). All the disulfide-linked oligomers could be fully 
reduced in the presence of DTT as expected. Consistently, the disulfide-linked complexes ER-
GFPfast were almost undetectable in pmt mutants even though a small amount of that was found 
in wild type cells (Figure 3-16). We concluded that O-mannosylation facilitates the formation of 
disulfide-linked oligomers of ER-GFP. It is possible that the O-mannosylation machinery 
specifically recognizes and modifies the ER-GFP with prolonged folding, which causes the 
misfolding of ER-GFP. The unfolded ER-GFP would keep a stretched conformation and thus 
those two cysteines become accessible to form intermolecular disulfide bonds. Such a situation 
could be further exacerbated by the oxidative environment of the ER. It might be interesting to 
grow the cells expressing ER-GFP with tolerable concentration of DTT and test whether the 
folding could be improved. Nevertheless, our results suggest that, apart from the intrinsic slow 
folding rate of the protein and the oxidative ER environment, the O-mannosylation machinery is 
an additional factor that contributes to the formation of disulfide-linked oligomers.  
 
Since reduced disulfide-linked oligomers of ER-GFP were observed in the pmt mutants, we 
expected there would be a folding improvement of ER-GFP in those mutants. To test this, we 
first analyzed the fluorescence signal of ER-GFP in wild type, ∆pmt1, ∆pmt2 and ∆pmt1∆pmt2 
cells. The fluorescence microscope imaging showed that ER-GFP emitted stronger fluorescence 
signal in the pmt single mutants (Figure 3-17A). The fluorescence intensity of ER-GFP was 
further increased in ∆pmt1∆pmt2 cells (Figure 3-17A). The quantitative analysis by flow 
cytometry showed that relative fluorescence signal of ER-GFP was around 110 in the single 
mutants and was 244 in the double mutant compared with that of 38 in the wild type cells (Figure 
3-17B). The protein levels of ER-GFP in wild type cells and pmt mutants were determined by 





Figure 3-16 O-mannosylation facilitates the disulfide linked oligomers formation. 
 
Total proteins were extracted from wild type cells or pmt mutants expressing ER-GFP or ER-
GFPfast by TCA precipitation and subjected to immunoblotting in the presence or absence of 





Figure 3-17 ER-GFP displays stronger fluorescence signal in the pmt mutants. 
 
WT, ∆pmt1, Δpmt2, or Δpmt1Δpmt2 cells expressing ER-GFP were grown to log phase at 30°C. 
GFP fluorescence was analyzed by confocal microscopy (A) and flow cytometry (B). GFP level 
of cells in (B) was analyzed by quantitative immunoblotting (see Figure 3-8). The fluorescence 





40%-50% of that in wild type cells (Figure 3-8). To directly compare the folding outcome of ER-
GFP in different strains, the relative folded ER-GFP was plotted by normalizing the GFP 
fluorescence intensity to steady state protein level. The relative level of folded ER-GFP was 
about 6-fold higher in each single mutant and over 15-fold higher in the double mutant over the 
wild type (Figure 3-17B).  
 
We were aware that both pmt1 and pmt2 are UPR target genes (Travers et al., 2000). 
Reciprocally, the mutation of either of them or both will strongly induce UPR (Arroyo et al., 
2011; Jonikas et al., 2009; Nakatsukasa et al., 2004). Upon external or internal stress challenge, 
the UPR program systematically attenuates secretory protein biosynthesis, expands ER volume, 
up-regulates ER chaperones and enhance ERAD, which all contribute to the re-establishment of 
ER homeostasis (Walter and Ron, 2011). This explains the reduced protein level of ER-GPF in 
pmt mutants. However, the general protein folding environment inside the ER might be 
improved upon UPR activation. Thus, it is possible that the activation of UPR rather than the 
disruption of the PMTs improves the folding of ER-GFP. In order to rule out this possibility, we 
designed the following experiments. We reasoned that, if UPR is directly related to the folding 
improvement of ER-GFP, an increased fluorescence signal of ER-GFP is expected in mutants in 
which UPR is activated.  Jonikas et al. performed a quantitative genome wide screen for yeast 
mutants in which UPR was induced (Jonikas et al., 2009). Several hundreds of genes were found 
to be related to ER protein folding and UPR activation. Among them, we chose several 
representative mutants which fell into distinct functional categories but all induced UPR to the 
similar extent to pmt1 or pmt2. The selected mutants included Δalg3, Δarv1, Δerj5, Δerv25, and 
Δhrd1. Alg3 encodes an α-1,3 mannosyltransferase, which is required for the biosynthesis of N-
glycans (Sharma et al., 2001). Arv1p is required for the GPI intermediate transport and is related 
to sterol and sphingolipid metabolism (Kajiwara et al., 2008; Swain et al., 2002; Tinkelenberg et 
al., 2000). Erj5p belongs to the Hsp40/DnaJ family and is required for ER protein folding (Carla 
Fama et al., 2007). Erv25p is a member of the p24 family and is involved in protein trafficking 
from ER to Golgi (Belden and Barlowe, 1996). Hrd1p is an ubiquitin ligase for ERAD-L and 
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ERAD-M substrates and probably functions as a retrotranslocon (Bays et al., 2001; Carvalho et 
al., 2010; Sato et al., 2009). We transformed ER-GFP construct to each of these mutants and 
analyzed the fluorescence intensities by both confocal microscope and flow cytometry. The 
relative fluorescence intensities of ER-GFP in all those five mutants were similar to that in wild 
type cells (Figure 3-18A). The small difference of the fluorescence intensity among different 
strains might be due to the variation during the experimental procedure. By contrast, ER-GFP 
displayed much stronger fluorescence signal in Δpmt2 (Figure 3-18A). Disruption of those five 
genes with distinct function causes different internal stress and elevates UPR to a similar level to 
pmt2. Yet, none of them displayed increased fluorescence signal of ER-GFP. Thus, it is very 
unlikely that the UPR activation itself is sufficient to improve ER-GPF folding. To further 
strengthen this point, a Hac1i construct was transformed into wild type cells expressing ER-GFP 
to maximize UPR induction (Cox and Walter, 1996). Upon UPR activation, the activated Ire1p 
cleaves the intron of Hac1 mRNA near the 3 prime end to generated Hac1i. Only the spliced 
Hac1 mRNA can be translated to Hac1p and eventually initiate the UPR transcription. Thus, 
constantly expressing the activated Hac1pi transcription factor can maximally induces the UPR 
pathway. It was found that ER-GFP in the cells expressing Hac1pi displays slightly enhanced 
fluorescence signal, yet much lower than that in ∆pmt1∆pmt2 cells (Figure 3-18B). Even though 
we cannot rule out the possibility that UPR has synergetic effects to improve ER-GFP folding 
after the O-mannosylation machinery is eliminated, our results showed conclusively the UPR 
activation is not the primary cause of folding improvement in pmt mutants.    
 
Since ER-GFP displayed stronger fluorescence signal in the pmt mutants, we also expected that 
they become more resistant to trypsin digestion. To test this, microsomal protein extracts were 
prepared from wild type, ∆pmt1, ∆pmt2 and ∆pmt1∆pmt2 cells expressing ER-GFP. Equal 
amount of crude protein extracts was subjected to limited trypsin digestion. Here, we also used 
Gas1p as a loading control for normalization. Even though Gas1p is an endogenous O-
mannosylated protein, the O-mannosylation of Gas1p is mediated by Pmt4p (Gentzsch and 





Figure 3-18 UPR induction is not sufficient to improve ER-GFP folding.  
 
(A) Folding improvement of ER-GFP is not observed in various mutants in which UPR are 
constitutively activated. Five mutants that had distinct defects and induced UPR to a similar 
extent to Δpmt2 were selected and transformed with ER-GFP. Mutants expressing ER-GFP were 
grown to log phase at 30°C. GFP fluorescence was analyzed by confocal microscope with 
Detector Gain of 535. Scale bar, 5 µm. Relative fluorescence level was quantified independently 
by flow cytometry.  
 
(B) The fluorescence signal of ER-GFP was measured in wild type, Δpmt1Δpmt2 and cells in 
which the UPR was maximally induced (WT+HAC1i) as described in (A). Scale bar, 5 µm. 
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Gas1p is Pmt1/Pmt2 independent (Goder and Melero, 2011). Indeed, it was found that Gas1p 
was resistant to trypsin digestion both in wild type cells and pmt mutants (Figure 3-19). Thus, 
Gas1p could still serve as an internal control. After calculating the remaining percentage of ER-
GFP over the protease digestion, it was found that ER-GFP extracted from pmt mutants 
displayed increased protease resistance compared with that in wild type cells (Figure 3-19).  
 
Together, we provided strong genetic evidence to show that the Pmt1/Pmt2 mediated O-
mannosylation can actively terminate protein folding inside the ER. Such a modification is 
specific because only the proteins with prolonged folding, like ER-GFP, are modified. For 
proteins with fast folding rate, such as ER-GFPfast, they can quickly fold and reach their native 





Figure 3-19 ER-GFP protein extracted from pmt mutants displays increased protease 
resistance. 
 
Microsomal protein extracts were prepared from WT, ∆ pmt1, Δpmt2, or Δpmt1Δpmt2 cells 
expressing ER-GFP. Sixty µg of solubilized microsomal proteins were subjected to limited 
trypsin digestion (5 μg/ml typsin). The reaction was terminated as time indicated. The protein 
amount of ER-GFP at each time point was determined by quantitative immunoblotting. The Gas1 




3.2.5 Unfolded protein O-mannosylation intrinsically impairs protein folding and reduces 
Kar2 association. 
 
We next sought to understand by which means the O-mannosylation machinery terminates the 
folding midstream. We reasoned that adding a bulky hydrophilic group to the folding 
intermediate might intrinsically impairs protein folding process. To test this, an in vitro refolding 
assay was designed (Figure 3-20A, see the experimental scheme). First, we planned to denature 
the purified H6-ER-GFP. The purified H6-ER-GFP was a mixture of the native ER-GFP and O-
mannosylated H6-ER-GFP.  The denatured protein was subsequently refolded in an in vitro 
system. The refolding outcome of the non-glycosylated and O-mannosylated H6-ER-GFP could 
be evaluated after ConA chromatography. Because this is an in vitro system and no chaperones 
are involved, we can directly compare the refolding potential of each population and study how 
O-mannosylation would affect protein folding. 
 
We denatured H6-ER-GFP by adding TCA into the solution (final concentration at 10%). After 
precipitation by a high speed centrifugation, the protein pellet was resuspended in the denaturing 
buffer, which contained 6M urea. The fluorescence measurement showed that the fluorescence 
activity of H6-ER-GFP was totally abolished due to TCA precipitation and high concentration of 
urea resuspension (Figure 3-20B). To allow the refolding, we gradually dilute the urea 
concentration by dialysis in the refolding buffer. After overnight dialysis, the refolded of H6-ER-
GFP was accessed by the fluorescence measurement. It was shown that the denatured H6-ER-
GFP, at least a substantial portion, was able to refold and thus succeeded to emit fluorescence 
(Figure 3-20B). The refolded H6-ER-GFP was subjected to ConA chromatography to separate 
the non-glycosylated and O-mannosylated H6-ER-GFP. The non-glycosylated fractions were 
collected and designated as the unbound fraction. Equal portion of the starting material and the 
unbound fraction was subjected to fluorescence measurement. It was found that the unbound 





Figure 3-20 A schematic representation of the refolding experiment.  
 
(A) The purified H6-ER-GFP was denatured by TCA precipitation, resuspended in buffer 
containing high concentration of urea and refolded by overnight dialysis. The refolded H6-ER-
GFP was subjected to ConA chromatography. T, U, B was referred to the total fraction, unbound 
fraction, and bound fraction, respectively. The ConA unbound fraction was defined as the sum of 
respective flow-through and wash fractions. An equal amount of the total and unbound fractions 
was subjected to fluorescence measurement.  
 
(B) The fluorescence signal of H6-ER-GFP was determined before refolding and after refolding.  
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the ConA bound H6-ER-GFP could not be quantitatively eluted under native condition, the 
maximal contribution of the fluorescence signal from the O-mannosylated H6-ER-GFP was 33%.  
The ConA bound fraction was eluted under denaturing conditions. The same portion of the 
starting material, unbound fraction, and bound fraction was subjected to quantitative 
immuneblotting. The relative H6-ER-GFP level of each fraction was normalized to that of the 
starting material and plotted (Figure 3-21B). To calculate the relative folded ratio of GFP, the 
fluorescence signal, which represented the folded species, was normalized to the total protein 
level, which could reflect the sum of folded and unfolded H6-ER-GFP. Such a way enabled us to 
estimate the refolding potential of the non-glycosylated and O-mannosylated species. It was 
found that the maximum refolding potential of the O-mannosylated protein was about 15% of the 
unmodified species (Figure 3-21C).   
 
It should be noted that this assay is not meant to replicate the environment of the ER. Rather, we 
aim to measure the relative folding potential of the non-glycosylated and O-mannosylated H6-
ER-GFP. The in vitro conditions may support folding for a small fraction of the modified form 
that is not competent in vivo. To our knowledge, there is no demannosylation mechanism exists 
inside the ER. Hence, we reached the conclusion that substrate folding is directly disabled by O-
mannosylation. It is very likely that the termination of folding mediated by Pmt1/Pmt2 is 
effectively irreversible. 
 
Why the cells need the protein folding termination machinery? We hypothesized that an 
important function of a folding termination mechanism is to end futile chaperone-dependent 
folding cycles. The futile cycles of chaperones binding and releasing has been proposed by 
others. In an in vitro study on the Bip association with aberrant proteins, Kassenbrock et al. 
proposed that the Bip binding is due to “a futile attempt to correct their aberration” (Kassenbrock 
et al., 1988).  We reasoned that such a futile attempt could be prevented through substrate O-
mannosylation. To address this question, we analyzed the binding between ER-∆2GFP and Kar2, 





Figure 3-21 Substrate O-mannosylation intrinsically impairs protein folding.  
 
(A) After refolding and ConA chromatography, the fluorescence signal of the total and unbound 
fractions was quantified. *P < 0.01.  
 
(B) The protein level of H6-ER-GFP of each fraction was determined by quantitative 
immunoblotting. T, U, F, W, B were referred to total, unbound, flow-through, wash, and bound 
fractions, respectively. The unbound fraction was defined as the sum of respective flow-through 
and wash fractions. The percentage of unbound and bound fractions was quantified and plotted 
the graph. The data plotted were three independent experiments with standard deviation of the 
mean indicated. P > 0.05 is not significant (NS), Student’s t-test.  
 
(C) The normalized ratio of fluorescence/protein level. *P < 0.01. 
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because it is the major protein folding chaperone of the yeast ER. (Ghaemmaghami et al., 2003). 
ER-∆2GFP, instead of ER-GFP, was used so that an unfolded conformation could be maintained 
in both strains (Figure 3-2 A and B) (Prasad et al., 2010). ER-GFP and ER-∆2GFP were 
transformed into wild type and ∆pmt1∆pmt2 cells. The whole protein extracts were prepared 
from those strains and subjected to ConA chromatography. It was found that the majority of both 
ER-GFP and ER-Δ2GFP was O-mannosylated in wild type cells (Figure 3-22A). The O-
mannosylation of ER-∆2GFP was reduced in ∆pmt1∆pmt2 cells, but not to the extent of ER-GFP 
in the double mutant (Figure 3-22A). This is because that ER-Δ2GFP does not have the 
competence to fold and is resistant to ERAD. Thus, it might be possible that the consistently 
exposed Ser/Thr could be recognized by other PMTs, such as Pmt3/Pmt5 and Pmt4 (Girrbach 
and Strahl, 2003; Murakami-Sekimata et al., 2009). We wondered whether the reduced O-
mannosylation will lead to increased Kar2 association. To test this, detergent solubilized 
microsomal protein extracts were prepared from wild type and ∆pmt1∆pmt2 cells expressing ER-
Δ2GFP. GFP antibody and lgG beads were incubated with the crude protein lysate. Thus, the 
ER-∆2GFP and its binding partners under native conditions could be associated with the lgG 
beads and precipitated by a low speed centrifugation. The immunoprecipitaed proteins were 
eluted under denaturing conditions and subjected to quantitative immunoblotting. In both strains, 
we found that Kar2 is associated with ER-∆2GFP (Figure 3-22B). After normalizing the co-
precipitated Kar2 protein level to the ER-Δ2GFP level, more Kar2 was found to be complexed 
with ER-∆2GFP in the mutant strain compared with that in wild type (Figure 3-22B).  As a 
control, we also prepared microsomal protein extracts from wild type cells expressing empty 
vector. Neither GFP nor Kar2 was detected after the immunoprecipitation. It was noted that the 
expression level of Kar2 in the mutant strain was higher than that in wild type. This could be 
attributed to the high activation of UPR in the ∆pmt1∆pmt2 cells, which in turn up-regulates 
Kar2 expression (Arroyo et al., 2011; Nakatsukasa et al., 2004).  
 
Together, we concluded that O-mannosylation reduces the substrate binding affinity with 





Figure 3-22 Kar2 associates more with ER-Δ2GFP in Δpmt1Δpmt2 cells compared with that 
in wild type cells. 
 
(A) The O-mannosylation of ER-Δ2GFP is reduced in Δpmt1Δpmt2 cells. Crude protein extracts 
were prepared from WT and ∆pmt1Δpmt2 cells expressing ER-GFP or ER-Δ2GFP and subjected 
to ConA chromatography to analyze the glycosylation status. An equal portion of total, unbound 
and bound fraction was subjected to immunoblotting and probed with anti-GFP antibody.  
 
(B) ER-Δ2GFP displays decreased association with Kar2 in wild type cells than that in 
Δpmt1Δpmt2 cells. Solubilized microsomes of ER-Δ2GFP in WT or Δpmt1Δpmt2 cells were 
immunoprecipitated with anti-GFP antibody under native conditions. Immunoprecipitated 
proteins were eluted under denaturing conditions and analyzed by quantitative immunoblotting. 
The Kar2p occupancy was calculated by normalizing the co-precipitated Kar2p to the 
precipitated ER-Δ2GFP levels. The data plotted were three independent experiments with 
standard deviation of the mean indicated. *p<0.01, Student’s t-test. 
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(Nakatsukasa et al., 2004). They found that O-mannosylation increases the solubility of the 
misfolded proteins and maintains them to be soluble even when Kar2 is dysfunction. Thus, they 
concluded that the misfolded protein O-mannosylation can save the limited chaperone resources 
by means of reducing the chaperone load.  Together, we propose that O-mannosylation is used to 
terminate non-productive protein folding and prevent futile folding cycles. 
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3.2.6 O-mannosylation facilitates ERAD by preventing aggregates formation. 
 
We next further confirmed the role of O-mannosylation in ERAD and preventing aggregates of 
misfolded proteins in our own hands. KHN is a folding-disabled protein and requires the ERAD-
L pathway for degradation (Vashist et al., 2001). The previous work also found that KHN 
receives O-mannosylation in a Pmt1/Pmt2 dependent manner (Hirayama et al., 2008; Vashist et 
al., 2001).  We transformed the KHN-HA construct into wild type, ∆pmt1, ∆pmt2 or ∆pmt1∆pmt2 
cells. To quantitatively study the degradation of newly synthesized KHN, pulse-chase assay was 
performed. Cells were grown to log phase and labeled with [35S] methionine/cysteine for 10 min. 
After that, cold methionine/cysteine was added to initiate the chase. The labeling/chase was 
terminated by the addition of TCA as time indicated. The whole cell protein extracts were 
prepared and subjected to immunoprecipitation by HA antibody.  The volume of lysate for 
immunoprecipitation was adjusted to make sure that equal amount of radio-labeled proteins was 
used. Thus, the KHN protein level at each time point could be directly compared. The 
immnoprecipitated KHN was separated by SDS-PAGE and quantified by using a Typhoon 8600 
scanner and ImageQuantTM TL software. It was found that KHN was degraded in wild type cells 
over the chase (Figure 3-23A). Over the chase, KHN displayed a decrease in motility, which 
suggests the newly synthesized KHN gradually becomes O-mannosylated. Such a phenomenon 
was not observed in the ∆pmt1∆pmt2 cells. Thus, the O-mannosylation of KHN was mainly 
mediated by Pmt1/Pmt2. Disruption of pmt1 or pmt2 caused a mild degradation defect, which 
was further exacerbated in ∆pmt1∆pmt2 cells (Figure 3-23A).   
 
We next examined why KHN requires O-mannosylation for efficient degradation. It was shown 
that the ERAD machinery cannot degrade protein aggregates efficiently (Nishikawa et al., 2001). 
Thus, it might be possible that the O-mannosylation maintains the solubility of KHN and thus 
facilities its degradation. To test this, cell lysate was prepared from wild type cells or pmt 
mutants expressing KHN and was subjected to sucrose gradient centrifugation for twenty hours. 





Figure 3-23 O-mannosylation facilitates KHN degradation by preventing aggregate 
formation.  
 
(A) The degradation of KHN is delayed in the O-mannosylation mutants. WT, Δpmt1, Δpmt2 and 
Δpmt1Δpmt2 cells expressing KHN were grown to log phase and pulse-labeled at 30°C with 
[35S]methionine/cysteine for 10 min followed by a cold chase for the time indicated. The total 
protein extracts were prepared by TCA precipitation. After immunoprecipitation, proteins were 
resolved by SDS-PAGE and quantified by Phosphorimager analysis. The data plotted reflected 
three independent experiments with the SD of the mean indicated. Error bars, mean ± SD (N = 
3).  
 
(B) KHN forms aggregates in O-mannosylation mutants. Whole cell lysate was prepared from 
WT, Δpmt1, Δpmt2, or Δpmt1Δpmt2 cells expressing KHN and subsequently subjected to a 5-
60% linear sucrose gradient centrifugation. Thirteen fractions collected from top to bottom and 
the pellet (P) were analyzed by immunoblotting. 
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resolved in denaturing buffer containing 3% SDS. The same portion of each fraction was 
analyzed by SDS-PAGE and immunoblotting. It was found that majority of the KHN in wild 
type cells was present in fraction six to nine and little was detected in the pellet fraction (Figure 
3-23B). In the single mutants, more KHN was found in the pellet (Figure 3-23B). Most of the 
KHN was present in fraction nine to the pellet in ∆pmt1∆pmt2 cells, which is distinct from the 
distribution of KHN in wild type cells (Figure 3-23B). Thus, the misfolded proteins form more 
aggregates in O-mannosylation mutants than in wild type cells.   
 
Together, we concluded that O-mannosylation facilitates ERAD efficiency by increasing the 
solubility of misfolded proteins and it seems that the cells coordinate those two machineries very 
well to eliminate the misfolded clients efficiently.  
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3.2.7 Searching for other factors that are required for ER protein folding termination. 
 
We wondered whether other factors inside the ER might also participate in the protein folding 
termination process. It might be possible that some other ER resident proteins are able to 
terminate futile protein folding through an independent mechanism. Alternatively, Pmt1/Pmt2 
might require the assistance of other factors to target proteins with prolonged folding. To address 
this question, we took a genetic approach. We reasoned that, if any other proteins are directly or 
indirectly involved in the folding termination, genetic elimination of those genes would increase 
the fluorescence signal of ER-GFP. Thus, we performed a reverse genetic screen to search for 
additional ER proteins that participate in the folding termination.  
 
Based on the annotation from the yeast genome database (SGD, http://www.yeastgenome.org/), 
the non-essential ER genes were selected. Mutants carrying the specific mutations were taken 
from the yeast genome knock-out library. In total, more than two hundred genes were selected. 
We started this screen with the collection of ER mutants rather than the whole knock-out library 
due to the following reasons. First, the ER-localized protein is more likely to have a direct role in 
ER protein folding. Second, the yeast knock-out collection consists of more than five thousand 
mutants. We currently do not have the equipment which can automatically grow yeast strains and 
measure the relative fluorescence signal. Thus, it is more feasible to analyze those two hundred 
mutants manually. We transformed ER-GFP to those mutants. The transformants were subjected 
to flow cytometry to analyze the fluorescence signal quantitatively. For each set of measurement, 
the fluorescence intensity of ER-GFP in mutants was normalized to that in wild type cells. Thus, 
we could directly compare the fluorescence signal of ER-GFP in different strains from different 
sets of experiments. It should be noted that the variation of ER-GFP expression level in different 
mutants is not taken into consideration in this experiment. However, this should not be a problem 




The relative fluorescence intensity of each mutant was calculated and plotted (Figure 3-24). 
Here, only those mutants, in which ER-GFP displayed more than 30% increase or 20% decrease 
of the fluorescence signal, were listed in Table 3-1. As expected, the genes related to the O-
mannosylaiton pathway, such as pmt1, pmt2, and cax4, were identified. Cax4p is required for the 
synthesis of dolichyl pyrophosphate (Dol-P-P) linked mannose and is necessary for efficient N-
linked glycosylation  (van Berkel et al., 1999). Our results showed that ER-GFP displayed strong 
fluorescence signal in Δcax4 cells, which suggests that Cax4p also provides mannose resource 
for the PMT-mediated O-mannosylation. Factors required for the protein translocation into the 
ER, such as Sbh1p, Sec66p, Ssh1p, and Sec72p, emerged from the screen. This is also expected 
as we have already shown that ER-GFP shows stronger fluorescence signal in a translocation 
mutant sec63-1. Interestingly, we also found that ER-GFP emitted higher fluorescence signal in 
mutants related to lipid metabolism. This indicates that the ERQC machinery might require an 
optimal lipid environment for proper function.  For example, the phosphotidylcholine (PC) de 
novo synthesis pathway was severely impaired in the Δcho2 and Δopi3 mutants. Especially in 
Δopi3 cells, the lipidomic data showed that PC is almost undetectable (Thibault et al., 2012). The 
pulse chase experiment showed that the newly synthesized protein processing of Gas1p but not 
CPY is delayed in those two mutants (Thibault et al., 2012). As discussed above, CPY requires 
N-linked glycosylation for folding and maturation while Gas1p receives both N-linked and O-
linked glycosyaltions. Thus, it might be possible the O-mannosylation pathway is impaired in PC 
deficient strains. It would be interesting to test how the altered ER membrane lipid composition 
affects the enzyme activity and stability of PMTs. Actually, our findings here are consistent with 
the early studies on the enzyme activity of Pmt1p. In the early 1990s, Elbein and colleagues 
partially purified a mannosyltransferase from detergent solubilized microsomal membrane 
extract, which turned out to be Pmt1p later (Sharma et al., 1991; Strahl-Bolsinger et al., 1993). 
Interestingly, it was found that the phospholipid composition of the membrane, including the 
head groups and the number of double bonds of the fatty acid chains, can greatly affect the 
enzyme activity of Pmt1p in vitro. Specifically, PC and its derivatives with shorter fatty acid 










Figure 3-24 A summary of the genetic screening for mutants in which ER-GFP emits 
stronger fluorescence signal. 
 
Mutants expressing ER-GFP were grown to log phase and subjected to fluorescence 
measurement by flow cytometry. The relative fluorescence level was calculated by normalizing 
the fluorescence intensity of ER-GFP in the mutant to that in wild type cells. Some of the genes 




Table 3- 1 The list of mutants in which ER-GFP displayed more than 30% increased or 20% decreased 





Gene Protein function 
3.8 opi3 Required for the de novo synthesis of phosphatidylcholine (PC) 
3.0 cax4 Involved in the dolichyl pyrophosphate (Dol-P-P) linked oligosaccharide synthesis, which is 
required for efficient N-linked glycosylation 
2.6 pmt2 Protein O-mannosyltransferase 2 
2.0 las21 Required for the biosynthesis of glycosylphosphatidylinositol (GPI) core structure  
1.9 cho2 Required for the de novo synthesis of phosphatidylcholine 
1.8 sbh1 A subunit of the ER translocon; forms a  complex with Sec61p and Sss1p 
1.7 isc1 Inositol phosphosphingolipid phospholipase C, which is involved in the lipid metabolism 
1.7 pmt1 Protein O-mannosyltransferase 1 
1.7 vma22 An integral membrane protein which is involved in the assembly of  vacuolar H+-ATPase  
1.6 sec66 A subunit of the Sec63 complex; involved in the SRP-dependent and independent 
translocation  
1.6 sec72 A subunit of the Sec63 complex; involved in the SRP-dependent and independent 
translocation 
1.5 erg3 A sterol desaturase which is involved in ergosterol biosynthesis 
1.5 vph2 An integral membrane protein which is involved in the assembly of  vacuolar H+-ATPase 
1.5 swa2 A protein that is involved in vesicular transport 
1.4 scs7 Involved in sphingolipid metabolism 
1.4 cne1 The yeast homologue of Calnexin that might be involved in glycoprotein folding and quality 
control 





Gene Protein function 
1.4 sel1 Involved in ERAD 
1.4 ost3 A subunit of the oligosaccharyltransferase complex that is involved in N-linked glycosylation 
1.4 yel043w A hypothetical cytoskeleton protein  
1.4 ilm1 A protein with unknown function 
1.4 rot2 The catalytic subunit of glucosidase II  
1.4 erv14 A component of the COPII-coated vesicles 
1.4 emc6 A transmembrane protein that is related to ER protein folding 
1.4 ssh1 Involved in co-translational translocation 
1.3 erv46 A component of the COPII-coated vesicles 
1.3 lhs1 An ER Hsp70 that is required for protein translocation and folding 
1.3 flc2 A protein that is required for the transport of flavin adenine dinucleotide into ER 
1.3 pkr1 Involved in the assembly of  vacuolar H+-ATPase 
1.3 alg6 A glucosyltransferase involved in N-liked glycosylation 
1.3 ypc1 Involved in ceramide metabolism 
1.3 zrg17 A protein with unknown function 
0.8 get1 A subunit of the GET complex that is required for the retention of proteins carrying HDEL 
0.7 sil1 A nucleotide exchange factor (NEF) of Kar2 





(Sharma et al., 1991). It might be possible that the enzyme activity of other PMT family 
members is also affected in the PC deficient mutant. Thus, this also helps to explain why we 
observed stronger fluorescence signal in Δcho2 and Δopi3 cells. ER-GFP also displayed a higher 
fluorescence signal in two chaperone mutants, such as Δcne1 and Δlhs1, which might indicate 
their roles in folding termination. Other factors emerged from the screen were more likely due to 
some unknown indirect effects. Intriguingly, even though we aimed to search for ER-GFP 
folding improvement, we also identified two chaperone mutants, Δsil1 and Δscj1, in which ER-
GFP displayed significantly lower fluorescence intensity. This provided the in vivo evidence to 
show that Silp and Scj1p are required for ER protein folding. 
 
Overall, we identified a set of factors, which are involved in ER protein folding and termination 
directly or indirectly. However, this screen is not exhausted. First, our ER mutant collection may 
not be complete. One of our on-going projects aims to identify the factors that related ER protein 
folding termination with the yeast knock-out library. Second, this approach limits ability to study 
roles of those essential ER chaperones, such as Kar2 and PDI. We might switch to biochemical 
approaches to identify those folding termination factors.  
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3.3 Conclusion and Discussion 
Protein folding requires multiple cycles of chaperons binding and releasing. To optimize the 
protein synthesis process, a well-tuned protein quality control system is required to disrupt the 
futile folding cycles and target the folding-disabled molecules for degradation. Such a process is 
pivotal because the folding process is at high energy cost and the chaperone resources are 
limited. However, how the futile protein folding cycles are terminated has been an enigma for 
many years. Here, we provided evidence to show that O-mannosylation serves to interrupt and 
terminate futile protein folding attempts.  
3.3.1 The O-mannosylation mediated protein folding termination. 
 
It has been well established by previous work that mutant proteins are O-mannosylated inside the 
ER (Coughlan et al., 2004; Goder and Melero, 2011; Harty et al., 2001; Hirayama et al., 2008; Li 
et al., 2012; Nakatsukasa et al., 2004; Rubenstein et al., 2012; Vashist et al., 2001). Because 
those mutant proteins do not have the competence to fold, whether the modification is the cause 
or consequence of the folding failure is unclear. Key to our study is to characterize ER-GFP as a 
new ER quality control substrate, which is a wild type protein but with very slow folding rate. 
We chose ER-GFP because it is a slow folding molecule and folds poorly in the mammalian ER 
(Aronson et al., 2011; Jain et al., 2001). The low folding of ER-GFP was confirmed by three 
independent assays. We reasoned that it could mimic the futile folding cycles in vivo. Thus, such 
a unique substrate overcomes the limits of the folding-disabled molecules and enables us to 
tackle how futile protein folding cycles are terminated.  
 
We found that ER-GFP is O-mannosylated in wild type cells by ConA chromatography. We 
purified and separated the non-glycosylated and O-mannosylated ER-GFP and specifically 
showed that the O-mannosylated ER-GFP fails to emit fluorescence. This indicates that the O-
mannosylated ER-GFP is folding-disabled. The modification occurred in a post-translational 
manner, which is consistent with the previous findings of O-mannosylation on folding-disabled 
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molecules (Harty et al., 2001; Nakatsukasa et al., 2004). Thus, ER-GFP, like those folding-
disabled molecules, is the client of the O-mannosylation machinery. Importantly, we observed 
remarkable folding improvement of ER-GFP by genetic ablation of the O-mannosylation 
machinery. These data strongly suggest that O-mannosylation machinery can actively terminate 
protein folding in vivo. In order to study how the modification intervened in the folding process, 
we set up an in vitro refolding experiment. In this assay, the folding potential of the non-
glycosylated and O-mannosylated ER-GFP could be directly compared. We found that the 
modification intrinsically and irreversibly disabled the folding potential of the substrate. Thus, 
we proposed that a protein folding termination can involve a covalent glycosylation event. 
 
We have noticed that Jigami and colleagues have studied the relationship between human 
antibody production and O-mannosylaiton in yeast, Ogataea minuta (Kuroda et al., 2008). A 
compound, which is a rhodanine-3-acetic acid derivative, was used to suppress the O-
mannosetransferase activity (Orchard et al., 2004). Interestingly, the fully assembled antibody 
could only be detected in the presence of PMT inhibitor, which also suggests the potential roles 
of O-mannosylation in folding disruption. However, this study focused on exploring the 
possibility to express human antibodies in a yeast system for applicable purposes. Unlike that, 
we provided mechanistic insights into the O-mannosylation mediated protein folding disruption. 
Our proposed model could fit well with their observations. It is possible that the maturation of 
the human antibody exceeds the folding timer set by the cell and thus gets O-mannosylated. 
Thus, the modification disrupts the antibody assembly as they observed. The A1 chain of Shiga-
like toxin is an ERAD substrate which is also a substrate of the O-mannosylation machinery (Li 
et al., 2012). After retrotranslocation, a sub-portion of the toxin might refold in the cytosol and 
exert toxic effects to the cells. Interestingly, it was speculated by the authors that the toxicity is 
probably attributed to the non-O-mannosylated toxin chain (Li et al., 2012). Our findings here 
indicate that the modification intrinsically impairs protein folding and thus the O-mannosylated 
toxin chain might fail to refold in the cytosol. 
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Recently, it was found that overexpression of a neutralizing peptide against interleukin-17A was 
O-glycosylated in mammalian cells, which greatly decreased the binding affinity of the peptide 
(Zhong et al., 2013). Whether this modification is related to the mammalian PMTs still needs 
further exploration. It is of great interest to figure out whether the protein folding termination 
mechanism we reported here is conserved throughout evolution. If not, what are other strategies 
that mammalian cells adopt to terminate futile protein folding? Furthermore, it is still not known 
how futile protein folding cycles in other organelles, such as cytosol, mitochondria and nucleus, 
are disrupted.  
3.3.2 How does the O-mannosylation machinery target its clients? 
 
Like other endogenous proteins, ER-GFP is a wild type molecule. But a majority of ER-GFP is 
O-mannosylated by Pmt1p-Pmt2p in wild type cells. Thus, how do cells specifically target ER-
GFP, but not other endogenous proteins, to avoid overzealous O-mannosylation or folding 
disruption under physiological conditions?  
 
Previous studies on glycoprotein degradation suggested that the timing of protein folding is 
crucial (Gauss et al., 2011; Helenius and Aebi, 2004). A bipartite signal, which consists of a 
local unstructured patch and an adjacent N-glycan, is required for the glycoprotein breakdown 
(Xie et al., 2009). If the protein folds correctly, such a signal is packed in a way that could not be 
recognized by the ERQC machinery. Thus, the accessibility of this bipartite signal serves as a 
sensor, which reflects the folding status of the proteins. Exposure of the bipartite signal caused 
by prolonged folding increases the probability of being recognized by the ERQC machinery and 
triggers the degradation. We reasoned that such a principle of ERQC might also be apt for the O-
mannosylation mediated folding termination. Interestingly, we noticed that the O-mannosylation 
machinery can specifically modify a mutant protein rather than its wild type form (Hirayama et 
al., 2008). It might be possible that the modification is due to the prolonged folding process, even 
though it cannot be tested with those mutant proteins. Here, we created another fast folding 
substrate, ER-GFPfast. This fast folding GFP variant was previously engineered by Fisher and 
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DeLisa (Fisher and DeLisa, 2008).  It was found that, unlike ER-GFP, a majority of ER-GFPfast 
is not O-mannosylated. Thus, the O-mannosylation of ER-GFP in WT cells is specifically due to 
a prolonged folding process, which makes the potential modification sites accessible to the 
machinery. Together, we concluded that the folding termination machinery targets its clients 
based on the folding rate. These findings here are consistent with the currently established 
concept of ERQC (Gauss et al., 2011).  
 
The prolonged folding of a human mutant protein, named transthyretin (TTR), also undergoes 
post-translational glycosylation (Sato et al., 2012). The wild type TTR is a non-glycoprotein, 
which is a transporter of thyroxine and holo-retinol binding protein (Hamilton and Benson, 
2001). Usually, the mutant variants of TTR are stable and prone to form aggregates, which is 
related to the pathogenesis of amyloidosis. Interestingly, there is a non-stable TTR mutant, 
named D18G TTR, which is only associated mild phenotypes (Sato et al., 2007).  It was shown 
that the prolonged folding of D18G TTR triggers the exposure of the cryptic N-linked 
glycosylation site (Sato et al., 2012). It is the post-translational N-glycosylation that renders the 
D18G TTR to be an ERAD substrate and thus prevents the aggregation of this mutant protein 
and protects against amyloidosis. Even though D18G TTR is a folding-disabled molecule, this 
study, together with our findings, indicates that the prolonged folding related post-translational 
glycosylation might be an important aspect of ERQC. 
3.3.3 The physiology of the unfolded protein O-mannosylation.  
 
Why would cells recruit the O-mannosylation machinery to terminate the inefficient or futile 
protein folding? Since protein biosynthesis requires high energy consumption, it looks like a 
waste to terminate the folding of molecules which have the capacity to fold, such as ER-GFP. 
This seeming paradox can be explained as follows.  
 
First, the intercellular environment is very crowded (Gershenson and Gierasch, 2011). Futile 
protein folding will cause prolonged exposure of hydrophobic segments and increase the chance 
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of protein aggregation. If slow folding molecules like ER-GFP were allowed to fold, mutant 
proteins, such as KHN and pαF, would have a higher chance to form aggregates and become 
toxic to the cells (Hirayama et al., 2008; Nakatsukasa et al., 2004). Therefore, cells do not 
determine the folding competence of a nascent polypeptide. Rather, they define a time window 
for molecules to fold and terminate the folding by O-mannosylation if the set time window is 
exceeded. Once the mutant proteins become O-mannosylated, the solubility is increased, which 
prevents the formation of aggregates. Second, the O-mannosylated substrates are more 
hydrophilic, which may decrease the binding affinity of chaperones and hence reduce the 
chaperone load (Nakatsukasa et al., 2004). Such a hypothesis was further verified by testing the 
chaperone association with misfolded protein ER-Δ2GFP in WT and Δpmt1Δpmt2 cells. We 
have shown that ER-Δ2GFP associates more with Hsp70 in Δpmt1Δpmt2 cells than in WT cells. 
This suggests that O-mannosyltion may help terminate futile folding cycles by releasing 
chaperones from O-mannosylated substrates. Together, such covalent substrate modification 
mediated by Pmt1-Pmt2p not only prevents protein aggregation but also avoids futile occupancy 
of chaperones. Third, O-mannosylation may be of particular importance under ER stress. Both 
pmt1 and pmt2 are UPR regulated genes and the expression level could be induced upon ER 
stress (Travers et al., 2000). It was observed that 35% more endogenous proteins are O-
mannosylated upon tunicamycin (Tm, an N-linked glycosylation inhibitor) treatment (Harty et 
al., 2001). It is possible that proteins that required N-linked glycosylation for folding and 
maturation become folding incompetent upon Tm treatment and thus need to be taken out from 
the futile folding cycles to save the limited chaperone resources. This intriguing phenomenon 
poses a new open question of how important the “overzealous” O-mannosylation is upon ER 
stress.  
 
Based on our findings, we proposed a unifying mechanism for the unfolded protein O-
mannosylation (UPOM) pathway (Figure 3-25). The machinery specifically targets proteins with 
prolonged folding. The addition of the hydrophilic sugar moieties disrupts protein folding by 





Figure 3- 25 A unifying model of the role of unfolded protein O-mannosylation (UPOM) in 
ERQC.  
Chaperones assist nascent polypeptides to fold in the ER. Proteins with slow folding rate would 
be O-mannosylated by Pmt1p-Pmt2p. Such a modification prevents the chaperone reengagement 
and impairs protein folding. In the meantime, O-mannosylation promotes the degradation of the 
folding-disabled molecules by means of inhibiting aggregates formation.   
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folding intermediates are removed from the futile folding cycles and the limited cellular 
chaperone resources are saved. Importantly, the modification also prevents the aggregation of the 
folding-disabled molecules and promotes their degradation. Taken together, it is a 
multifunctional modification that contributes to the balance of the proteostasis network in the 
ER. 
3.3.4 Other factors that are required for ER protein folding termination. 
 
How the O-mannosylation machinery specifically recognizes its clients is still not clear. 
Interestingly, a recent study showed that Pmt1p-Pmt2p is associated with the ER protein folding 
chaperones, Pdi1p and Ero1p, and the ERAD components (Goder and Melero, 2011). Such a 
finding indicates that the folding termination machinery is connected with the folding machinery 
as well as the degradation machinery. How the connection is achieved is not known. It might be 
possible that the Pmt1p-Pmt2p complex behaves like the ER mannosidase Htm1p, which 
requires the assistance of other factors for the specific recognition of its clients. Furthermore, the 
protein O-mannosyltransferase family contains six members, Pmt1p-Pmt6p, which share great 
similarities in their primary amino acid sequences (Lommel and Strahl, 2009). Among them, 
only Pmt1p and Pmt2p, but not the other Pmts, are involved in unfolded protein folding 
termination. Thus, it is likely that some other factors may directly monitor protein folding inside 
the ER and target the substrates with prolonged folding to Pmt1p-Pmt2p. It would be of great 
interest to identify such factors.  
 
To explore this possibility, we set up a small scale reverse genetic screening for other potential 
ER factors. ER-GFP in mutants which are defective in folding termination is expected to display 
stronger fluorescence signal than that in wild type cells. Several factors emerged from the 
primary screen. Factors involved in the UPOM pathway, including Cax4p, Pmt1p, and Pmt2p, 
were found. Interestingly, previous work only showed that Cax4p is required for efficient N-
linked glycosylation (van Berkel et al., 1999). Our result suggests that the Dol-P-P linked 
mannose synthesized by Cax4p can also be utilized by the UPOM pathway. Other factors were 
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found, such as ER chaperones and enzymes involved in lipid metabolism. Even though the role 
of those factors seems to be indirect, it shows the UPOM pathway requires the involvement of 
multiple factors for the optimal efficiency. As our initial screening may not cover all the ER 
mutants, the on-going genome-wide screen is aimed to systematically identify all the factors that 
directly or indirectly affect ER protein folding termination. However, such an approach would 
fail if the factors involved in folding termination are essential. For example, both Kar2 and PDI 
are required for ER protein folding and quality control but the respective knock-out mutants are 
not viable. Recently, a new essential ER chaperone, named Rot1p, was identified (Takeuchi et 
al., 2006). In vitro, the purified Rot1p prevents the denatured proteins to form aggregates 
(Takeuchi et al., 2008). In vivo, Rot1p genetically and physically interacts with Kar2 and is 
required for efficient N-linked glycosyaltion and O-mannosylation (Pasikowska et al., 2012; 
Takeuchi et al., 2006). It might be possible that these three chaperones are the promising 
candidates that specifically target proteins with prolonged folding to the O-mannosylation 
machinery. To test this possibility, detailed biochemical analysis is needed. 
3.3.5 A translational aspect of the study 
 
We are also aware that our findings here might pave the way for some translational research. 
Yeast has been used as an expression system to produce mammalian proteins. Due to the 
relatively low cultivation costs, rapid cell growth and the high similarities to mammalian cells, 
yeast is a promising system to produce human antibodies. The ER oxidative environment is 
essential for the assembly of the heavy chain and light chain through disulfide linker. Efforts 
have been taken to genetically modify yeast to optimize the expression system. Our study here 
demonstrated the existence of protein folding termination inside the ER. Using the established 
system here, the on-going project is going to identify more factors that directly or indirectly 
influence the protein folding termination inside the ER (data not shown here).  So far, most of 
the factors we found in the primary screen not only conserve in different fungi but also are 
present in metazoan.  Thus, those factors must be taken into consideration when engineering the 
yeast expression system. To optimize the exogenous protein expression, it is important to 
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attenuate or disrupt the expression of folding termination machinery. Indeed, it was found that 
the antibody expressed in yeast, O. minuta, fails to assemble in the presence of the O-
mannosylation machinery (Kuroda et al., 2008). Our future work should provide more guidelines 
to create a better yeast expression system to produce antibodies.  
3.3.6 Summary 
 
In brief, we have provided genetic and biochemical evidences to show that the folding 
competence does not guarantee that a nascent polypeptide can complete folding and achieve its 
native status in vivo. Rather, it is the folding that really matters. Molecules that remain unfolded 
after a defined time window would have their folding irreversibly terminated by the covalent 
mannosyl-modification.  Such a mechanism advances our current view of chaperones assisted 
protein folding in vivo and indicates that cells do adopt some previously unappreciated strategies 




3.4 Future Perspectives 
In this thesis, we have created novel substrates to study ER protein folding termination, which 
allows us to demonstrate that the O-mannosylation machinery is involved in the folding 
termination.  With this new substrate system, we can answer more important questions in the 
future. 
 
First, we can systematically search for other factors that are directly or indirectly involved in ER-
GFP folding termination with the yeast knockout library. Actually, this is one of our on-going 
projects. With the help from the research technician, Mrs. Bouzelmat Nassira, we are trying to 
transform the ER-GFP construct into all the yeast knockout mutants and measure the GFP 
fluorescence change in each of the mutants. Now, a dozen of new genes have already emerged 
from the on-going screening, which are all different from those described here.  Using this 
approach, we might be able to systematically understand the folding termination process. From 
the perspective of translational research, this screening might provide us more clues about how 
to improve exogenous protein folding in yeast.  
 
Second, we can search for chemical chaperones that intrinsically improve the ER-GFP folding. 
Because the folding outcome of ER-GFP can be easily measured by monitoring the fluorescence 
signal, we can quickly screen through the small molecule library, which is composed of 
thousands of small molecules, for chemicals that can significantly accelerate protein folding. It is 
of great interests to identify chemical chaperones that can improve protein folding. They will 
become powerful tools that enable us to understand the mechanistic insights of protein folding in 
the oxidative environment. Furthermore, those chemical chaperones might have the potential to 
improve protein folding in mammalian cells.  Protein folding failures are directly related to 
numerous human diseases. For example, cystic fibrosis is related to the mutation of cystic 
fibrosis transmembrane conductance regulator (CFTR).  The mutant variants of CFTR fail to fold 
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in the ER and are quickly degraded by ERAD. The chemicals that can improve ER-GFP folding 
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